
<html lang="en"     class="pb-page"  data-request-id="6a819a52-bc1a-4c51-b5ad-c39948d20721"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.6b01208;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2016.59.issue-23;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists" /></meta><meta name="dc.Creator" content="Xin  Chen" /></meta><meta name="dc.Creator" content="John D.  McCorvy" /></meta><meta name="dc.Creator" content="Matthew G.  Fischer" /></meta><meta name="dc.Creator" content="Kyle V.  Butler" /></meta><meta name="dc.Creator" content="Yudao  Shen" /></meta><meta name="dc.Creator" content="Bryan L.  Roth" /></meta><meta name="dc.Creator" content="Jian  Jin" /></meta><meta name="dc.Description" content="Biased ligands (also known as functionally selective ligands) of G protein-coupled receptors are valuable tools for dissecting the roles of G protein-dependent and independent signaling pathways in..." /></meta><meta name="Description" content="Biased ligands (also known as functionally selective ligands) of G protein-coupled receptors are valuable tools for dissecting the roles of G protein-dependent and independent signaling pathways in..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 16, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01208" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01208" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01208" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01208" /></link>
        
    
    

<title>Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01208" /></meta><meta property="og:title" content="Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0001.jpeg" /></meta><meta property="og:description" content="Biased ligands (also known as functionally selective ligands) of G protein-coupled receptors are valuable tools for dissecting the roles of G protein-dependent and independent signaling pathways in health and disease. Biased ligands have also been increasingly pursued by the biomedical community as promising therapeutics with improved efficacy and reduced side effects compared with unbiased ligands. We previously discovered first-in-class β-arrestin-biased agonists of dopamine D2 receptor (D2R) by extensively exploring multiple regions of aripiprazole, a balanced D2R agonist. In our continuing efforts to identify biased agonists of D2R, we unexpectedly discovered a G protein-biased agonist of D2R, compound 1, which is the first G protein-biased D2R agonist from the aripiprazole scaffold. We designed and synthesized novel analogues to explore two regions of 1 and conducted structure–functional selectivity relationship (SFSR) studies. Here we report the discovery of 1, findings from our SFSR studies, and characterization of novel G protein-biased D2R agonists." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01208"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01208">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01208&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01208&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01208&amp;href=/doi/10.1021/acs.jmedchem.6b01208" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 10601-10618</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01156" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01161" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xin++Chen">Xin Chen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+D.++McCorvy">John D. McCorvy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+G.++Fischer">Matthew G. Fischer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kyle+V.++Butler">Kyle V. Butler</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yudao++Shen">Yudao Shen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bryan+L.++Roth">Bryan L. Roth</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Jin">Jian Jin</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Departments of Pharmacological Sciences and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New York, New York 10029, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">Department of Pharmacology and National Institute of Mental Health Psychoactive Drug Screening Program, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States</span></div><div class="corresp-info"><strong>*</strong>For J.J.: phone, 212-659-8699; fax, 212-849-2456; E-mail, <a href="/cdn-cgi/l/email-protection#e18b88808fcf8b888fa18c92928ccf848594"><span class="__cf_email__" data-cfemail="fc96959d92d2969592bc918f8f91d2999889">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For B.L.R.: phone, 919-966-7535; Email, <a href="/cdn-cgi/l/email-protection#ccaebeb5ada293bea3b8a48ca1a9a8e2b9a2afe2a9a8b9"><span class="__cf_email__" data-cfemail="dfbdada6beb180adb0abb79fb2babbf1aab1bcf1babbaa">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01208&amp;href=/doi/10.1021%2Facs.jmedchem.6b01208" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 10601–10618</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 2, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>10 August 2016</li><li><span class="item_label"><b>Published</b> online</span>16 November 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 December 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01208" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01208</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10601%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXin%2BChen%252C%2BJohn%2BD.%2BMcCorvy%252C%2BMatthew%2BG.%2BFischer%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D23%26contentID%3Dacs.jmedchem.6b01208%26title%3DDiscovery%2Bof%2BG%2BProtein-Biased%2BD2%2BDopamine%2BReceptor%2BPartial%2BAgonists%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10618%26publicationDate%3DDecember%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01208"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2080</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">31</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01208" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of G Protein-Biased D2 Dopamine Receptor Partial Agonists&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xin&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;D. McCorvy&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;G. Fischer&quot;},{&quot;first_name&quot;:&quot;Kyle&quot;,&quot;last_name&quot;:&quot;V. Butler&quot;},{&quot;first_name&quot;:&quot;Yudao&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Bryan&quot;,&quot;last_name&quot;:&quot;L. Roth&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Jin&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;10601-10618&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01208&quot;},&quot;abstract&quot;:&quot;Biased ligands (also known as functionally selective ligands) of G protein-coupled receptors are valuable tools for dissecting the roles of G protein-dependent and independent signaling pathways in health and disease. Biased ligands have also been increasingly pursued by the biomedical community as promising therapeutics with improved efficacy and reduced side effects compared with unbiased ligands. We previously discovered first-in-class β-arrestin-biased agonists of dopamine D2 receptor (D2R) by extensively exploring multiple regions of aripiprazole, a balanced D2R agonist. In our continuing efforts to identify biased agonists of D2R, we unexpectedly discovered a G protein-biased agonist of D2R, compound 1, which is the first G protein-biased D2R agonist from the aripiprazole scaffold. We designed and synthesized novel analogues to explore two regions of 1 and conducted structure–functional selectivity relationship (SFSR) studies. Here we report the discovery of 1, findings from our SFSR studies, and charac&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01208&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01208" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01208&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01208" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01208&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01208" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01208&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01208&amp;href=/doi/10.1021/acs.jmedchem.6b01208" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01208" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01208" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01208%26sid%3Dliteratum%253Aachs%26pmid%3D27805392%26genre%3Darticle%26aulast%3DChen%26date%3D2016%26atitle%3DDiscovery%2Bof%2BG%2BProtein-Biased%2BD2%2BDopamine%2BReceptor%2BPartial%2BAgonists%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D23%26spage%3D10601%26epage%3D10618%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/jmcmar.2016.59.issue-23/20161208/jmcmar.2016.59.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Biased ligands (also known as functionally selective ligands) of G protein-coupled receptors are valuable tools for dissecting the roles of G protein-dependent and independent signaling pathways in health and disease. Biased ligands have also been increasingly pursued by the biomedical community as promising therapeutics with improved efficacy and reduced side effects compared with unbiased ligands. We previously discovered first-in-class β-arrestin-biased agonists of dopamine D2 receptor (D2R) by extensively exploring multiple regions of aripiprazole, a balanced D2R agonist. In our continuing efforts to identify biased agonists of D2R, we unexpectedly discovered a G protein-biased agonist of D2R, compound <b>1</b>, which is the first G protein-biased D2R agonist from the aripiprazole scaffold. We designed and synthesized novel analogues to explore two regions of <b>1</b> and conducted structure–functional selectivity relationship (SFSR) studies. Here we report the discovery of <b>1</b>, findings from our SFSR studies, and characterization of novel G protein-biased D2R agonists.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18767" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18767" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The D2 dopamine receptor (D2R) remains a main target for the development of anti-Parkinson<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and antipsychotic agents.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Although all five dopamine receptors (D1R–D5R) are expressed in the brain,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> D2R is by far the most highly studied<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and is involved in many neuropsychiatric diseases<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> including attention-deficit disorders<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and schizophrenia.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> It is therefore not surprising that all of the current FDA-approved drugs for the treatment of schizophrenia have direct action at D2R.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Despite the prevalence of drugs targeting D2R, early typical antipsychotic drugs are known to have debilitating motor side effects including extrapyramidal symptoms (EPS),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> often leading to permanent symptoms such as tardive dyskinesia.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Thus, safer and more effective drugs that target D2R are needed not only to treat the positive and negative symptoms of schizophrenia<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> but also to minimize the motor side effects commonly observed with chronic antipsychotic treatment.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Newer generation antipsychotics such as aripiprazole<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> possess partial agonist actions at D2R<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and have less propensity to produce motor side effects,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> but mounting evidence in the past decade has suggested that aripiprazole, which is a balanced D2R agonist,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> can activate a plethora of downstream signaling pathways.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17, 18)</a></div><div class="NLM_p">The growing realization of the complexity of G protein coupled receptor (GPCR) mediated signal transduction pathways, specifically D2R mediated signaling pathways, has provided a theoretical framework for the development of functionally selective or biased ligands,<a onclick="showRef(event, 'ref4 ref19'); return false;" href="javascript:void(0);" class="ref ref4 ref19">(4, 19)</a> which refer to a ligand’s ability to differentially modulate canonical (e.g., G protein-dependent) versus noncanonical (e.g., G protein-independent, β-arrestin-mediated) signaling pathways.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> We previously discovered novel β-arrestin-biased agonists of D2R by extensively exploring multiple regions of the aripiprazole scaffold.<a onclick="showRef(event, 'ref16 ref21'); return false;" href="javascript:void(0);" class="ref ref16 ref21">(16, 21)</a> Using these β-arrestin-biased D2R agonists, which were tested in a battery of in vitro and in vivo assays, we found that the β-arrestin bias appears to be important to exert superior therapeutic utility in animal models of schizophrenia and elicit a lower level of catalepsy compared to the D2R antagonist haloperidol.<a onclick="showRef(event, 'ref16 ref22'); return false;" href="javascript:void(0);" class="ref ref16 ref22">(16, 22)</a> Others have recently reported the discovery of multiple functionally selective D2R ligands based on the potential antipsychotic agent cariprazine and other D2R targeting compounds.<a onclick="showRef(event, 'ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref25 ref26">(23-26)</a> In addition, the first G protein-biased agonist of D2R was recently reported.<a onclick="showRef(event, 'ref25 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref27">(25, 27)</a> Biased D2R ligands are thought to stabilize different conformations of D2R, leading to the preference for either G protein-dependent or G protein-independent signaling,<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28-30)</a> usually through recruitment or inhibition of β-arrestin.<a onclick="showRef(event, 'ref31 ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref31 ref32 ref33 ref34">(31-34)</a> Future characterization of biochemical and behavioral effects of biased D2R ligands and optimization of their drug-like properties could ultimately lead to improved antipsychotic drugs that are safer and more effective than existing antipsychotics. While a number of β-arrestin-biased D2R agonists have been generated and progressed toward clinical development, there is only one reported G protein-biased D2R agonist.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></div><div class="NLM_p last">To develop G protein-biased D2R agonists as useful tools for elucidating the role of G protein-mediated D2R signaling in physiology and pathophysiology, we extended our structure–functional selectivity relationship (SFSR) studies based on the aripiprazole scaffold. From these studies, we discovered compound <b>1</b>, a benzothiazole containing D2R agonist with an unexpected bias for G protein signaling. We then explored two regions of this lead and uncovered structural features that affect ligand bias. By combining preferred structural motifs, novel G protein-biased D2R agonists devoid of any measurable β-arrestin recruitment were discovered.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04022" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04022" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Discovery of Compound <b>1</b></h3><div class="NLM_p">We previously identified UNC9994 (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) as a β-arrestin-biased D2R agonist that lacks Gα<sub>i/o</sub> activity.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> A close analogue of this compound with the middle piperidine replaced by piperazine, UNC9995 (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), retained the β-arrestin-biased feature for D2R with slightly decreased potency.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Adding a simple methyl group at the 2 position of the benzothiazole ring resulted in compound <b>2</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), which is a balanced D2R agonist with similar efficacy and potency in both β-arrestin and Gi/o pathways. Surprisingly, extending the middle linker from propoxy (compound <b>2</b>) to butoxy (compound <b>1</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) resulted in the first G protein-biased D2R ligand from the aripiprazole scaffold, which exhibited D2R Gi/o partial agonist activity (EC<sub>50</sub> = 15 nM, <i>E</i><sub>max</sub> = 50%) with weak efficacy for β-arrestin recruitment (EC<sub>50</sub> = 13 nM, <i>E</i><sub>max</sub> = 23%).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0003.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Discovery of compound <b>1</b>, a G protein-biased D2R partial agonist. Benzothiazole substitution and linker modification of a β-arrestin-biased D2R agonist led to compound <b>1</b>, which is a D2R Gi/o partial agonist with weak efficacy for β-arrestin recruitment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">To develop more G protein-biased D2R agonists, we conducted structure–functional selectivity relationship (SFSR) studies based on this newly identified G protein-biased lead. We designed, synthesized, and evaluated derivatives of compound <b>1</b> to determine which structural modifications would favor Gi/o activation over β-arrestin recruitment. We previously found that conformationally constrained central linkers could lead to a significant bias for β-arrestin recruitment over Gi/o signaling.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> We and others also found that the butoxy was preferred compared to propoxy (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) or pentoxy<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> as a central linker. On the basis of these findings, we kept the butoxy constant as the central linker for the SFSR studies. We then focused our exploration on two regions of compound <b>1</b>, namely the left-hand side (LHS) phenylpiperazine and right-hand side (RHS) benzothiazole moieties.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> SFSR Studies of the Benzothiazole Moiety</h3><div class="NLM_p">To determine the effects of substituents at the 2-position of the benzothiazole moiety on ligand bias, we designed the analogues of compound <b>1</b> outlined in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. The synthesis of these compounds is summarized in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Generally, our previously well-established two-step alkylation sequence<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> was employed to prepare these compounds. Commercially available 2-methylbenzo[<i>d</i>]thiazol-5-ol, 2-methylbenzo[<i>d</i>]thiazol-6-ol, 2-methylbenzo[<i>d</i>]oxazol-5-ol, 2-chlorobenzo[<i>d</i>]thiazol-5-ol, and 5-hydroxybenzo[<i>d</i>]thiazol-2(3<i>H</i>)-one were reacted with 1,4-dibromobutane to give the bromo intermediates, which were then reacted with 1-(2,3-dichlorophenyl)piperazine (<b>5</b>) to afford the target compounds <b>1</b>, <b>3</b>, <b>4</b>, <b>6</b>, and <b>7</b>. The 2-trifluoromethyl benzo[<i>d</i>]thiazole-5-ol (<b>10</b>) was synthesized from commercially available 3-methoxyaniline. Trifluoroacetic acid was reacted with 3-methoxyaniline to give intermediate <b>8</b>, which was treated with NaSH·H<sub>2</sub>O and then cyclized to yield intermediate <b>9</b>.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Subsequent dimethylation reaction afforded intermediate <b>10</b>,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> which underwent the two-step alkylation sequence to furnish compound <b>11</b>. The 2-ethyl, 2-isopropyl, 2-methylamine, and 2-dimethylamine substituted benzothiazole building blocks were synthesized starting from commercially available 1-isothiocyanoto-3-methoxybenzene. Typical Grignard reaction procedures with ethylmagnesium chloride and isopropylmagnesium chloride yielded the corresponding thioamide compounds <b>12</b> and <b>13</b>, which were then cyclized to give intermediates <b>14</b> and <b>15</b>.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Removal of the methyl group followed by the two-step alkylation reactions afforded compounds <b>18</b> and <b>19</b>. In addition, 1-isothiocyanato-3-methoxybenzene was treated with methanamine or dimethylamine in the presence of PhCH<sub>2</sub>N(CH<sub>3</sub>)<sub>3</sub>Br<sub>3</sub> to give aminobenzothiazoles <b>21</b> and <b>22</b>,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> which were subjected the deprotection and two-step alkylation sequence to furnish the desired compounds <b>24</b> and <b>25</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SFSR of the RHS Benzothiazole Moiety<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0009.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0010.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> and <i>E</i><sub>max</sub> values are the average of at least three independent experiments performed in triplicate. Standard error of the mean (SEM) < ±20%. N/C: not calculated. N/A: no activity.</p></div></div><div></div></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0006.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>1</b> Analogues to Explore the RHS Benzothiazole Moiety<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, EtOH, reflux, 6 h, 30–80% yield; (b) NaI/K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 6 h, 50–70% yield; (c) (i) Ph<sub>3</sub>P, Et<sub>3</sub>N, CCl<sub>4</sub>, TFA, 0 °C, 10 min, (ii) 3-methoxyaniline/CCl<sub>4</sub>, reflux, 3 h, 86% yield; (d) NaSH·<i>x</i>H<sub>2</sub>O, PdCl<sub>2</sub>, DMSO, 50–110 °C, 3 h, 85% yield; (e) HI, reflux, 5 h, 83–90%; (f) RMgBr, THF, −10 °C, 90 min, ∼100% yield; (g) (i) K<sub>3</sub>Fe(CN)<sub>6</sub>, NaOH, H<sub>2</sub>O, CH<sub>3</sub>OH, 60 °C, 2 h, (ii) K<sub>2</sub>CO<sub>3</sub>, 60 °C, 1 h, 82–87% yield; (h) NHR′R′′, PhCH<sub>2</sub>N(CH<sub>3</sub>)<sub>3</sub>Br<sub>3</sub>, THF, rt, overnight, 93–96% yield.</p></p></figure><div class="NLM_p">All the newly synthesized compounds were evaluated in (1) D2R-mediated cAMP accumulation assay, which measures inhibition of isoproterenol-stimulated cAMP production,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and (2) D2R-mediated β-arrestin-2 recruitment Tango assay to determine potency and efficacy for β-arrestin recruitment.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Quinpirole, a full agonist of D<sub>2</sub>R,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> was used as the positive control in both cAMP inhibition and β-arrestin-2 recruitment Tango assays.</div><div class="NLM_p last">As summarized in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, by reversing the positions of nitrogen and sulfur in the thiazole structure, compound <b>3</b> retained similar efficacy in both β-arrestin and Gi/o pathways but showed decreased potencies. The potency in β-arrestin recruitment decreased more than that in Gi/o assay (5-fold versus 2-fold), thus favoring G protein-bias. By replacing sulfur in the thiazole ring with oxygen, the bioisostere compound <b>4</b> exhibited similar potency and efficacy in β-arrestin pathway but its efficacy in Gi/o pathway decreased, resulting in a less G protein-biased compound compared with compound <b>1</b>. With 2-Cl substitution, compound <b>6</b> showed similar efficacy in Gi/o pathway compared to compound <b>1</b> whereas its efficacy in β-arrestin recruitment was similar to Gi/o activity, exhibiting less G protein-bias. Interestingly, the 2-OH substitution, tautomerized to 2-keto, in compound <b>7</b> reversed the bias for G protein, demonstrating balanced signaling for both Gi/o signaling and β-arrestin recruitment with high potencies. Incorporation of a trifluoromethyl group, in most instances, in place of a methyl group, has been a commonly pursued modification to lead compounds in medicinal chemistry.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> However, changing the methyl group (compound <b>1</b>) to a trifluoromethyl group (compound <b>11</b>) suffered from reduced potency in both assays and its efficacy in the β-arrestin pathway increased whereas its Gi/o activity decreased, making it a balanced D2R agonist like compounds <b>6</b> and <b>7</b>, albeit with much weaker potency in both pathways. Replacing the methyl group with an ethyl, isopropyl, or methylamine group (in compounds <b>18</b>, <b>19</b>, and <b>24</b>, respectively) resulted in very weak efficacy in β-arrestin recruitment (<i>E</i><sub>max</sub> < 20%) but maintained low to moderate Gi/o efficacy (<i>E</i><sub>max</sub> = 43%, 33% and 40%, respectively). Although the potency of compound <b>18</b> and <b>19</b> in the Gi/o pathway was reduced by 5–7-fold, compound <b>24</b> was able to maintain similar potency as compound <b>1</b> in Gi/o pathway (EC<sub>50</sub> = 24 nM). Surprisingly, with the dimethylamine substitution, compound <b>25</b> did not show any activity in both pathways. Taken together, these results suggest that D2R G protein-bias is sensitive to subtle structural modifications to the 2-position of the benzothiazole moiety and only limited substitutions are tolerated in order to achieve G protein-biased compounds. 2-Methyl, 2-ethyl, 2-isopropyl, and 2-methylamine are possible RHS benzothizole substitutions that may favor Gi/o signaling over β-arrestin recruitment.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> SFSR Studies of the Phenylpiperazine Moiety</h3><div class="NLM_p">We next investigated the LHS phenylpiperazine moiety of compound <b>1</b>. We previously reported that this moiety was very tolerant to modifications, but most single substitutions on the phenyl ring appeared to generate balanced compounds with similar efficacy in both β-arrestin and Gi/o pathways.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Therefore, we designed most compounds with 2,3-disubstitutions, including cyclized 2,3-disubstitutions on the phenyl ring. 2-Methoxy substitution on the phenyl ring was found to increase the compound’s binding affinity toward D2R as well as the potency in both signaling pathways,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> therefore 1-(2-methoxyphenyl)piperazine was selected as the only single-substituted phenylpiperazine. Because 7-(piperazin-1-yl)benzo[<i>d</i>]oxazol-2(3<i>H</i>)-one is present in the structure of bifeprunox,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> which exhibited extraordinary potency and efficacy in both signaling pathways in our assays, we included this moiety in our design to enhance the comparatively low efficacy and low potency of compound <b>1</b>. In addition, piperazine was replaced by piperidine, homopiperazine, or substituted piperazine to explore whether any one of these ring replacements would favor Gi/o signaling over β-arrestin recruitment. The synthesis of these compounds is outlined in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0007.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>1</b> Analogues to Explore the LHS Phenylpiperazine Moiety<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaI/K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 6 h, 50–70% yield; (b) Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, <i>t</i>-BuONa, toluene, sealed tube, 100 °C, overnight, 52–89% yield; (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1 h, 92–96% yield; (d) Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, <i>t</i>-BuONa, toluene, sealed tube, 100 °C, 4 h, 56–67% yield; (e) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, microwave, 93% yield.</p></p></figure><div class="NLM_p">4-(2,3-Dichlorophenyl)piperidine (<b>27</b>)<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> and 1-(2,3-dichlorophenyl)-1,4-diazepane (<b>28</b>)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> were prepared according to the previously published procedures. Compounds <b>30</b>, <b>31</b>, and <b>32</b> were prepared by the nucleophilic displacement of 5-(4-bromobutoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>26</b>) with corresponding starting materials <b>27</b>, <b>28</b>, and commercially available 1-(2-methoxyphenyl)piperazine (<b>29</b>). Buchwald–Hartwig amination between 1-bromo-2,3-dichlorobenzene and Boc-protected methylpiperazine,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> followed by the removal of the Boc protecting group, gave intermediate <b>33</b>, which underwent the nucleophilic displacement reaction with bromide <b>26</b> to furnish compound <b>34</b>. Similarly, 8-bromo-2-methylquinoline underwent the Buchwald–Hartwig amination reaction with unprotected piperazine and yielded intermediate <b>35</b>. It was necessary to reduce the reaction time from overnight to 4 h to minimize the over-reacted byproduct. Likewise, intermediates <b>37</b> and <b>38</b> were synthesized by the reaction of piperazine with 8-bromo-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine and 5-bromo-2,3-dihydrobenzo[<i>b</i>][1,4]dioxine. Nucleophilic displacement of bromide <b>26</b> with intermediates <b>35</b>, <b>37</b>, and <b>38</b> afforded compounds <b>36</b>, <b>39</b> and <b>40</b>, respectively. Overnight Buchwald–Hartwig amination of 1,3-dibromo-2-methylbenzene with Boc-protected piperazine yielded intermediate <b>41</b>, which was reacted with phenylboronic acid under typical Suzuki coupling reaction conditions to afford intermediate <b>42</b>. Removal of the Boc protecting group, followed by the nucleophilic displacement reaction with bromide <b>26</b>, furnished compound <b>44</b>. Compound <b>45</b> was prepared from the nucleophilic displacement reaction of 7-(piperazin-1-yl)benzo[<i>d</i>]oxazol-2(3<i>H</i>)-one<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> with bromide <b>26</b>.</div><div class="NLM_p">Results of these compounds in β-arrestin-2 recruitment Tango and inhibition of cAMP accumulation assays are summarized in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Replacing the piperazine group in compound <b>1</b> with piperidine group in compound <b>30</b> resulted in a similar bias for G protein with slightly higher efficacy but slightly lower potency in both Gi/o and β-arrestin pathways. By contrast, replacing the piperazine group (compound <b>1</b>) with homopiperazine (compound <b>31</b>) led to significantly decreased efficacy in both Gi/o and β-arrestin signaling, resulting in a highly potent low efficacy partial agonist at activating Gi/o-mediated cAMP inhibition (EC<sub>50</sub> = 1.9 nM, <i>E</i><sub>max</sub> = 22%), which was inactive for β-arrestin recruitment. With 1-(2-methoxyphenyl)piperazine as the LHS group, compound <b>32</b> exhibited slight improvement in efficacy in both assays, but the potency in Gi/o pathway dropped around 5-fold compared to compound <b>1</b>, resulting in less bias for G protein-signaling. Surprisingly, the methyl substitution in the middle piperazine region (compound <b>34</b>) reduced the potency and efficacy drastically in both pathways and led to no appreciable activity in either Gi/o signaling or β-arrestin recruitment. Interestingly, by replacing the 2,3-dichlorophenyl in compound <b>1</b> with the 2-methylquinoline, compound <b>36</b> displayed considerably reduced efficacy in both Gi/o and β-arrestin signaling, making compound <b>36</b> a potent G protein-biased partial agonist with low efficacy (EC<sub>50</sub> = 15 nM, <i>E</i><sub>max</sub> = 25%). Similarly, compound <b>39</b>, with the dihydrobenzooxazine as the LHS moiety, did not recruit β-arrestin at all but had improved Gi/o potency yet decreased efficacy compared to compound <b>1</b> (EC<sub>50</sub> = 5.2 nM, <i>E</i><sub>max</sub> = 29%). Interestingly, the close analogue, compound <b>40</b>, with dihydrobenzodioxine as the LHS moiety, displayed markedly improved potency (EC<sub>50</sub> = 0.64 nM) and similar efficacy (<i>E</i><sub>max</sub> = 50%) for activating Gi/o signaling compared to compound <b>1</b>. Although its efficacy and potency in β-arrestin recruitment also improved, <b>40</b> exhibited a similar bias for G protein as <b>1</b> and <b>30</b>. By replacing the 2,3-dichloro substitutions (compound <b>1</b>) with the 2-methyl-3-phenyl substitutions, compound <b>44</b> was found to be completely inactive in both Gi/o and β-arrestin assays. With the benzooxazolone as the LHS moiety, compound <b>45</b> displayed significantly improved efficacy and potency in both Gi/o and β-arrestin signaling pathways, making it a potent, balanced, full-agonist of D2R. In summary, although this region is generally more tolerant to modifications than the RHS benzothiazole region, subtle structural changes can still lead to a very significant impact on ligand bias. Our SFSR studies on this region resulted in the identification of several additional motifs including 2-methylquinoline, dihydrobenzooxazine, and dihydrobenzodioxine that favor Gi/o signaling over β-arrestin recruitment.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SFSR of the LHS Phenylpiperazine Moiety<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0011.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0012.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> and <i>E</i><sub>max</sub> values are the average of at least three independent experiments performed in triplicate. SEM < ±20%. N/C: not calculated. N/A: no activity.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> SFSR Studies of Combination Compounds</h3><div class="NLM_p">We next designed and synthesized a number of combination compounds (outlined in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a> and <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>), which incorporate some of the preferred RHS and LHS structural motifs we identified from the above studies. We selected 2-ethyl, 2-isopropyl, 2-methylamino, 2-dimethylaminobenzothiazol-5-yl, and 2-methylbenzothiazol-6-yl as the RHS moiety, and 4-(2,3-dichlorophenyl)piperidine, 2-methylquinoline piperazine, dihydrobenzooxazine piperazine, and dihydrobenzodioxine piperazine as the LHS moiety. The synthetic routes for these combination compounds are summarized in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. These compounds (<b>46</b>–<b>58</b>) were prepared by following the same synthetic approach developed for compounds <b>1</b>, <b>3</b>, and <b>4</b> using the corresponding LHS and RHS intermediates.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0008.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Combination Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3,</sub> EtOH, reflux, 6 h, 30–80% yield; (b) NaI/K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 6 h, 50–70% yield.</p></p></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SFSR of Combination Compounds<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0013.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">EC<sub>50</sub> and <i>E</i><sub>max</sub> values are the average of at least three independent experiments performed in triplicate. SEM < ±20%. N/C: not calculated. N/A: no activity.</p></div></div><div></div></div><div class="NLM_p">We then evaluated compounds <b>46</b>–<b>58</b> in the D2R β-arrestin-2 recruitment Tango and Gi/o-mediated cAMP inhibition assays (results are summarized in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Interestingly, seven out of the 13 combination compounds (<b>46</b>–<b>49</b> and <b>53</b>–<b>55</b>) were significantly biased for G protein over β-arrestin recruitment with no activity in β-arrestin recruitment, and four other compounds (<b>50</b>, <b>51</b>, <b>56</b>, and <b>58</b>) exhibited some extent of Gi/o bias with improved potency and/or efficacy in the Gi/o pathway. Surprisingly, two of the combination compounds, <b>52</b> and <b>57</b>, with dihydrobenzodioxinylpiperazine as the LHS moiety and 2-ethyl or 2-methylamino benzothiazole as the RHS moiety, were inactive in both assays. All seven extremely G protein-biased compounds (<b>46</b>–<b>49</b> and <b>53</b>–<b>55</b>) were agonists at Gi/o signaling with low to moderate efficacy and moderate to high potency but did not display appreciable β-arrestin-2 recruitment activity (<20% of quinpirole). Additionally, we also tested these compounds in cells not expressing D2R to rule out nonspecific cAMP inhibition not related to D2R and observed no significant cAMP inhibition at concentrations lower than 10 μM (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b01208/suppl_file/jm6b01208_si_001.pdf" class="ext-link">Figure S1</a>). Most notably, as illustrated in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, compounds <b>46</b> and <b>54</b>, similar to compounds <b>18</b> and <b>24</b>, were more efficacious for Gi/o signaling with <i>E</i><sub>max</sub> 40–50% of quinpirole, and compounds <b>49</b> and <b>53</b> exhibited high Gi/o potencies (EC<sub>50</sub> < 10 nM) but lower efficacies (<i>E</i><sub>max</sub> = 30–40%). A bias plot<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> comparing relative concentration responses in the Gi/o GloSensor assay versus Tango β-arrestin-2 recruitment activity reveals that quinpirole is equi-efficacious in both assays (noted by the dotted line) but that compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> deviate from quinpirole and cluster toward G protein activation (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>C). These ligands, which have unique bias profiles, are potentially useful tools for elucidating signaling pathways that may contribute to antipsychotic efficacy and/or side effects.</div><figure id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0004.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> are G protein-biased D2R partial agonists. (A) Activity of compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, <b>54</b>, and quinpirole in the D2R-mediated Gi/o coupled isoproterenol-stimulated cAMP production assay using HEK293T cells expressing D2R and GloSensor-22F. All six tested compounds were partial agonists compared to quinpirole (EC<sub>50</sub> = 1.7 nM), which was used as a positive control. (B) Activity of compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, <b>54</b>, and quinpirole in the D2R-mediated β-arrestin-2 translocation Tango assay using HTLA cells transfected with a D2 V2-TCS-tTA construct. <b>1</b> recruited β-arrestin weakly, and the other five compounds did not substantially recruit β-arrestin compared to the full agonist quinpirole (EC<sub>50</sub> = 0.8 nM). Data are representative of at least three independent experiments performed in triplicate. (C) Bias plot of compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, <b>54</b>, and quinpirole in the D2R-mediated cAMP inhibition GloSensor assay versus the D2R-mediated β-arrestin-2 translocation Tango assay. Quinpirole shows equal activity in both assays, but compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> cluster toward G protein activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">From these SFSR studies, we observed the following general trends: (1) 2-substitution at the RHS benzothiazole moiety is a critical contributor to bias for Gi/o signaling. 2-Methyl, 2-ethyl, 2-isopropyl, and 2-methylamino are preferred substituents that lead to bias for the G protein signaling over β-arrestin recruitment; (2) the LHS 2,3-dichlorophenyl can be replaced with 2-methylquinoline, dihydrobenzooxazine, and dihydrobenzodioxine, resulting in significant bias for the Gi/o signaling pathway over β-arrestin recruitment; (3) a small substituent such as methyl at the middle piperazine ring can completely abolish agonist activity in both pathways and a bulky substituent such as phenyl at the LHS ring can also completely diminish agonist activity in both pathways; and (4) subtle ligand structural changes can result in major changes in ligand bias, which is consistent with our previous findings.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Further Characterization of G Protein-Biased D2R Agonists</h3><div class="NLM_p">Considering that the determination of ligand bias can be problematic due to either system or observational bias,<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> which is dependent on cell background (e.g., HEK, CHO cell lines) and signal amplification (i.e., receptor reserve, time-dependence),<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> we wanted to confirm the D2R G protein bias of these ligands by orthologous measures of β-arrestin-2 recruitment and G protein activity using bioluminescence resonance energy transfer (BRET)-based assays. Aripiprazole has been previously reported to be either a D2R antagonist<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> or a partial agonist<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> in the BRET β-arrestin-2 recruitment assay dependent on GRK2 coexpression and has been observed to act as either a D2R antagonist or partial agonist in G protein-activation assays dependent on receptor expression.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Although we have quantified the extent of D2R expression comparing D2R expressed in the GloSensor assay versus D2R expressed in the Tango assay and found similar expression levels (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b01208/suppl_file/jm6b01208_si_001.pdf" class="ext-link">Table S1</a>), time-dependent or assay kinetic differences may still interfere with the interpretation of ligand bias.</div><div class="NLM_p">Therefore, we chose to use the D2R β-arrestin-2 recruitment BRET assay, where D2R arrestin recruitment is measured after only 5 min, and compared compound <b>1</b> to aripiprazole and the previously reported D2R G protein-biased ligand, MLS1547 (<b>59</b>).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In HEK293T cells coexpressing D2R C-terminal-tagged renilla luciferase (Rluc), a Venus-tagged β-arrestin-2, and G protein-coupled receptor kinase 2 (GRK2), both aripiprazole and compound <b>59</b> displayed partial agonist activity for D2R-mediated β-arrestin-2 recruitment (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A, <i>E</i><sub>max</sub> = 26% and 68% of quinpirole, respectively) while compound <b>1</b> exhibited no activity up to 1 μM (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>A). In fact, <b>59</b> also showed robust β-arrestin recruitment in the Tango assay (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>B), albeit with moderate potency in both Tango and Gi/o assays (EC<sub>50</sub> = 102 and 46 nM) (<a class="ref internalNav" href="#fig3" aria-label="Figures 3">Figures 3</a>B,C). To address the discrepant partial agonist activity of <b>59</b> in the β-arrestin-2 recruitment BRET assay compared to the previously published lack of β-arrestin-2 recruitment as measured using DiscoverX,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> we further evaluated compounds <b>1</b>, <b>53</b>, and <b>59</b> relative to quinpirole using the D2R DiscoverX β-arrestin recruitment assay and confirmed lack of β-arrestin-2 recruitment activity for these compounds (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>D). The lack of robust β-arrestin-2 recruitment activity by <b>59</b> using DiscoverX assays may reflect cell type differences (DiscoverX uses CHO cells versus BRET and Tango use HEK cell background) but also likely reflect the lack of GRK2 coexpression, where GRK2 coexpression has been shown to be necessary for robust β-arrestin-2 recruitment for the μ-opioid receptor using the DiscoverX system.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Importantly, compound <b>53</b> shows no activity in all three measures of D2R β-arrestin-2 recruitment.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0005.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> do not activate β-arrestin recruitment in the D2R-mediated BRET assay, while compound <b>59</b> is a partial agonist in the D2R β-arrestin-2 recruitment Tango assay and D2R Gi/o-mediated cAMP inhibition assay. (A) Activity of aripiprazole, compound <b>1</b>, compound <b>59</b>, and quinpirole in the D2R-mediated BRET-based β-arrestin-2 recruitment assay using HEK293 cells expressing GRK2. Aripiprazole and compound <b>59</b> were partial agonists that promote β-arrestin recruitment to D2R, while compound <b>1</b> was not active in the BRET assay. Quinpirole (EC<sub>50</sub> = 7.0 nM) was used as a positive control. (B) Activity of compound <b>59</b> and quinpirole in the D2R-mediated β-arrestin-2 translocation Tango assay using HTLA cells transfected with a D2 V2-TCS-tTA construct. Compound <b>59</b> displayed robust β-arrestin recruitment in the Tango assay (EC<sub>50</sub> = 46 nM, <i>E</i><sub>max</sub> = 67%) compared to the full agonist quinpirole (EC<sub>50</sub> = 2.3 nM). (C) Activity of compound <b>59</b> and quinpirole in the D2R-mediated Gi/o coupled isoproterenol-stimulated cAMP production assay using HEK293T cells expressing D2R and GloSensor-22F. Compound <b>59</b> was a partial agonist (EC<sub>50</sub> = 102 nM, <i>E</i><sub>max</sub> = 63%) compared to quinpirole (EC<sub>50</sub> = 1.2 nM), which was used as a positive control. (D) D2R β-arrestin recruitment activity by compounds <b>1</b>, <b>53</b>, and <b>59</b> as measured by DiscoverX in D2R-expressing CHO cells. Compounds <b>1</b>, <b>53</b>, and <b>59</b> showed no activity up to 10 μM. Quinpirole (EC<sub>50</sub> = 28 nM) was used as a positive control. (E) Compound <b>1</b> (IC<sub>50</sub> = 18 nM) blocked dopamine (DA, EC<sub>50</sub> = 11 nM) stimulated β-arrestin recruitment in the BRET assay. (F) Activity of compounds <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> in the BRET assay. All compounds were not active in the BRET-based β-arrestin-2 recruitment assay, while quinpirole (EC<sub>50</sub> = 12 nM) was used as a positive control. (G) Activity of aripiprazole and compounds <b>1</b> and <b>53</b> in the D2R Gαi1–Gγ2 dissociation BRET assay. Aripiprazole (EC<sub>50</sub> = 0.99 nM), compound <b>1</b> (EC<sub>50</sub> = 3.6 nM), and <b>53</b> (EC<sub>50</sub> = 4.6 nM) all displayed partial agonist activity (78%, 57%, and 47%, respectively) relative to quinpirole. Quinpirole (EC<sub>50</sub> = 1.7 nM) was used as a positive control. Except for the DiscoverX assay (<i>n</i> = 1, performed in duplicate), data are representative of at least three independent experiments performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite the lack of agonist activity by <b>1</b> in the BRET assay, <b>1</b> displayed full antagonist activity by blocking dopamine-stimulated β-arrestin-2 recruitment (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>E). In contrast, <b>1</b> showed partial inhibition of dopamine-stimulated D2R G protein activation as measured by cAMP inhibition (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b01208/suppl_file/jm6b01208_si_001.pdf" class="ext-link">Figure S2</a>). Similarly, as observed with compound <b>1</b>, compounds <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> showed no β-arrestin recruitment up to 1 μM as measured by the BRET assay with GRK2 coexpressed (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>F). Finally, to confirm D2R G protein activation using an orthologous assay, we tested compounds <b>1</b> and <b>53</b> relative to aripiprazole and quinpirole using a Gαi1–Gγ2 dissociation BRET-based assay (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>G). In this assay, compounds <b>1</b> and <b>53</b> still exhibited potent partial agonist activity (57% and 47% of quinpirole, respectively) compared to aripiprazole (78%). Therefore, using BRET-based orthologous assay platforms for either G protein activation or arrestin recruitment, we confirmed that compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> are G protein-biased D2R agonists. As illustrated in <a class="ref internalNav" href="#fig2" aria-label="Figures 2">Figures 2</a>,<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>, these ligands are superior in their D2R G protein-bias profile compared to the previously reported compound <b>59</b>.</div><div class="NLM_p">Finally, we determined binding affinity of our G protein-biased D2R agonists <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> against a panel of aminergic GPCRs and neurotransmitter transporters (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Compound <b>1</b> exhibited 10-fold higher binding affinity toward D3R than D2R, whereas all of the other five compounds displayed similar binding affinity to D3R compared to D2R. With the exception of compounds <b>1</b> and <b>53</b>, which had similar D4R and D2R binding affinity, all compounds showed low or no affinity for other dopamine receptors (i.e., D1R, D4R, and D5R). At serotonin [also known as 5-hydroxytryptamine (5-HT or 5HT)] receptors, all tested compounds displayed moderate to high binding affinities toward 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, 5-HT<sub>2C</sub>, and 5-HT<sub>7</sub>. All six compounds displayed similar or higher binding affinities for 5-HT<sub>1A</sub> and 5-HT<sub>2B</sub> as comparing to D2R. Notably, compound <b>53</b> showed very high affinity for 5-HT<sub>1A</sub> (<i>K</i><sub>i</sub> = 1.4 nM). High affinities were also observed for compound <b>49</b> toward 5-HT<sub>1A</sub> as well as compounds <b>24</b> and <b>54</b> toward 5-HT<sub>2B</sub> (<i>K</i><sub>i</sub> < 20 nM). All compounds exhibited low or no affinities toward dopamine transporter (DAT), serotonin transporter (SERT), and H2-histamine receptor with the exception of compound <b>54</b> toward SERT. For H1-histamine receptor, compounds <b>1</b>, <b>24</b>, <b>53</b>, and <b>54</b> displayed moderate binding affinities, while compound <b>46</b> showed low affinity and compound <b>49</b> did not exhibit appreciable affinity.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Radioligand Binding Affinity of Compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> at Select GPCRs<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">binding affinity <i>K</i><sub>i</sub> (nM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">receptor</th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>24</b></th><th class="colsep0 rowsep0" align="center"><b>46</b></th><th class="colsep0 rowsep0" align="center"><b>49</b></th><th class="colsep0 rowsep0" align="center" char="."><b>53</b></th><th class="colsep0 rowsep0" align="center" char="."><b>54</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D2R</td><td class="colsep0 rowsep0" align="center">150</td><td class="colsep0 rowsep0" align="center">60</td><td class="colsep0 rowsep0" align="center">170</td><td class="colsep0 rowsep0" align="center">45</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">99</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D1R</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">1100</td><td class="colsep0 rowsep0" align="center">1700</td><td class="colsep0 rowsep0" align="center">2000</td><td class="colsep0 rowsep0" align="char" char=".">2000</td><td class="colsep0 rowsep0" align="char" char=".">1100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D3R</td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="center">35</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">64</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D4R</td><td class="colsep0 rowsep0" align="center">82</td><td class="colsep0 rowsep0" align="center">280</td><td class="colsep0 rowsep0" align="center">1800</td><td class="colsep0 rowsep0" align="center">7100</td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">430</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">D5R</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">1500</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">1500</td><td class="colsep0 rowsep0" align="char" char=".">1100</td><td class="colsep0 rowsep0" align="char" char=".">1800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1A</sub></td><td class="colsep0 rowsep0" align="center">86</td><td class="colsep0 rowsep0" align="center">55</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">14</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1B</sub></td><td class="colsep0 rowsep0" align="center">1700</td><td class="colsep0 rowsep0" align="center">1400</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">1600</td><td class="colsep0 rowsep0" align="char" char=".">420</td><td class="colsep0 rowsep0" align="char" char=".">2600</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>1D</sub></td><td class="colsep0 rowsep0" align="center">320</td><td class="colsep0 rowsep0" align="center">390</td><td class="colsep0 rowsep0" align="center">820</td><td class="colsep0 rowsep0" align="center">94</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">410</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>2A</sub></td><td class="colsep0 rowsep0" align="center">120</td><td class="colsep0 rowsep0" align="center">72 12</td><td class="colsep0 rowsep0" align="center">140</td><td class="colsep0 rowsep0" align="center">110</td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="char" char=".">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>2B</sub></td><td class="colsep0 rowsep0" align="center">38</td><td class="colsep0 rowsep0" align="center">12</td><td class="colsep0 rowsep0" align="center">71</td><td class="colsep0 rowsep0" align="center">43</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>2C</sub></td><td class="colsep0 rowsep0" align="center">160</td><td class="colsep0 rowsep0" align="center">58</td><td class="colsep0 rowsep0" align="center">210</td><td class="colsep0 rowsep0" align="center">140</td><td class="colsep0 rowsep0" align="char" char=".">92</td><td class="colsep0 rowsep0" align="char" char=".">73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>3</sub></td><td class="colsep0 rowsep0" align="center">130</td><td class="colsep0 rowsep0" align="center">330</td><td class="colsep0 rowsep0" align="center">1500</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="char" char=".">2600</td><td class="colsep0 rowsep0" align="char" char=".">370</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>5A</sub></td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="center">1300</td><td class="colsep0 rowsep0" align="center">1600</td><td class="colsep0 rowsep0" align="center">1400</td><td class="colsep0 rowsep0" align="char" char=".">330</td><td class="colsep0 rowsep0" align="char" char=".">810</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>6</sub></td><td class="colsep0 rowsep0" align="center">720</td><td class="colsep0 rowsep0" align="center">350</td><td class="colsep0 rowsep0" align="center">960</td><td class="colsep0 rowsep0" align="center">2200</td><td class="colsep0 rowsep0" align="char" char=".">2300</td><td class="colsep0 rowsep0" align="char" char=".">410</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5-HT<sub>7</sub></td><td class="colsep0 rowsep0" align="center">140</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="center">160</td><td class="colsep0 rowsep0" align="center">69</td><td class="colsep0 rowsep0" align="char" char=".">31</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">DAT</td><td class="colsep0 rowsep0" align="center">690</td><td class="colsep0 rowsep0" align="center">2800</td><td class="colsep0 rowsep0" align="center">4000</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="char" char=".">2500</td><td class="colsep0 rowsep0" align="char" char=".">2100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SERT</td><td class="colsep0 rowsep0" align="center">340</td><td class="colsep0 rowsep0" align="center">450</td><td class="colsep0 rowsep0" align="center">580</td><td class="colsep0 rowsep0" align="center">480</td><td class="colsep0 rowsep0" align="char" char=".">330</td><td class="colsep0 rowsep0" align="char" char=".">62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H1</td><td class="colsep0 rowsep0" align="center">57</td><td class="colsep0 rowsep0" align="center">56</td><td class="colsep0 rowsep0" align="center">690</td><td class="colsep0 rowsep0" align="center">N/A</td><td class="colsep0 rowsep0" align="char" char=".">52</td><td class="colsep0 rowsep0" align="char" char=".">28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">H2</td><td class="colsep0 rowsep0" align="center">680</td><td class="colsep0 rowsep0" align="center">310</td><td class="colsep0 rowsep0" align="center">2100</td><td class="colsep0 rowsep0" align="center">430</td><td class="colsep0 rowsep0" align="char" char=".">240</td><td class="colsep0 rowsep0" align="char" char=".">330</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last"><i>K</i><sub>i</sub> values are the average of at least two duplicate experiments. SEM < ±20%. N/A: not active.</p></div></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58131" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58131" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, by introducing 2-methyl to the RHS benzothiazole and changing the middle linker from propoxy to butoxy, we unexpectedly converted a β-arrestin-biased D2R agonist to a G protein-biased D2R agonist, compound <b>1</b>. We conducted structure–functional selectivity studies that focus on exploring two regions of the scaffold represented by this lead. These studies revealed a number of interesting general trends and identified multiple structural motifs that contribute to significant bias for the Gi/o signaling over β-arrestin recruitment. We discovered multiple G protein-biased D2R partial agonists including compounds <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b>, which were completely inactive in two measures of β-arrestin recruitment, and in the case of compound <b>53</b> inactive in all three measures of β-arrestin recruitment. On the basis of our assay results, these newly identified ligands are superior G protein-biased D2R partial agonists compared with the previously reported G protein-biased D2R agonist, compound <b>59</b>. Among the G protein-biased D2R agonists we have identified, compounds <b>24</b>, <b>46</b>, and <b>54</b> are most efficacious for the Gi/o signaling with <i>E</i><sub>max</sub> around 40–50% and compounds <b>49</b> and <b>53</b> exhibit the most potent Gi/o activity (EC<sub>50</sub> < 10 nM). The unique bias profiles of these ligands make them a set of potentially useful tools for elucidating the role of G protein-mediated D2R signaling in health and disease. Our studies and results will also help identify the next generation of D2R G protein-biased and β-arrestin-biased ligands</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11301" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11301" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry General Procedures</h3><div class="NLM_p">Unless stated to the contrary, where applicable, the following conditions apply: All commercial grade reagents were used without further purification. MeCN and CH<sub>2</sub>Cl<sub>2</sub> were distilled from CaH<sub>2</sub> under a N<sub>2</sub> atmosphere before use; THF was distilled from Na/benzophenone under N<sub>2</sub>. All other dry solvents were of anhydrous quality purchased from Sigma-Aldrich. Brine (NaCl), NaHCO<sub>3</sub>, and NH<sub>4</sub>Cl refer to saturated aqueous (satd aq) solutions. Column chromatography was performed on silica gel G (200–300 mesh) with reagent grade solvents. Melting points were uncorrected. NMR spectra were recorded on a Varian spectrometer (400 MHz for <sup>1</sup>H NMR and 100 MHz for <sup>13</sup>C NMR, respectively) at ambient temperature. All <sup>1</sup>H and <sup>13</sup>C chemical shifts are reported in ppm (δ) relative to CDCl<sub>3</sub> (7.26 and 77.16, respectively) or CD<sub>3</sub>OD (3.30 and 49.00, respectively).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> HPLC data for all compounds were acquired using an Agilent 6110 series system with a UV detector set to 220 nm. Samples were injected (<10 μL) onto an Agilent Eclipse Plus 4.6 mm × 50 mm, 1.8 μm, C18 column at room temperature (rt) at a flow rate of 1.0 mL/min. A linear gradient from 10% to 100% (v/v) B over 5.0 min followed by 2.0 min at 100% B with a mobile phase of (A) H<sub>2</sub>O + 0.1% acetic acid and (B) MeOH + 0.1% acetic acid was used. Mass spectra (MS) data were acquired in positive ion mode using an Agilent 6110 series single quadrupole mass spectrometer with an electrospray ionization (ESI) source. High-resolution (positive ion) mass spectra (HRMS) were acquired using a Shimadzu LCMS-IT-Tof time-of-flight mass spectrometer. HPLC was used to establish the purity of targeted compounds. All compounds that were evaluated in biological assays had >95% purity using the HPLC methods described above.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 5-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>1</b>)</h4><div class="NLM_p last">A mixture of 2-methylbenzo[<i>d</i>]thiazol-5-ol (202.7 mg, 1.23 mmol), 1,4-dibromobutane (990.8 mg, 4.91 mmol), and anhydrous K<sub>2</sub>CO<sub>3</sub> (203.5 mg, 1.47 mmol) was dissolved in EtOH (5 mL), and the solution was heated to reflux for 6 h. The solution was diluted with water and extracted with EtOAc. The combined organic layers were washed with saturated aq NaHCO<sub>3</sub> and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and purified by flash chromatography on silica gel column to give 5-(4-bromobutoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>25</b>, 251.1 mg, 68% yield) as a white solid. Compound <b>25</b> (89 mg, 0.30 mmol) was redissolved in CH<sub>3</sub>CN. To this mixture was added NaI (63.2 mg, 0.42 mmol), and the reaction mixture was heated to reflux for 30 min and then cooled to rt. The commercially available compound <b>4</b> (70.8 mg, 0.31 mmol) and anhydrous K<sub>2</sub>CO<sub>3</sub> (56.5 mg, 0.41 mmol) were added to the mixture. The resulting mixture was heated to reflux and stirred for 6 h. Precipitated crystals were filtered off, and the filtrate was evaporated under reduced pressure. The residue was extracted with EtOAc. The combined EtOAc layers was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, concentrated in vacuo, and purified by flash chromatography on silica gel column (elution with DCM/MeOH = 50:1) to give 5-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>1</b>) as white solid (87.8 mg, yield 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.64 (d, <i>J</i> = 8.8 Hz, 1H), 7.44 (d, <i>J</i> = 2.4 Hz, 1H), 7.17–7.10 (m, 2H), 6.98 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 6.95 (dd, <i>J</i> = 6.8, 2.8 Hz, 1H), 4.07 (t, <i>J</i> = 6.3 Hz, 2H), 3.08 (bs, 4H), 2.80 (s, 3H), 2.68 (bs, 4H), 2.55–2.48 (m, 2H), 1.93–1.83 (m, 2H), 1.75 (ddd, <i>J</i> = 15.1, 8.8, 6.0 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.26, 158.32, 154.75, 151.36, 134.13, 127.63, 127.56, 127.40, 124.70, 121.69, 118.75, 115.15, 106.04, 68.19, 58.30, 53.40, 51.34, 27.32, 23.51, 20.30. HPLC 99%, RT 4.819 min. MS (ESI) <i>m</i>/<i>z</i> 450.2 [M + H]<sup>+</sup>. HRMS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>26</sub>Cl<sub>2</sub>N<sub>3</sub>OS 450.1174, found 450.1168.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 5-(3-(4-(2,3-Dichlorophenyl)piperazin-1-yl)propoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>2</b>)</h4><div class="NLM_p last">Compound <b>2</b> (73 mg) was prepared as white solid by the same procedure as preparing <b>1</b> starting from 2-methylbenzo[<i>d</i>]thiazol-5-ol and 1,3-dibromopropane, yield 64%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.65 (d, <i>J</i> = 8.8 Hz, 1H), 7.46 (d, <i>J</i> = 2.4 Hz, 1H), 7.18–7.11 (m, 2H), 7.00 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 6.96 (dd, <i>J</i> = 6.4, 3.2 Hz, 1H), 4.12 (t, <i>J</i> = 6.3 Hz, 2H), 3.08 (bs, 4H), 2.81 (s, 3H), 2.65 (dd, <i>J</i> = 15.6, 8.4 Hz, 6H), 2.10–1.99 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.27, 158.33, 154.78, 151.46, 134.15, 127.66, 127.56, 127.47, 124.66, 121.70, 118.75, 115.15, 106.16, 66.76, 55.25, 53.49, 51.50, 26.89, 20.33. HPLC 99%, RT 4.766 min. MS (ESI) <i>m</i>/<i>z</i> 436.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 6-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>3</b>)</h4><div class="NLM_p last">Compound <b>3</b> (63 mg) was prepared as white solid by the same procedure as preparing <b>1</b> starting from 2-methylbenzo[<i>d</i>]thiazol-6-ol and 1,4-dibromobutane, yield 67%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.80 (d, <i>J</i> = 8.9 Hz, 1H), 7.27 (d, <i>J</i> = 2.5 Hz, 1H), 7.18–7.10 (m, 2H), 7.02 (dd, <i>J</i> = 8.9, 2.5 Hz, 1H), 6.95 (dd, <i>J</i> = 7.2, 2.3 Hz, 1H), 4.04 (t, <i>J</i> = 6.0 Hz, 2H), 3.14 (t, <i>J</i> = 4.3 Hz, 4H), 2.77 (bs, 7H), 2.64–2.56 (m, 2H), 1.94–1.75 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 164.42, 156.76, 150.97, 147.94, 136.95, 134.15, 127.63, 124.93, 122.86, 118.82, 115.47, 105.09, 68.29, 58.17, 53.26, 50.85, 27.27, 23.14, 20.07. HPLC 99%, RT 4.857 min. MS (ESI) <i>m</i>/<i>z</i> 450.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 6-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-2-methylbenzo[<i>d</i>]oxazole (<b>4</b>)</h4><div class="NLM_p last">Starting from 2-methylbenzo[<i>d</i>]oxazol-5-ol and 1,4-dibromobutane, compound <b>4</b> (58 mg) was prepared as white solid by the same procedure as preparing compound <b>1</b>, yield 62%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.32 (d, <i>J</i> = 8.8 Hz, 1H), 7.14 (dt, <i>J</i> = 6.9, 4.1 Hz, 3H), 6.96 (dd, <i>J</i> = 7.2, 2.3 Hz, 1H), 6.86 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 4.02 (t, <i>J</i> = 5.6 Hz, 2H), 3.18 (bs, 4H), 2.82 (bs, 4H), 2.64 (t, <i>J</i> = 6.9 Hz, 2H), 2.59 (s, 3H), 1.93–1.77 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 164.73, 156.38, 150.82, 145.71, 142.44, 134.14, 127.64, 127.61, 125.02, 118.87, 113.23, 110.38, 103.69, 68.43, 58.14, 53.17, 50.61, 27.25, 23.00, 14.72. HPLC 99%, RT 4.681 min. MS (ESI) <i>m</i>/<i>z</i> 434.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-Chloro-5-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)benzo[<i>d</i>]thiazole (<b>6</b>)</h4><div class="NLM_p last">Starting from 2-chlorobenzo[<i>d</i>]thiazol-5-ol and 1,4-dibromobutane, compound <b>6</b> (48 mg) was prepared as white solid by the same procedure as preparing compound <b>1</b>, yield 57%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 7.83 (d, <i>J</i> = 8.9 Hz, 1H), 7.50 (d, <i>J</i> = 2.4 Hz, 1H), 7.38–7.29 (m, 2H), 7.18 (ddd, <i>J</i> = 11.4, 8.0, 2.5 Hz, 2H), 4.20 (dd, <i>J</i> = 7.6, 3.9 Hz, 2H), 3.74 (d, <i>J</i> = 11.7 Hz, 2H), 3.59 (d, <i>J</i> = 13.6 Hz, 2H), 3.43–3.35 (m, 4H), 3.15 (t, <i>J</i> = 12.4 Hz, 2H), 2.11–1.94 (m, 4H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 160.06, 155.72, 153.32, 150.65, 135.16, 129.18, 128.65, 123.26, 123.11, 120.51, 117.15, 107.26, 107.13, 68.58, 57.84, 53.50, 29.16, 27.31, 22.23. HPLC 99%, RT 5.164 min. MS (ESI) <i>m</i>/<i>z</i> 470.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 5-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)benzo[<i>d</i>]thiazol-2(3<i>H</i>)-one (<b>7</b>)</h4><div class="NLM_p last">Starting from 5-hydroxybenzo[<i>d</i>]thiazol-2(3<i>H</i>)-one and 1,4-dibromobutane, compound <b>7</b> (51 mg) was prepared as white solid by the same procedure as preparing compound <b>1</b>, yield 53%. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): δ 10.40 (s, 1H), 7.23 (dd, <i>J</i> = 8.1, 1.5 Hz, 1H), 7.17 (t, <i>J</i> = 8.0 Hz, 1H), 7.11 (d, <i>J</i> = 8.6 Hz, 1H), 6.98 (dd, <i>J</i> = 8.0, 1.5 Hz, 1H), 6.67 (d, <i>J</i> = 2.2 Hz, 1H), 6.61 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 3.94 (dd, <i>J</i> = 13.3, 7.7 Hz, 2H), 3.82 (d, <i>J</i> = 11.4 Hz, 2H), 3.42 (d, <i>J</i> = 12.6 Hz, 2H), 3.37–3.18 (m, 4H), 3.09 (t, <i>J</i> = 10.3 Hz, 2H), 2.11–1.98 (m, 2H), 1.90–1.78 (m, 2H). <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): δ 173.39, 157.98, 149.06, 136.78, 134.39, 128.02, 127.77, 126.30, 122.98, 119.24, 115.34, 110.40, 98.47, 67.17, 57.19, 52.58, 48.49, 26.26, 21.05. HPLC 99%, RT 4.773 min. MS (ESI) <i>m</i>/<i>z</i> 452.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>Z</i>)-2,2,2-Trifluoro-<i>N</i>-(3-methoxyphenyl)acetohydrazonoyl Chloride (<b>8</b>)</h4><div class="NLM_p last">A 3-necked flask was charged with Ph<sub>3</sub>P (17.25 g, 66 mmol), Et<sub>3</sub>N (3.65 mL, 26.5 mmol), CCl<sub>4</sub> (10.55 mL, 110 mmol), and TFA (1.7 mL, 22 mmol). After the solution was stirred at 0 °C for about 10 min, 3-methoxyaniline (3.24 g, 26.5 mmol) in CCl<sub>4</sub> (10.55 mL, 110 mmol) was added. The mixture was then refluxed under stirring for 3 h. Solvent was removed under reduced pressure, and the residue was diluted with hexane and filtered. Residual solid was washed with hexane several times. The filtrate was concentrated and purified by flash chromatography on silica gel column to give compound <b>8</b> as white solid (4.7792 g, 86%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.34 (t, <i>J</i> = 8.1 Hz, 1H), 6.85 (ddd, <i>J</i> = 8.4, 2.5, 0.8 Hz, 1H), 6.68 (ddd, <i>J</i> = 7.9, 1.9, 0.8 Hz, 1H), 6.62 (t, <i>J</i> = 2.2 Hz, 1H), 3.83 (s, 3H). HPLC 99%, RT 4.881 min. MS (ESI) <i>m</i>/<i>z</i> 253.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 5-Methoxy-2-(trifluoromethyl)benzo[<i>d</i>]thiazole (<b>9</b>)</h4><div class="NLM_p last">To a solution of compound <b>8</b> (242.0 mg, 1.02 mmol) in DMSO (3 mL) was added NaSH·<i>x</i>H<sub>2</sub>O (81.5 mg, 1.02 mmol). The resulting mixture was then stirred at 50 °C for 30 min. PdCl<sub>2</sub> (9.0 mg, 0.05 mmol) was added, and the temperature was increased to 110 °C. After stirring for 3 h at 110 °C, H<sub>2</sub>O was added and the reaction mixture was cooled and extracted with EtOAc. Organic layers were combined and concentrated to give the residue which was purified on silica gel column to give compound <b>9</b> as white solid (202.2 mg, 85%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.78 (d, <i>J</i> = 9.0 Hz, 1H), 7.60 (d, <i>J</i> = 2.5 Hz, 1H), 7.17 (dd, <i>J</i> = 8.9, 2.5 Hz, 1H), 3.88 (s, 3H). HPLC 99%, RT 5.855 min. MS (ESI) <i>m</i>/<i>z</i> 234.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 2-(Trifluoromethyl)benzo[<i>d</i>]thiazol-5-ol (<b>10</b>)</h4><div class="NLM_p last">To the flask containing compound <b>9</b> (202.2 mg, 0.87 mmol) was added 47% HI (3 mL). The resulting mixture was refluxed while stirring for 5 h. After basifying with NaOH (1N), the mixture was extracted with EtOAc. Organic layers were combined and concentrated to give the residue which was purified on silica gel column to give compound <b>10</b> as white solid (174.8 mg, 92%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81 (dd, <i>J</i> = 8.8, 0.9 Hz, 1H), 7.61 (d, <i>J</i> = 2.0 Hz, 1H), 7.16 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 6.33 (bs, 1H). HPLC 99%, RT 5.429 min. MS (ESI) <i>m</i>/<i>z</i> 220.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 5-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-2-(trifluoromethyl)benzo[<i>d</i>]thiazole (<b>11</b>)</h4><div class="NLM_p last">Starting from 2-(trifluoromethyl)benzo[<i>d</i>]thiazol-5-ol (<b>10</b>) and 1,4-dibromobutane, compound <b>11</b> (68 mg) was prepared as white solid by the same procedure as preparing compound <b>1</b>, yield 63%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (d, <i>J</i> = 8.9 Hz, 1H), 7.63 (d, <i>J</i> = 2.4 Hz, 1H), 7.19 (dd, <i>J</i> = 8.9, 2.5 Hz, 1H), 7.17–7.09 (m, 2H), 6.95 (dd, <i>J</i> = 6.8, 2.7 Hz, 1H), 4.10 (t, <i>J</i> = 6.3 Hz, 2H), 3.10 (s, 4H), 2.70 (s, 4H), 2.60–2.48 (m, 2H), 1.97–1.86 (m, 2H), 1.78 (dt, <i>J</i> = 14.7, 7.4 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 159.23, 156.87 (d, <i>J</i> = 40.3 Hz), 153.69, 151.28, 134.14, 127.63, 127.59, 126.91, 124.77, 122.34 (d, <i>J</i> = 4.7 Hz), 119.93 (q, <i>J</i> = 272 Hz), 118.76, 118.57, 107.15 (d, <i>J</i> = 6.4 Hz), 68.30, 58.21, 53.39, 51.27, 27.15, 23.39. HPLC 99%, RT 5.298 min. MS (ESI) <i>m</i>/<i>z</i> 504.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> 2-Ethyl-5-methoxybenzo[<i>d</i>]thiazole (<b>14</b>)</h4><div class="NLM_p last">To a solution of 1-isothiocyanato-3-methoxybenzene (2.9475 g, 17.84 mmol) in THF (12 mL) at −10 °C was added ethylmagnesium chloride (2.0 M in THF, 17.84 mL, 35.68 mmol). The resulting mixture was then stirred at −10 °C for 90 min. Saturated NH<sub>4</sub>Cl was added, and the mixture was extracted with EtOAc three times. Organic layers were combined, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated to give crude <i>N</i>-(3-methoxyphenyl)propanethioamide (<b>12</b>), which was used for the next reaction without further purification. To a suspension of K<sub>3</sub>Fe(CN)<sub>6</sub> (19.384 g, 58.87 mmol) in H<sub>2</sub>O (49 mL) at 60 °C was added the mixture of compound <b>12</b> (17.84 mmol) and NaOH (5.2806 g, 132.01 mmol) in H<sub>2</sub>O (81 mL) and CH<sub>3</sub>OH (6 mL). The resulting mixture was the stirred at 60 °C for 2 h before K<sub>2</sub>CO<sub>3</sub> (13.0679 g, 94.55 mmol) was added. The mixture was then stirred at 60 °C for another hour. After cooling, the mixture was extracted with Et<sub>2</sub>O. Organic layers were combined and concentrated to give the residue which was purified on silica gel column to give compound <b>14</b> as colorless oil (2.8272 g, 82% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.67 (d, <i>J</i> = 8.8 Hz, 1H), 7.47 (d, <i>J</i> = 2.4 Hz, 1H), 6.99 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 3.88 (s, 3H), 3.13 (q, <i>J</i> = 7.6 Hz, 2H), 1.46 (t, <i>J</i> = 7.6 Hz, 3H). HPLC 99%, RT 5.398 min. MS (ESI) <i>m</i>/<i>z</i> 194.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 2-Isopropyl-5-methoxybenzo[<i>d</i>]thiazole (<b>15</b>)</h4><div class="NLM_p last">Starting from 1-isothiocyanato-3-methoxybenzene and isopropylmagnesium chloride, compound <b>15</b> (2.5738 g, 87%) was prepared as yellow oil via the same procedure as preparing compound <b>14</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.67 (d, <i>J</i> = 8.8 Hz, 1H), 7.48 (d, <i>J</i> = 2.5 Hz, 1H), 6.98 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 3.86 (s, 3H), 3.39 (hept, <i>J</i> = 6.9 Hz, 1H), 1.47 (d, <i>J</i> = 6.9 Hz, 6H). HPLC 99%, RT 5.689 min. MS (ESI) <i>m</i>/<i>z</i> 208.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 2-Ethylbenzo[<i>d</i>]thiazol-5-ol (<b>16</b>)</h4><div class="NLM_p last">Using the same procedure as preparing compound <b>10</b>, compound <b>16</b> was prepared from compound <b>14</b> as white solid (890 mg, 83% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.66 (d, <i>J</i> = 8.7 Hz, 1H), 7.29 (d, <i>J</i> = 2.3 Hz, 1H), 6.91 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 3.07 (q, <i>J</i> = 7.6 Hz, 2H), 1.40 (t, <i>J</i> = 7.6 Hz, 3H). HPLC 99%, RT 4.852 min. MS (ESI) <i>m</i>/<i>z</i> 180.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-Isopropylbenzo[<i>d</i>]thiazol-5-ol (<b>17</b>)</h4><div class="NLM_p last">Using the same procedure as preparing compound <b>10</b>, compound <b>17</b> was prepared from compound <b>15</b> as white solid (1.2270 g, 87% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.70 (d, <i>J</i> = 8.7 Hz, 1H), 7.30 (d, <i>J</i> = 2.3 Hz, 1H), 6.92 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 3.44–3.34 (m, 1H), 1.45 (d, <i>J</i> = 6.9 Hz, 6H). HPLC 99%, RT 5.189 min. MS (ESI) <i>m</i>/<i>z</i> 194.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 5-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-2-ethylbenzo[<i>d</i>]thiazole (<b>18</b>)</h4><div class="NLM_p last">Starting from 2-ethylbenzo[<i>d</i>]thiazol-5-ol (<b>16</b>) and 1,4-dibromobutane, compound <b>18</b> (59 mg) was prepared as white solid by the same procedure as preparing compound <b>1</b>, yield 64%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.67 (d, <i>J</i> = 8.7 Hz, 1H), 7.46 (d, <i>J</i> = 2.3 Hz, 1H), 7.17–7.10 (m, 2H), 6.97 (ddd, <i>J</i> = 9.5, 7.7, 2.6 Hz, 2H), 4.07 (t, <i>J</i> = 6.3 Hz, 2H), 3.18–3.02 (m, 6H), 2.67 (bs, 4H), 2.55–2.46 (m, 2H), 1.93–1.82 (m, 2H), 1.74 (dt, <i>J</i> = 7.3 Hz, 2H), 1.46 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 174.94, 158.33, 154.66, 151.44, 134.15, 127.66, 127.56, 126.83, 124.67, 121.82, 118.75, 115.22, 106.06, 68.22, 58.33, 53.43, 51.44, 29.85, 27.96, 27.35, 23.57, 13.93. HPLC 99%, RT 4.981 min. MS (ESI) <i>m</i>/<i>z</i> 463.9 [M + H]<sup>+</sup>. HRMS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>3</sub>OS 464.1330, found 464.1321.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 5-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-2-isopropylbenzo[<i>d</i>]thiazole (<b>19</b>)</h4><div class="NLM_p last">Starting from 2-isopropylbenzo[<i>d</i>]thiazol-5-ol (<b>17</b>) and 1,4-dibromobutane, compound <b>19</b> (63 mg) was prepared as white solid by the same procedure as preparing compound <b>1</b>, yield 68%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.68 (d, <i>J</i> = 8.8 Hz, 1H), 7.46 (d, <i>J</i> = 2.4 Hz, 1H), 7.22–7.12 (m, 2H), 6.98 (dd, <i>J</i> = 9.0, 2.3 Hz, 2H), 4.08 (t, <i>J</i> = 5.6 Hz, 2H), 3.39 (dt, <i>J</i> = 13.8, 6.9 Hz, 1H), 3.28 (bs, 4H), 2.94 (bs, 4H), 2.76 (bs, 2H), 1.92 (bs, 4H), 1.47 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 180.16, 158.08, 154.54, 134.26, 127.77, 126.72, 125.37, 121.96, 119.04, 115.12, 106.15, 67.86, 58.05, 53.06, 50.11, 34.27, 27.10, 23.03. HPLC 99%, RT 5.106 min. MS (ESI) <i>m</i>/<i>z</i> 478.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 5-Methoxy-<i>N</i>-methylbenzo[<i>d</i>]thiazol-2-amine (<b>20</b>)</h4><div class="NLM_p last">To a solution of 1-isothiocyanato-3-methoxybenzene (235.8 mg, 1.43 mmol) in THF (5 mL) was added CH<sub>3</sub>NH<sub>2</sub> (0.75 mL, 1.50 mmol). The resulting mixture was stirred at room temperature for 30 min before PhCH<sub>2</sub>NMe<sub>3</sub>Br<sub>3</sub> (556.5 mg, 1.43 mmol) was added. The reaction mixture was then stirred overnight at room temperature. The reaction was diluted with DCM and neutralized with aqueous NaHCO<sub>3</sub>. The organic layer was dried and concentrated to give the residue which was purified on silica gel column to give compound <b>20</b> as white solid (258.3 mg, yield 93%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.42 (d, <i>J</i> = 8.6 Hz, 1H), 7.08 (d, <i>J</i> = 2.5 Hz, 1H), 6.70 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 6.22 (bs, 1H), 3.82 (s, 3H), 3.07 (s, 3H). HPLC 99%, RT 4.194 min. MS (ESI) <i>m</i>/<i>z</i> 195.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 5-Methoxy-<i>N</i>,<i>N</i>-dimethylbenzo[<i>d</i>]thiazol-2-amine (<b>21</b>)</h4><div class="NLM_p last">Starting from 1-isothiocyanato-3-methoxybenzene and (CH<sub>3</sub>)<sub>2</sub>NH, compound <b>21</b> (white solid, 2.895 g, 96% yield) was prepared by the same procedure as preparing compound <b>20</b>. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.42 (d, <i>J</i> = 8.6 Hz, 1H), 7.13 (d, <i>J</i> = 2.5 Hz, 1H), 6.67 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 3.81 (s, 3H), 3.16 (s, 6H). HPLC 99%, RT 4.931 min. MS (ESI) <i>m</i>/<i>z</i> 209.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-(Methylamino)benzo[<i>d</i>]thiazol-5-ol (<b>22</b>)</h4><div class="NLM_p last">Using the same procedure as preparing compound <b>10</b>, compound <b>22</b> was prepared from compound <b>20</b> as white solid (2.563 g, 85% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.33 (d, <i>J</i> = 8.5 Hz, 1H), 6.91 (d, <i>J</i> = 2.4 Hz, 1H), 6.62–6.50 (m, 1H), 3.00 (s, 3H). HPLC 99%, RT 2.969 min. MS (ESI) <i>m</i>/<i>z</i> 181.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 2-(Dimethylamino)benzo[<i>d</i>]thiazol-5-ol (<b>23</b>)</h4><div class="NLM_p last">Using the same procedure as preparing compound <b>10</b>, compound <b>23</b> was prepared from compound <b>21</b> as white solid (1.227 g, 89% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 7.39 (d, <i>J</i> = 8.5 Hz, 1H), 6.94 (d, <i>J</i> = 2.4 Hz, 1H), 6.58 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 3.17 (s, 6H). HPLC 99%, RT 3.880 min. MS (ESI) <i>m</i>/<i>z</i> 195.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 5-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-<i>N</i>-methylbenzo[<i>d</i>]thiazol-2-amine (<b>24</b>)</h4><div class="NLM_p last">Starting from 2-(methylamino)benzo[<i>d</i>]thiazol-5-ol (<b>22</b>) and 1,4-dibromobutane, compound <b>24</b> (45 mg) was prepared as white solid by the same procedure as preparing compound <b>1</b>, yield 53%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.43 (d, <i>J</i> = 8.6 Hz, 1H), 7.20–7.13 (m, 2H), 7.11 (d, <i>J</i> = 2.4 Hz, 1H), 6.98 (dd, <i>J</i> = 7.4, 2.2 Hz, 1H), 6.71 (dd, <i>J</i> = 8.6, 2.5 Hz, 1H), 4.04 (t, <i>J</i> = 5.6 Hz, 2H), 3.22 (bs, 4H), 3.10 (s, 3H), 2.86 (bs, 4H), 2.68 (bs, 2H), 1.91–1.81 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.61, 158.38, 153.96, 134.23, 127.71, 125.11, 122.37, 121.04, 118.97, 110.64, 110.22, 104.30, 67.91, 58.17, 53.16, 50.19, 31.85, 27.24, 22.83. HPLC 99%, RT 4.522 min. MS (ESI) <i>m</i>/<i>z</i> 465.0 [M + H]<sup>+</sup>. HRMS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>27</sub>Cl<sub>2</sub>N<sub>4</sub>OS 465.1283, found 465.1266.</div></div><div id="sec4_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 5-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-<i>N</i>,<i>N</i>-dimethylbenzo[<i>d</i>]thiazol-2-amine (<b>25</b>)</h4><div class="NLM_p last">Starting from 2-(dimethylamino)benzo[<i>d</i>]thiazol-5-ol (<b>23</b>) and 1,4-dibromobutane, compound <b>25</b> (53 mg) was prepared as white solid by the same procedure as preparing compound <b>1</b>, yield 58%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.41 (d, <i>J</i> = 8.6 Hz, 1H), 7.17–7.08 (m, 3H), 6.94 (dd, <i>J</i> = 6.9, 2.6 Hz, 1H), 6.67 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 4.01 (t, <i>J</i> = 6.3 Hz, 2H), 3.17 (s, 6H), 3.08 (bs, 4H), 2.67 (bs, 4H), 2.55–2.45 (m, 2H), 1.89–1.78 (m, 2H), 1.72 (dt, <i>J</i> = 9.5, 7.1 Hz, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 170.10, 158.43, 154.52, 151.34, 134.07, 127.58, 127.53, 124.63, 122.59, 120.89, 118.73, 110.23, 103.83, 68.04, 58.28, 53.34, 51.29, 40.23, 27.35, 23.48. HPLC 99%, RT 4.747 min. MS (ESI) <i>m</i>/<i>z</i> 479.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 5-(4-(4-(2,3-Dichlorophenyl)piperidin-1-yl)butoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>30</b>)</h4><div class="NLM_p last">Starting from 4-(2,3-dichlorophenyl)piperidine (<b>27</b>) and 5-(4-bromobutoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>26</b>), compound <b>30</b> (53 mg) was prepared as white solid by the same procedure as preparing compound <b>1</b>, yield 61%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.66 (d, <i>J</i> = 8.7 Hz, 1H), 7.41 (d, <i>J</i> = 2.4 Hz, 1H), 7.35 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.29 (dd, <i>J</i> = 7.9, 1.6 Hz, 1H), 7.20 (t, <i>J</i> = 7.9 Hz, 1H), 6.97 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 4.08 (t, <i>J</i> = 5.9 Hz, 2H), 3.55 (d, <i>J</i> = 12.0 Hz, 2H), 3.33 (tt, <i>J</i> = 12.2, 3.3 Hz, 1H), 2.99–2.90 (m, 2H), 2.80 (s, 3H), 2.70 (t, <i>J</i> = 11.5 Hz, 2H), 2.38 (q, <i>J</i> = 12.1 Hz, 2H), 2.13–2.04 (m, 2H), 2.00 (d, <i>J</i> = 13.9 Hz, 2H), 1.96–1.87 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.51, 157.92, 154.70, 143.14, 133.37, 131.60, 129.02, 128.03, 127.78, 125.63, 121.85, 114.85, 106.18, 67.58, 57.83, 53.58, 38.09, 29.48, 26.93, 21.94, 20.32. HPLC 99%, RT 4.797 min. MS (ESI) <i>m</i>/<i>z</i> 449.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 5-(4-(4-(2,3-Dichlorophenyl)-1,4-diazepan-1-yl)butoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>31</b>)</h4><div class="NLM_p last">Compound <b>31</b> (58 mg) was prepared as white solid by the same procedure as preparing <b>1</b> from the reaction of 1-(2,3-dichlorophenyl)-1,4-diazepane (<b>28</b>) and 5-(4-bromobutoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>26</b>), yield 53%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.64 (d, <i>J</i> = 8.8 Hz, 1H), 7.39 (d, <i>J</i> = 2.4 Hz, 1H), 7.19 (dd, <i>J</i> = 8.0, 1.7 Hz, 1H), 7.13 (t, <i>J</i> = 8.0 Hz, 1H), 7.02 (dd, <i>J</i> = 7.9, 1.7 Hz, 1H), 6.96 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 4.07 (t, <i>J</i> = 5.8 Hz, 2H), 3.69–3.41 (m, 6H), 3.32–3.18 (m, 4H), 2.79 (s, 3H), 2.48 (bs, 2H), 2.26–2.13 (m, 2H), 1.98–1.87 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.50, 157.77, 154.65, 151.22, 134.22, 127.97, 127.85, 125.79, 121.86, 120.97, 114.78, 106.16, 4, 67.29, 57.63, 56.25, 52.93, 51.95, 49.92, 26.70, 24.17, 21.53, 20.29. HPLC 99%, RT 4.820 min. MS (ESI) <i>m</i>/<i>z</i> 464.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 5-(4-(4-(2-Methoxyphenyl)piperazin-1-yl)butoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>32</b>)</h4><div class="NLM_p last">Compound <b>32</b> (52 mg) was prepared as white solid by the same procedure as preparing <b>1</b> from the reaction of 1-(2-methoxyphenyl)piperazine (<b>29</b>) and 5-(4-bromobutoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>26</b>), yield 62%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.64 (d, <i>J</i> = 8.8 Hz, 1H), 7.41 (d, <i>J</i> = 2.4 Hz, 1H), 7.03–6.95 (m, 2H), 6.95–6.87 (m, 2H), 6.85 (d, <i>J</i> = 7.8 Hz, 1H), 4.05 (t, <i>J</i> = 5.8 Hz, 2H), 3.84 (s, 3H), 3.28 (bs, 4H), 2.95 (bs, 4H), 2.79 (s, 3H), 2.78–2.70 (m, 2H), 1.98–1.81 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.30, 158.06, 154.63, 152.22, 140.36, 127.50, 123.60, 121.70, 121.14, 118.59, 114.94, 111.30, 106.06, 67.84, 57.94, 55.46, 53.04, 49.29, 27.02, 22.51, 20.23. HPLC 99%, RT 4.503 min. MS (ESI) <i>m</i>/<i>z</i> 412.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (<i>S</i>)-1-(2,3-Dichlorophenyl)-2-methylpiperazine (<b>33</b>)</h4><div class="NLM_p last">To a solution of 1-bromo-2,3-dichlorobenzene (394.3 mg, 1.75 mmol) in toluene (5 mL) was added <i>tert</i>-butyl (<i>S</i>)-3-methylpiperazine-1-carboxylate (402.0 mg, 2.01 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (7.99 mg, 0.0087 mmol), BINAP (21.7 mg, 0.035 mmol), and <i>t</i>-BuONa (754.8 mg, 7.85 mmol). The resulting mixture was stirred overnight at 100 °C in a sealed tube. After cooling down, the reaction mixture was filtered through a pad of Celite and the filtrate was concentrated to give the residue which was purified on silica gel column to give <i>tert</i>-butyl (<i>S</i>)-4-(2,3-dichlorophenyl)-3-methylpiperazine-1-carboxylateas as white solid, which was treated with TFA in DCM at room temperature for 1 h to give crude compound <b>33</b> as TFA salt (263.2 mg, 52% yield) after removal of all the solvent. This crude compound <b>33</b> was used for the next reaction without further purification.</div></div><div id="sec4_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>S</i>)-5-(4-(4-(2,3-Dichlorophenyl)-3-methylpiperazin-1-yl)butoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>34</b>)</h4><div class="NLM_p last">Compound <b>34</b> (52 mg) was prepared as white solid by the same procedure as preparing <b>1</b> from the reaction of (<i>S</i>)-1-(2,3-dichlorophenyl)-2-methylpiperazine (<b>33</b>) and 5-(4-bromobutoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>26</b>), yield 51%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.66 (d, <i>J</i> = 8.8 Hz, 1H), 7.42 (d, <i>J</i> = 2.5 Hz, 1H), 7.30–7.26 (m, 1H), 7.19 (t, <i>J</i> = 8.0 Hz, 1H), 7.11 (d, <i>J</i> = 7.7 Hz, 1H), 6.97 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 4.07 (t, <i>J</i> = 5.6 Hz, 2H), 3.62 (bs, 1H), 3.42–2.84 (m, 7H), 2.81 (s, 3H), 2.52 (s, 1H), 2.04–1.83 (m, 4H), 0.93 (d, <i>J</i> = 6.1 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.46, 162.81, 158.02, 154.73, 134.09, 127.73, 127.55, 127.11, 123.08, 121.83, 118.29, 114.95, 106.12, 67.64, 58.86, 57.63, 52.84, 51.76, 39.29, 26.87, 25.56, 21.94, 20.32. HPLC 99%, RT 4.935 min. MS (ESI) <i>m</i>/<i>z</i> 464.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-Methyl-8-(piperazin-1-yl)quinoline (<b>35</b>)</h4><div class="NLM_p last">To a sealed tube was added 8-bromo-2-methylquinoline (213.4 mg, 0.96 mmol), piperazine (95.2 mg, 1.11 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (8.8 mg, 0.0096 mmol), BINAP (12.0 mg, 0.019 mmol), <i>t</i>-BuONa (230.8 mg, 2.40 mmol), and toluene (2 mL). The mixture was then stirred at 100 °C for 4 h. After cooling, the mixture was filtered through a pad of Celite and the filtrate was concentrated to give the residue which was purified on silica gel column to give compound <b>35</b> as white solid (146.2 mg, 67% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.95 (d, <i>J</i> = 8.4 Hz, 1H), 7.39–7.29 (m, 2H), 7.21 (d, <i>J</i> = 8.4 Hz, 1H), 7.07 (dd, <i>J</i> = 6.5, 2.4 Hz, 1H), 3.41 (d, <i>J</i> = 4.5 Hz, 4H), 3.30–3.18 (m, 4H), 2.70 (s, 3H). HPLC 99%, RT 2.628 min. MS (ESI) <i>m</i>/<i>z</i> 228.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 2-Methyl-5-(4-(4-(2-methylquinolin-8-yl)piperazin-1-yl)butoxy)benzo[<i>d</i>]thiazole (<b>36</b>)</h4><div class="NLM_p last">Compound <b>36</b> (57 mg) was prepared as white solid by the same procedure as preparing <b>1</b> from the reaction of 2-methyl-8-(piperazin-1-yl)quinoline (<b>35</b>) and 5-(4-bromobutoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>26</b>), yield 55%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.97 (d, <i>J</i> = 8.4 Hz, 1H), 7.65 (d, <i>J</i> = 8.7 Hz, 1H), 7.44 (d, <i>J</i> = 2.4 Hz, 1H), 7.40–7.32 (m, 2H), 7.23 (d, <i>J</i> = 8.4 Hz, 1H), 7.09 (dd, <i>J</i> = 6.0, 2.9 Hz, 1H), 6.99 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 4.08 (t, <i>J</i> = 6.1 Hz, 2H), 3.50 (bs, 4H), 2.88 (bs, 4H), 2.80 (s, 3H), 2.72 (s, 3H), 2.63–2.57 (m, 2H), 1.96–1.77 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.22, 158.32, 156.76, 154.74, 148.61, 142.03, 136.71, 127.79, 127.38, 125.86, 121.67, 121.62, 121.51, 115.97, 115.15, 106.06, 68.23, 58.49, 53.45, 51.85, 27.38, 25.96, 23.48, 20.29. HPLC 99%, RT 4.572 min. MS (ESI) <i>m</i>/<i>z</i> 447.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 8-(Piperazin-1-yl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine (<b>37</b>)</h4><div class="NLM_p last">Compound <b>37</b> (529.2 mg, 56% yield) was prepared starting from 8-bromo-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine and piperazine via the same procedure as preparing compound <b>35</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.66 (t, <i>J</i> = 8.0 Hz, 1H), 6.39 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 6.34 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 4.25–4.18 (m, 2H), 3.37–3.32 (m, 2H), 3.15–3.09 (m, 4H), 3.09–3.01 (m, 4H). HPLC 99%, RT 1.737 min. MS (ESI) <i>m</i>/<i>z</i> 220.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 1-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl)piperazine (<b>38</b>)</h4><div class="NLM_p last">Compound <b>38</b> (719.0 mg, 59% yield) was prepared starting from 5-bromo-2,3-dihydrobenzo[<i>b</i>][1,4]dioxine and piperazine via the same procedure as preparing compound <b>35</b>. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 6.75 (t, <i>J</i> = 8.1 Hz, 1H), 6.56 (ddd, <i>J</i> = 10.3, 8.1, 1.5 Hz, 2H), 4.30–4.25 (m, 2H), 4.25–4.20 (m, 2H), 3.15–3.06 (m, 8H). HPLC 99%, RT 2.977 min. MS (ESI) <i>m</i>/<i>z</i> 221.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 8-(4-(4-((2-Methylbenzo[<i>d</i>]thiazol-5-yl)oxy)butyl)piperazin-1-yl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine (<b>39</b>)</h4><div class="NLM_p last">Compound <b>39</b> (68 mg) was prepared as white solid by the same procedure as preparing <b>1</b> from the reaction of 8-(piperazin-1-yl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine (<b>37</b>) and 5-(4-bromobutoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>26</b>), yield 56%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.65 (d, <i>J</i> = 8.8 Hz, 1H), 7.42 (d, <i>J</i> = 2.4 Hz, 1H), 6.97 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 6.77 (t, <i>J</i> = 8.1 Hz, 1H), 6.59 (d, <i>J</i> = 8.2 Hz, 1H), 6.53 (dd, <i>J</i> = 8.0, 1.0 Hz, 1H), 4.30 (dd, <i>J</i> = 7.4, 3.4 Hz, 2H), 4.24 (dd, <i>J</i> = 7.8, 3.3 Hz, 2H), 4.06 (t, <i>J</i> = 5.6 Hz, 2H), 3.20 (bs, 4H), 2.82 (bs, 4H), 2.80 (s, 3H), 2.63 (t, <i>J</i> = 6.4 Hz, 2H), 1.92–1.79 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.32, 158.22, 154.73, 144.23, 141.35, 136.55, 127.49, 121.73, 120.85, 115.07, 112.31, 110.96, 106.10, 68.06, 64.49, 64.10, 58.21, 53.24, 50.09, 27.22, 23.06, 20.30. HPLC 99%, RT 4.585 min. MS (ESI) <i>m</i>/<i>z</i> 439.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 5-(4-(4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl)piperazin-1-yl)butoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>40</b>)</h4><div class="NLM_p last">Compound <b>40</b> (57 mg) was prepared as white solid by the same procedure as preparing <b>1</b> from the reaction of 1-(2,3-dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl)piperazine (<b>38</b>) and 5-(4-bromobutoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>26</b>), yield 61%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.65 (d, <i>J</i> = 8.8 Hz, 1H), 7.41 (d, <i>J</i> = 2.4 Hz, 1H), 6.97 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 6.69 (t, <i>J</i> = 8.0 Hz, 1H), 6.35 (d, <i>J</i> = 8.0 Hz, 2H), 4.31–4.24 (m, 2H), 4.06 (t, <i>J</i> = 5.9 Hz, 2H), 3.43–3.32 (m, 6H), 3.12 (bs, 4H), 2.95–2.85 (m, 2H), 2.80 (s, 3H), 2.10–1.99 (m, 2H), 1.95–1.84 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.43, 157.98, 154.68, 139.83, 136.45, 134.34, 127.68, 121.80, 121.17, 114.91, 111.52, 108.75, 106.14, 67.68, 65.41, 57.73, 52.76, 48.56, 40.82, 26.91, 21.97, 20.29. HPLC 99%, RT 4.804 min. MS (ESI) <i>m</i>/<i>z</i> 440.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>tert</i>-Butyl 4-(3-Bromo-2-methylphenyl)piperazine-1-carboxylate (<b>41</b>)</h4><div class="NLM_p last">Compound <b>41</b> (1.8375 g, 89% yield) was prepared starting from 1,3-dibromo-2-methylbenzene and <i>tert</i>-butyl piperazine-1-carboxylate via the same procedure as preparing compound <b>35</b>. HPLC 99%, RT 6.703 min. MS (ESI) <i>m</i>/<i>z</i> 355.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> <i>tert</i>-Butyl 4-(2-Methyl-[1,1′-biphenyl]-3-yl)piperazine-1-carboxylate (<b>42</b>)</h4><div class="NLM_p last">To a solution of <i>tert</i>-Butyl 4-(3-bromo-2-methylphenyl)piperazine-1-carboxylate (<b>41</b>, 1.0664 g, 3.00 mmol) in dioxane (20 mL) and H<sub>2</sub>O (5 mL) was added phenylboronic acid (732.0 mg, 6.00 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (346.9 mg, 0.30 mmol), K<sub>2</sub>CO<sub>3</sub> (829.7 mg, 6.00 mmol). The mixture was then stirred at 110 °C under microwave irradiation for 20 min. Solvent was removed and the residue was purified on silica gel column to give compound <b>42</b> as yellow oil (983.5 mg, 93% yield). HPLC 99%, RT 6.120 min. MS (ESI) <i>m</i>/<i>z</i> 353.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-(2-Methyl-[1,1′-biphenyl]-3-yl)piperazine (<b>43</b>)</h4><div class="NLM_p last">To a solution of compound <b>42</b> (983.5 mg, 2.79 mmol) in DCM (20 mL) was added TFA (3 mL). The resulting mixture was stirred at room temperature for 1 h to give crude compound <b>43</b> as TFA salt (off-white solid, 1.0222 g, 100% yield) after removal of all the solvent, which was used for the next reaction without further purification. HPLC 95%, RT 4.910 min. MS (ESI) <i>m</i>/<i>z</i> 253.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 2-Methyl-5-(4-(4-(2-methyl-[1,1′-biphenyl]-3-yl)piperazin-1-yl)butoxy)benzo[<i>d</i>]thiazole (<b>44</b>)</h4><div class="NLM_p last">Compound <b>44</b> (69 mg) was prepared as white solid by the same procedure as preparing <b>1</b> from the reaction of 1-(2-methyl-[1,1′-biphenyl]-3-yl)piperazine (<b>43</b>) and 5-(4-bromobutoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>26</b>), yield 66%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.82 (d, <i>J</i> = 8.9 Hz, 1H), 7.43–7.36 (m, 2H), 7.36–7.26 (m, 4H), 7.22 (t, <i>J</i> = 7.8 Hz, 1H), 7.10–7.06 (m, 1H), 7.04 (dd, <i>J</i> = 8.9, 2.5 Hz, 1H), 7.00–6.97 (m, 1H), 4.06 (t, <i>J</i> = 6.1 Hz, 2H), 3.08 (t, <i>J</i> = 4.7 Hz, 4H), 2.79 (s, 3H), 2.74 (bs, 4H), 2.62–2.54 (m, 2H), 2.19 (s, 3H), 1.96–1.73 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 164.39, 156.81, 151.77, 147.94, 143.83, 142.57, 136.96, 130.44, 129.40, 128.11, 126.82, 126.18, 125.12, 122.87, 118.21, 115.49, 115.47, 105.13, 105.09, 68.53, 68.36, 62.54, 58.30, 53.73, 51.67, 29.58, 27.35, 25.96, 23.29, 20.07, 15.93. HPLC 99%, RT 5.123 min. MS (ESI) <i>m</i>/<i>z</i> 472.3 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 7-(4-(4-((2-Methylbenzo[<i>d</i>]thiazol-5-yl)oxy)butyl)piperazin-1-yl)benzo[<i>d</i>]oxazol-2(3<i>H</i>)-one (<b>45</b>)</h4><div class="NLM_p last">Compound <b>45</b> (85 mg) was prepared as white solid by the same procedure as preparing <b>1</b> from the reaction of 7-(piperazin-1-yl)benzo[<i>d</i>]oxazol-2(3<i>H</i>)-one and 5-(4-bromobutoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>26</b>), yield 62%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.65 (d, <i>J</i> = 8.8 Hz, 1H), 7.44 (d, <i>J</i> = 2.4 Hz, 1H), 7.04 (t, <i>J</i> = 8.1 Hz, 1H), 6.99 (dd, <i>J</i> = 8.8, 2.5 Hz, 1H), 6.66–6.58 (m, 2H), 4.07 (t, <i>J</i> = 6.2 Hz, 2H), 3.36 (bs, 4H), 2.81 (s, 3H), 2.73 (bs, 4H), 2.60–2.52 (m, 2H), 1.91–1.84 (m, 2H), 1.84–1.75 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.36, 158.30, 154.72, 154.69, 136.00, 134.25, 130.19, 127.44, 124.85, 121.74, 115.18, 110.75, 110.15, 106.04, 102.54, 68.12, 58.28, 53.12, 48.92, 27.26, 23.28, 20.31. HPLC 99%, RT 4.132 min. MS (ESI) <i>m</i>/<i>z</i> 439.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 5-(4-(4-(2,3-Dichlorophenyl)piperidin-1-yl)butoxy)-2-ethylbenzo[<i>d</i>]thiazole (<b>46</b>)</h4><div class="NLM_p last">Compound <b>46</b> (63 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-ethylbenzo[<i>d</i>]thiazol-5-ol (<b>16</b>) and 1,4-dibromobutane, yield 65%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.66 (d, <i>J</i> = 8.7 Hz, 1H), 7.46 (d, <i>J</i> = 2.4 Hz, 1H), 7.31 (dd, <i>J</i> = 7.5, 1.9 Hz, 1H), 7.22–7.12 (m, 2H), 6.98 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 4.06 (t, <i>J</i> = 6.3 Hz, 2H), 3.16–3.02 (m, 5H), 2.51–2.42 (m, 2H), 2.11 (t, <i>J</i> = 11.1 Hz, 2H), 1.90–1.81 (m, 4H), 1.78–1.69 (m, 4H), 1.46 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 174.90, 158.35, 154.66, 145.77, 133.20, 131.94, 128.18, 127.50, 126.80, 125.42, 121.80, 115.23, 106.06, 68.25, 58.71, 54.38, 39.95, 32.20, 27.96, 27.47, 23.79, 13.92. HPLC 99%, RT 4.917 min. MS (ESI) <i>m</i>/<i>z</i> 463.0 [M + H]<sup>+</sup>. HRMS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>29</sub>Cl<sub>2</sub>N<sub>2</sub>OS 463.1378, found 463.1365.</div></div><div id="sec4_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 5-(4-(4-(2,3-Dichlorophenyl)piperidin-1-yl)butoxy)-2-isopropylbenzo[<i>d</i>]thiazole (<b>47</b>)</h4><div class="NLM_p last">Compound <b>47</b> (68 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-isopropylbenzo[<i>d</i>]thiazol-5-ol (<b>17</b>) and 1,4-dibromobutane, yield 69%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.69 (d, <i>J</i> = 8.7 Hz, 1H), 7.43 (d, <i>J</i> = 2.4 Hz, 1H), 7.39–7.30 (m, 2H), 7.22 (t, <i>J</i> = 7.9 Hz, 1H), 6.97 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 4.08 (t, <i>J</i> = 5.7 Hz, 2H), 3.75 (d, <i>J</i> = 11.5 Hz, 2H), 3.53–3.41 (m, 1H), 3.41–3.36 (m, 1H), 3.21–3.10 (m, 2H), 2.96 (t, <i>J</i> = 11.6 Hz, 2H), 2.70 (d, <i>J</i> = 11.9 Hz, 2H), 2.30–2.18 (m, 2H), 2.07 (d, <i>J</i> = 14.2 Hz, 2H), 1.99–1.88 (m, 2H), 1.46 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 180.35, 157.70, 154.50, 142.16, 133.45, 131.49, 129.36, 128.25, 127.05, 125.72, 122.08, 114.80, 106.27, 67.30, 53.29, 37.38, 34.25, 28.46, 26.72, 23.00, 21.24. HPLC 99%, RT 5.069 min. MS (ESI) <i>m</i>/<i>z</i> 477.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 2-Ethyl-5-(4-(4-(2-methylquinolin-8-yl)piperazin-1-yl)butoxy)benzo[<i>d</i>]thiazole (<b>48</b>)</h4><div class="NLM_p last">Compound <b>48</b> (72 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-ethylbenzo[<i>d</i>]thiazol-5-ol (<b>16</b>) and 1,4-dibromobutane, yield 63%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.98 (d, <i>J</i> = 8.4 Hz, 1H), 7.67 (d, <i>J</i> = 8.7 Hz, 1H), 7.47 (d, <i>J</i> = 2.4 Hz, 1H), 7.39–7.35 (m, 2H), 7.24 (d, <i>J</i> = 8.4 Hz, 1H), 7.10 (dd, <i>J</i> = 5.3, 3.6 Hz, 1H), 7.00 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 4.08 (t, <i>J</i> = 6.3 Hz, 2H), 3.47 (bs, 4H), 3.12 (q, <i>J</i> = 7.6 Hz, 2H), 2.83 (bs, 4H), 2.73 (s, 3H), 2.61–2.50 (m, 2H), 1.96–1.85 (m, 2H), 1.85–1.74 (m, 2H), 1.46 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 174.89, 158.38, 156.74, 154.67, 148.85, 142.11, 136.70, 127.82, 126.80, 125.89, 121.80, 121.61, 121.40, 115.91, 115.25, 106.09, 68.33, 58.61, 53.58, 52.16, 27.96, 27.46, 25.99, 23.71, 13.93. HPLC 99%, RT 4.471 min. MS (ESI) <i>m</i>/<i>z</i> 461.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 2-Isopropyl-5-(4-(4-(2-methylquinolin-8-yl)piperazin-1-yl)butoxy)benzo[<i>d</i>]thiazole (<b>49</b>)</h4><div class="NLM_p last">Compound <b>49</b> (76 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-isopropylbenzo[<i>d</i>]thiazol-5-ol (<b>17</b>) and 1,4-dibromobutane, yield 67%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.98 (d, <i>J</i> = 8.4 Hz, 1H), 7.68 (d, <i>J</i> = 8.7 Hz, 1H), 7.48 (s, 1H), 7.41–7.32 (m, 2H), 7.28–7.20 (m, 1H), 7.14–7.07 (m, 1H), 6.99 (dd, <i>J</i> = 8.7, 1.9 Hz, 1H), 4.08 (t, <i>J</i> = 5.8 Hz, 2H), 3.54 (bs, 4H), 3.44–3.33 (m, 1H), 2.94 (bs, 4H), 2.73 (s, 3H), 2.65 (bs, 2H), 1.89 (bs, 4H), 1.47 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 180.01, 158.26, 156.85, 154.54, 148.44, 142.02, 136.76, 127.82, 126.54, 125.89, 121.88, 121.68, 116.06, 115.25, 106.10, 77.48, 77.16, 76.84, 68.18, 58.44, 53.39, 51.60, 34.25, 29.84, 27.34, 26.00, 23.33, 23.03. HPLC 99%, RT 4.746 min. MS (ESI) <i>m</i>/<i>z</i> 475.1 [M + H]<sup>+</sup>. HRMS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>34</sub>N<sub>4</sub>OS 475.2532, found 475.2510.</div></div><div id="sec4_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 8-(4-(4-((2-Ethylbenzo[<i>d</i>]thiazol-5-yl)oxy)butyl)piperazin-1-yl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine (<b>50</b>)</h4><div class="NLM_p last">Compound <b>50</b> (52 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-ethylbenzo[<i>d</i>]thiazol-5-ol (<b>16</b>) and 1,4-dibromobutane, yield 56%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.66 (d, <i>J</i> = 8.8 Hz, 1H), 7.46 (d, <i>J</i> = 2.4 Hz, 1H), 6.98 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 6.69 (t, <i>J</i> = 8.0 Hz, 1H), 6.39 (dd, <i>J</i> = 8.0, 1.3 Hz, 1H), 6.32 (dd, <i>J</i> = 7.9, 1.3 Hz, 1H), 4.35–4.29 (m, 2H), 4.06 (t, <i>J</i> = 6.3 Hz, 2H), 3.68 (bs, 1H), 3.45–3.38 (m, 2H), 3.12 (dd, <i>J</i> = 15.2, 7.6 Hz, 6H), 2.66 (bs, 4H), 2.52–2.45 (m, 2H), 1.92–1.82 (m, 2H), 1.73 (dt, <i>J</i> = 9.6, 7.2 Hz, 2H), 1.46 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 174.89, 158.36, 154.66, 141.60, 136.74, 134.14, 126.80, 121.80, 120.93, 115.24, 110.80, 108.65, 106.08, 68.30, 65.35, 58.51, 53.60, 50.89, 40.94, 27.96, 27.42, 23.68, 13.93. HPLC 99%, RT 4.275 min. MS (ESI) <i>m</i>/<i>z</i> 453.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 8-(4-(4-((2-Isopropylbenzo[<i>d</i>]thiazol-5-yl)oxy)butyl)piperazin-1-yl)-3,4-dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazine (<b>51</b>)</h4><div class="NLM_p last">Compound <b>51</b> (69 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-isopropylbenzo[<i>d</i>]thiazol-5-ol (<b>17</b>) and 1,4-dibromobutane, yield 69%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.67 (d, <i>J</i> = 8.8 Hz, 1H), 7.46 (d, <i>J</i> = 2.4 Hz, 1H), 6.98 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 6.69 (t, <i>J</i> = 8.0 Hz, 1H), 6.38 (dd, <i>J</i> = 8.0, 1.4 Hz, 1H), 6.33 (dd, <i>J</i> = 7.9, 1.4 Hz, 1H), 4.34–4.27 (m, 2H), 4.06 (t, <i>J</i> = 6.1 Hz, 2H), 3.70 (bs, 1H), 3.44–3.33 (m, 3H), 3.16 (bs, 4H), 2.77 (bs, 4H), 2.62–2.54 (m, 2H), 1.93–1.75 (m, 4H), 1.47 (d, <i>J</i> = 6.9 Hz, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 180.01, 158.23, 154.53, 141.18, 136.67, 134.19, 126.53, 121.87, 120.99, 115.22, 110.97, 108.67, 106.09, 68.13, 65.36, 58.32, 53.40, 50.33, 40.91, 34.24, 27.29, 23.26, 23.02. HPLC 99%, RT 4.529 min. MS (ESI) <i>m</i>/<i>z</i> 467.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 5-(4-(4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl)piperazin-1-yl)butoxy)-2-ethylbenzo[<i>d</i>]thiazole (<b>52</b>)</h4><div class="NLM_p last">Compound <b>52</b> (58 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-ethylbenzo[<i>d</i>]thiazol-5-ol (<b>16</b>) and 1,4-dibromobutane, yield 63%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.66 (d, <i>J</i> = 8.8 Hz, 1H), 7.46 (d, <i>J</i> = 2.4 Hz, 1H), 6.98 (dd, <i>J</i> = 8.8, 2.4 Hz, 1H), 6.77 (t, <i>J</i> = 8.1 Hz, 1H), 6.58 (dd, <i>J</i> = 8.2, 1.1 Hz, 1H), 6.54 (dd, <i>J</i> = 8.0, 1.2 Hz, 1H), 4.36–4.28 (m, 2H), 4.28–4.21 (m, 2H), 4.06 (t, <i>J</i> = 6.3 Hz, 2H), 3.12 (dd, <i>J</i> = 15.2, 7.6 Hz, 6H), 2.66 (bs, 4H), 2.53–2.44 (m, 2H), 1.93–1.81 (m, 2H), 1.80–1.67 (m, 2H), 1.46 (t, <i>J</i> = 7.6 Hz, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 174.90, 158.34, 154.66, 144.20, 141.98, 136.59, 126.80, 121.79, 120.76, 115.22, 111.98, 110.82, 106.07, 68.27, 64.47, 64.12, 58.46, 53.53, 50.91, 27.95, 27.38, 23.65, 13.92. HPLC 99%, RT 4.502 min. MS (ESI) <i>m</i>/<i>z</i> 454.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 5-(4-(4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl)piperazin-1-yl)butoxy)-2-isopropylbenzo[<i>d</i>]thiazole (<b>53</b>)</h4><div class="NLM_p last">Compound <b>53</b> (53 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-isopropylbenzo[<i>d</i>]thiazol-5-ol (<b>17</b>) and 1,4-dibromobutane, yield 67%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.67 (d, <i>J</i> = 8.7 Hz, 1H), 7.47 (d, <i>J</i> = 2.4 Hz, 1H), 6.98 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H), 6.70 (t, <i>J</i> = 7.9 Hz, 1H), 6.41–6.36 (m, 1H), 6.35–6.30 (m, 1H), 4.35–4.28 (m, 2H), 4.06 (t, <i>J</i> = 6.1 Hz, 2H), 3.45–3.34 (m, 3H), 3.15 (bs, 4H), 2.75 (bs, 4H), 2.61–2.52 (m, 2H), 1.93–1.74 (m, 4H), 1.51–1.43 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 180.01, 158.26, 154.54, 141.26, 136.69, 134.18, 126.52, 121.87, 120.99, 115.24, 110.94, 108.68, 106.09, 68.17, 65.37, 58.36, 53.44, 50.44, 40.92, 34.25, 27.32, 23.35, 23.03. HPLC 99%, RT 4.333 min. MS (ESI) <i>m</i>/<i>z</i> 468.1 [M + H]<sup>+</sup>. HRMS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>26</sub>H<sub>34</sub>N<sub>3</sub>O<sub>3</sub>S 468.2322, found 468.2317.</div></div><div id="sec4_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 5-(4-(4-(2,3-Dichlorophenyl)piperidin-1-yl)butoxy)-<i>N</i>-methylbenzo[<i>d</i>]thiazol-2-amine (<b>54</b>)</h4><div class="NLM_p last">Compound <b>54</b> (51 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-(methylamino)benzo[<i>d</i>]thiazol-5-ol (<b>22</b>) and 1,4-dibromobutane, yield 53%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.42 (d, <i>J</i> = 8.6 Hz, 1H), 7.34 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.29–7.23 (m, 1H), 7.19 (t, <i>J</i> = 7.9 Hz, 1H), 7.07 (d, <i>J</i> = 2.4 Hz, 1H), 6.68 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 4.02 (t, <i>J</i> = 5.9 Hz, 2H), 3.50 (d, <i>J</i> = 11.8 Hz, 2H), 3.36–3.26 (m, 1H), 3.08 (s, 3H), 2.93–2.85 (m, 2H), 2.72–2.57 (m, 3H), 2.39–3.25 (m, 2H), 2.08–1.93 (m, 4H), 1.92–1.82 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.76, 158.25, 153.89, 133.30, 131.72, 128.72, 127.85, 125.57, 125.48, 122.27, 121.20, 110.42, 104.26, 67.76, 58.16, 55.86, 53.85, 38.77, 31.81, 30.47, 27.16, 22.62. HPLC 99%, RT 4.607 min. MS (ESI) <i>m</i>/<i>z</i> 464.0 [M + H]<sup>+</sup>. HRMS <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>23</sub>H<sub>28</sub>Cl<sub>2</sub>N<sub>3</sub>OS 464.1330, found 464.1319.</div></div><div id="sec4_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>N</i>-Methyl-5-(4-(4-(2-methylquinolin-8-yl)piperazin-1-yl)butoxy)benzo[<i>d</i>]thiazol-2-amine (<b>55</b>)</h4><div class="NLM_p last">Compound <b>55</b> (57 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-(methylamino)benzo[<i>d</i>]thiazol-5-ol (<b>22</b>) and 1,4-dibromobutane, yield 55%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.00 (d, <i>J</i> = 8.4 Hz, 1H), 7.43 (d, <i>J</i> = 8.5 Hz, 2H), 7.37 (t, <i>J</i> = 7.7 Hz, 1H), 7.26 (d, <i>J</i> = 8.4 Hz, 1H), 7.14–7.07 (m, 2H), 6.71 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 5.47 (s, 1H), 4.05 (t, <i>J</i> = 6.0 Hz, 2H), 3.71 (bs, 4H), 3.20 (bs, 4H), 3.08 (s, 3H), 2.94–2.80 (m, 2H), 2.73 (s, 3H), 2.09–1.97 (m, 2H), 1.97–1.83 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.72, 158.25, 157.17, 153.91, 147.44, 141.81, 136.91, 127.84, 125.89, 122.32, 122.28, 121.86, 121.19, 116.47, 110.45, 104.24, 67.77, 58.06, 52.93, 50.24, 31.80, 27.12, 26.02, 22.40. HPLC 99%, RT 4.086 min. MS (ESI) <i>m</i>/<i>z</i> 462.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 5-(4-(4-(3,4-Dihydro-2<i>H</i>-benzo[<i>b</i>][1,4]oxazin-8-yl)piperazin-1-yl)butoxy)-<i>N</i>-methylbenzo[<i>d</i>]thiazol-2-amine (<b>56</b>)</h4><div class="NLM_p last">Compound <b>56</b> (74 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-(methylamino)benzo[<i>d</i>]thiazol-5-ol (<b>22</b>) and 1,4-dibromobutane, yield 59%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.42 (d, <i>J</i> = 8.6 Hz, 1H), 7.06 (d, <i>J</i> = 2.4 Hz, 1H), 6.69 (dd, <i>J</i> = 13.0, 5.1 Hz, 2H), 6.39–6.31 (m, 2H), 4.31–4.24 (m, 2H), 4.02 (t, <i>J</i> = 5.9 Hz, 2H), 3.804 (bs, 1H), 3.46 (t, <i>J</i> = 4.5 Hz, 4H), 3.43–3.37 (m, 3H), 3.35–3.12 (m, 4H), 3.08 (s, 3H), 3.04–2.97 (m, 2H), 2.11 (dt, <i>J</i> = 15.5, 7.7 Hz, 2H), 1.93–1.82 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.81, 158.06, 153.84, 139.38, 136.41, 134.41, 122.39, 121.24, 111.72, 110.27, 108.82, 104.23, 67.45, 65.45, 57.55, 52.55, 47.95, 40.82, 31.80, 26.80, 21.54. HPLC 99%, RT 3.652 min. MS (ESI) <i>m</i>/<i>z</i> 454.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 5-(4-(4-(2,3-Dihydrobenzo[<i>b</i>][1,4]dioxin-5-yl)piperazin-1-yl)butoxy)-<i>N</i>-methylbenzo[<i>d</i>]thiazol-2-amine (<b>57</b>)</h4><div class="NLM_p last">Compound <b>57</b> (86 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-(methylamino)benzo[<i>d</i>]thiazol-5-ol (<b>22</b>) and 1,4-dibromobutane, yield 61%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.42 (d, <i>J</i> = 8.6 Hz, 1H), 7.09 (d, <i>J</i> = 2.4 Hz, 1H), 6.77 (t, <i>J</i> = 8.1 Hz, 1H), 6.70 (dd, <i>J</i> = 8.6, 2.4 Hz, 1H), 6.62–6.57 (m, 1H), 6.53 (dd, <i>J</i> = 8.0, 1.2 Hz, 1H), 5.55 (s, 1H), 4.35–4.28 (m, 2H), 4.27–4.21 (m, 2H), 4.02 (t, <i>J</i> = 5.7 Hz, 2H), 3.19 (bs, 4H), 3.08 (s, 3H), 2.80 (bs, 4H), 2.60 (t, <i>J</i> = 6.9 Hz, 2H), 1.90–1.75 (m, 4H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.74, 158.40, 153.88, 144.22, 141.44, 136.55, 122.07, 121.13, 120.83, 112.24, 110.94, 110.50, 104.21, 68.01, 64.48, 64.10, 58.25, 53.27, 50.21, 31.80, 27.29, 23.15. HPLC 99%, RT 3.968 min. MS (ESI) <i>m</i>/<i>z</i> 455.0 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 6-(4-(4-(2,3-Dichlorophenyl)piperidin-1-yl)butoxy)-2-methylbenzo[<i>d</i>]thiazole (<b>58</b>)</h4><div class="NLM_p last">Compound <b>58</b> (52 mg) was prepared as white solid via the same procedure as preparing <b>1</b> starting from 2-methylbenzo[<i>d</i>]thiazol-6-ol and 1,4-dibromobutane, yield 58%. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.81 (d, <i>J</i> = 8.9 Hz, 1H), 7.36 (d, <i>J</i> = 7.9 Hz, 1H), 7.31 (d, <i>J</i> = 7.7 Hz, 1H), 7.28 (d, <i>J</i> = 2.5 Hz, 1H), 7.21 (t, <i>J</i> = 7.9 Hz, 1H), 7.00 (dd, <i>J</i> = 8.9, 2.5 Hz, 1H), 4.07 (t, <i>J</i> = 5.8 Hz, 2H), 3.73 (d, <i>J</i> = 11.5 Hz, 2H), 3.42 (ddd, <i>J</i> = 12.3, 9.0, 3.3 Hz, 1H), 3.18–3.08 (m, 2H), 2.92 (t, <i>J</i> = 11.4 Hz, 2H), 2.78 (s, 3H), 2.69–2.51 (m, 2H), 2.26–2.15 (m, 2H), 2.07 (d, <i>J</i> = 13.8 Hz, 2H), 1.99–1.89 (m, 2H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 164.82, 156.32, 148.22, 142.24, 137.07, 133.48, 131.53, 129.34, 128.20, 125.68, 122.99, 115.36, 105.25, 67.63, 57.66, 53.44, 37.50, 39.82, 28.70, 26.82, 21.39, 20.12. HPLC 99%, RT 4.712 min. MS (ESI) <i>m</i>/<i>z</i> 449.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 5-Chloro-7-((4-(pyridin-2-yl)piperazin-1-yl)methyl)quinolin-8-ol (<b>59</b>)</h4><div class="NLM_p last">Compound <b>59</b> was purchased from <a href="http://www.molport.com" class="extLink">www.molport.com</a> from the supplier Vitas-M laboratory Ltd. (catalogue no. STK973418) and was also obtained from David Sibley and Benjamin Free at NIH. The identity and purity of compound <b>59</b> was determined by LC-MS.</div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Experimental Procedures for in Vitro Pharmacology Assays</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> General Procedures</h4><div class="NLM_p last">Experimental procedures for the secondary radioligand binding for the GPCRs listed in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a> are available online through the Psychoactive Drug Screening Program (PDSP) Web site: <a href="http://pdsp.med.unc.edu/" class="extLink">http://pdsp.med.unc.edu/</a>. The PDSP Assay Protocol book is freely available at <a href="http://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf" class="extLink">http://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf</a>. Protocols of the cAMP biosensor, β-arrestin recruitment Tango, D2R radioligand binding, and bioluminescent resonance energy transfer (BRET) assays are detailed below. Human D2L receptors were used for these assays except the BRET assay, whereas mouse D2L receptors were used.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> D2R Gi/o-Mediated cAMP Inhibition Assay</h4><div class="NLM_p last">D2R Gi/o-mediated cAMP inhibition assays were performed in parallel with D2R β-arrestin recruitment Tango assays. HEK293T cells coexpressing the cAMP biosensor GloSensor-22F (Promega) and hD<sub>2L</sub> receptors were seeded (15000 cells/40 μL/well) into white 384-well clear-bottom, tissue culture plates in DMEM containing 1% dialyzed FBS. Next day, drug dilutions were made in HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4. The same drug dilutions used for the D2R Gi/o-mediated cAMP inhibition assays were also used for D2R β-arrestin recruitment Tango assay, which was performed in parallel. Next, media was removed on 384-well plates and 20 μL of drug buffer (HBSS, 20 mM HEPES, pH 7.4) was added per well and allowed to equilibrate for at least 15 min room temperarture. To start the assay, cells were treated with 10 μL per well of 3× drug diluted in HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4, using a FLIPR (Molecular Devices). After 15 min, cAMP accumulation was initiated by addition of 10 μL/well of 0.3 μM isoproterenol (final concentration) in GloSensor reagent. Luminescence per well per second was read on a Wallac TriLux microbeta plate counter. Data were normalized to maximum cAMP inhibition by quinpirole (100%) and basal cAMP accumulation by isoproterenol (0%). Data were analyzed using the sigmoidal dose–response function built into GraphPad Prism 5.0. Notably, HEK293T cells expressing the GloSensor-22F alone (no hD2R) were assayed in parallel and displayed no inhibition of isoproterenol-stimulated cAMP, either by quinpirole or by the test compounds, suggesting that the effect observed in hD<sub>2L</sub>-expressing cells was due to compound acting via the recombinant receptor (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b01208/suppl_file/jm6b01208_si_001.pdf" class="ext-link">Figure S1</a>).</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> D2R β-Arrestin Recruitment Tango Assay</h4><div class="NLM_p last">Recruitment of β-arrestin to agonist-stimulated D<sub>2L</sub> receptors was performed using a previously described “Tango”-type assay.<a onclick="showRef(event, 'ref41 ref52'); return false;" href="javascript:void(0);" class="ref ref41 ref52">(41, 52)</a> Briefly, HTLA cells stably expressing β-arrestin-TEV protease and a tetracycline transactivator-driven luciferase were plated in 15 cm dishes in DMEM containing 10% FBS and transfected (via calcium phosphate) with 10 μg of a D<sub>2</sub>V<sub>2</sub>-TCS-tTA construct. The next day, cells were plated in white, clear-bottom, 384-well plates (Greiner; 15000 cells/well, 40 μL/well) in DMEM containing 1% dialyzed FBS. The following day, media was decanted and exchanged for fresh DMEM media containing 1% dialyzed FBS. The same drug dilutions used for the D2R Gi/o-mediated cAMP inhibition assay were used for the Tango assay. Cells were treated with 20 μL/well of drug using a FLIPR and after at least 20 h, the medium was removed and replaced with 1× BriteGlo reagent (Promega), and luminescence per well was read using a TriLux plate reader (1 s/well). Data were normalized to vehicle (0%) and quinpirole (100%) controls and analyzed using the sigmoidal dose–response function built into GraphPad Prism 5.0.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> HEK-D<sub>2</sub> Membrane Preparation and Radioligand Binding Assay</h3><div class="NLM_p">HEK-D<sub>2</sub> membrane preparation. HEK293T cells were transfected in 15 cm dishes (in DMEM containing 10% FBS) with human D2<sub>L</sub> similarly described for D2 Gi/o-mediated cAMP inhibition assays. After 48 h transfection, cells were washed with PBS, pH 7.4, and lysed with cold hypotonic lysis buffer (1 mM HEPES, 2 mM EDTA, pH 7.4), resuspended, and centrifuged at 30000<i>g</i> for 30 min. The supernatant was removed, and membrane pellets were resuspended in standard binding buffer (50 mM Tris-HCl, 10 mM MgCl<sub>2</sub>, 0.5 mM EDTA, pH 7.4), mechanically homogenized, aliquoted, and stored at −80 °C until used for radioligand binding assays.</div><div class="NLM_p">Membranes prepared as above were resuspended, and 50 μL was added to each well of a polypropylene 96-well plate containing (per well) 50 μL of 0.1 nM [<sup>3</sup>H]<i>N</i>-methylspiperone (final concentration) and reference or test ligands at various concentrations ranging from 10 pM to 32 μM (final concentrations). After a 2.5 h incubation in the dark at room temperature, the reactions were harvested onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac) and washed three times with ice-cold 50 mM Tris, pH 7.4, using a PerkinElmer Filtermate 96-well harvester. Filters were dried and placed on a hot plate (100 °C), and Melitilex-A (Wallac) scintillant was applied. Filters were allowed to cool and counted on a Wallac TriLux microbeta counter (1 min/well). Bound [<sup>3</sup>H]<i>N</i>-methylspiperone binding to filtered membranes was plotted as a function of log[ligand], and the data were analyzed using One-Site-Fit <i>K</i><sub>i</sub> model built into Prism 5.0 (GraphPad software).</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Bioluminescence Resonance Energy Transfer (BRET) Arrestin Assay.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></h4><div class="NLM_p last">To measure D2R-mediated β-Arrestin recruitment, HEK293T cells were cotransfected in a 1:1:15 ratio with mouse D2Long containing a C-terminal renilla luciferase (RLuc8), GRK2, and Venus-tagged N-terminal β-arrestin2. Next day, transfected cells were plated in poly lysine coated 96-well white clear bottom cell culture plates in plating media (DMEM + 1% dialyzed FBS) at a density of 40000–50000 cells in 200 μL per well and incubated overnight. The next day, media was decanted and cells were washed twice with 60 uL of drug buffer (1× HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4). Then 60 μL of drug buffer was added per well, and drug stimulation was initiated with addition of 30 uL of drug (3×) per well. Plates were incubated at room temperature for at least 5 min before addition of 10 μL per well of RLuc substrate, coelenterazine h (Promega, 5 μM final concentration). Plates were read for both luminescence at 485 nm and fluorescent eYFP emission at 530 nm for 1 s per well using a Mithras LB940. The ratio of eYFP/RLuc was calculated per well, and the net BRET ratio was calculated by subtracting the eYFP/RLuc per well from the eYFP/RLuc ratio in wells without Venus-β-arrestin present. The net BRET ratio was plotted as a function of drug concentration using Graphpad Prism 5 (Graphpad Software Inc., San Diego, CA). Data were normalized to % quinpirole or dopamine stimulation and analyzed using nonlinear regression log(agonist) vs response.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> DiscoverX D2R β-Arrestin-2 Recruitment Assay</h4><div class="NLM_p last">β-Arrestin-2 recruitment was measured by using the PathHunter enzyme complementation assay (DiscoverX, 93-0579E2CPM2M), which uses CHO-K1 cells stably expressing the human D2R<sub>long</sub> and β-arrestin-2 fused to a split β-galactosidase enzyme. Assays were performed exactly according to the manufacturer’s instructions, except drugs were diluted in drug buffer used for all other assays (1× HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4). Cells were incubated with drug for 90 min at 37 °C as per the manufacturer’s instructions. Luminescence was read one second per well on a Wallac TriLux microbeta plate counter. Data were normalized to maximum β-arrestin-2 recruitment by quinpirole (100%) and analyzed using nonlinear regression log(agonist) vs response.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> BRET Gαi1-γ2 Dissociation Assay</h4><div class="NLM_p last">To measure D2R-mediated Gαi1-γ2 dissociation, HEK293T cells were cotransfected in a 1:5:5:5 ratio of Gαi1-RLuc, Gβ1, GFP<sub>10</sub>-Gγ2, and human D2R<sub>long</sub>, respectively. Gαi1-RLuc, Gβ1, and GFP<sub>210</sub>-Gγ2 constructs were generously provided by Dr. Michel Bouvier. Cells were plated and assays were performed exactly similar to the BRET arrestin assay, except the substrate used was Coelenterazine 400a (Nanolight, 5 μM final concentration). Plates were read after 5 min drug incubation measuring luminescence at 400 nm and fluorescent GFP<sub>10</sub> emission at 515 nm for 1 s per well using a Mithras LB940. The ratio of GFP<sub>10</sub>/RLuc was calculated per well and plotted as a function of drug concentration using Graphpad Prism 5 (Graphpad Software Inc., San Diego, CA). Data were normalized to % quinpirole stimulation and analyzed using nonlinear regression log(agonist) vs response.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i78"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01208">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21535" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21535" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01208" class="ext-link">10.1021/acs.jmedchem.6b01208</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline"><sup>1</sup>H and <sup>13</sup>C NMR spectra of compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b>. <i>K</i><sub>d</sub> and <i>B</i><sub>MAX</sub> estimates comparing D2R GloSensor and D2R Tango cell types. GloSensor cAMP inhibition with no D2R expressed. D2R G protein antagonism by compound <b>1</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01208/suppl_file/jm6b01208_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01208/suppl_file/jm6b01208_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01208/suppl_file/jm6b01208_si_001.pdf">jm6b01208_si_001.pdf (3.89 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01208/suppl_file/jm6b01208_si_002.csv">jm6b01208_si_002.csv (2.63 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01208" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18108" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18108" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bryan L. Roth</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and National Institute of Mental Health Psychoactive
Drug Screening Program, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#83e1f1fae2eddcf1ecf7ebc3eee6e7adf6ede0ade6e7f6"><span class="__cf_email__" data-cfemail="2e4c5c574f40715c415a466e434b4a005b404d004b4a5b">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Jin</span> - <span class="hlFld-Affiliation affiliation">Departments
of Pharmacological Sciences and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New
York, New York 10029, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2c46454d42024645426c415f5f4102494859"><span class="__cf_email__" data-cfemail="fa90939b94d4909394ba97898997d49f9e8f">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin Chen</span> - <span class="hlFld-Affiliation affiliation">Departments
of Pharmacological Sciences and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New
York, New York 10029, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John D. McCorvy</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and National Institute of Mental Health Psychoactive
Drug Screening Program, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew G. Fischer</span> - <span class="hlFld-Affiliation affiliation">Departments
of Pharmacological Sciences and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New
York, New York 10029, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kyle V. Butler</span> - <span class="hlFld-Affiliation affiliation">Departments
of Pharmacological Sciences and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New
York, New York 10029, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yudao Shen</span> - <span class="hlFld-Affiliation affiliation">Departments
of Pharmacological Sciences and Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue, New
York, New York 10029, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>X.C. and J.D.M contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5950-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41436" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41436" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The research described here was supported by the grant U19MH082441 (to J.J. and B.L.R.) from the National Institutes of Health.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i81" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i81"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i82" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i82"> Abbreviations Used</h2><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein-coupled receptor</p></td></tr><tr><td class="NLM_term">SFSR</td><td class="NLM_def"><p class="first last">structure–functional selectivity relationships</p></td></tr><tr><td class="NLM_term">D2R</td><td class="NLM_def"><p class="first last">dopamine D<sub>2</sub> receptor</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">LHS</td><td class="NLM_def"><p class="first last">left-hand side</p></td></tr><tr><td class="NLM_term">RHS</td><td class="NLM_def"><p class="first last">right-hand side</p></td></tr><tr><td class="NLM_term">BRET</td><td class="NLM_def"><p class="first last">bioluminescence resonance energy transfer</p></td></tr><tr><td class="NLM_term">GRK2</td><td class="NLM_def"><p class="first last">G protein-coupled receptor kinase 2</p></td></tr><tr><td class="NLM_term">D1R</td><td class="NLM_def"><p class="first last">dopamine D<sub>1</sub> receptor</p></td></tr><tr><td class="NLM_term">D3R</td><td class="NLM_def"><p class="first last">dopamine D<sub>3</sub> receptor</p></td></tr><tr><td class="NLM_term">D4R</td><td class="NLM_def"><p class="first last">dopamine D<sub>4</sub> receptor</p></td></tr><tr><td class="NLM_term">D5R</td><td class="NLM_def"><p class="first last">dopamine D<sub>5</sub> receptor</p></td></tr><tr><td class="NLM_term">5-HT</td><td class="NLM_def"><p class="first last">5-hydroxytryptamine</p></td></tr><tr><td class="NLM_term">DAT</td><td class="NLM_def"><p class="first last">dopamine transporter</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term">H1</td><td class="NLM_def"><p class="first last">histamine receptor 1</p></td></tr><tr><td class="NLM_term">H2</td><td class="NLM_def"><p class="first last">histamine receptor 2</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57835" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57835" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 52 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Hisahara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimohama, S.</span><span> </span><span class="NLM_article-title">Dopamine receptors and Parkinson’s Disease</span> <span class="citation_source-journal">Int. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">403039</span><span class="refDoi"> DOI: 10.1155/2011/403039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1155%2F2011%2F403039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=25954517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A280%3ADC%252BC2MfitVyqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=403039&author=S.+Hisaharaauthor=S.+Shimohama&title=Dopamine+receptors+and+Parkinson%E2%80%99s+Disease&doi=10.1155%2F2011%2F403039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptors and Parkinson's disease</span></div><div class="casAuthors">Hisahara Shin; Shimohama Shun</div><div class="citationInfo"><span class="NLM_cas:title">International journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">403039</span>
        ISSN:<span class="NLM_cas:issn">2090-2069</span>.
    </div><div class="casAbstract">Parkinson's disease (PD) is a progressive extrapyramidal motor disorder.  Pathologically, this disease is characterized by the selective dopaminergic (DAergic) neuronal degeneration in the substantia nigra.  Correcting the DA deficiency in PD with levodopa (L-dopa) significantly attenuates the motor symptoms; however, its effectiveness often declines, and L-dopa-related adverse effects emerge after long-term treatment.  Nowadays, DA receptor agonists are useful medication even regarded as first choice to delay the starting of L-dopa therapy.  In advanced stage of PD, they are also used as adjunct therapy together with L-dopa.  DA receptor agonists act by stimulation of presynaptic and postsynaptic DA receptors.  Despite the usefulness, they could be causative drugs for valvulopathy and nonmotor complication such as DA dysregulation syndrome (DDS).  In this paper, physiological characteristics of DA receptor familyare discussed.  We also discuss the validity, benefits, and specific adverse effects of pharmaceutical DA receptor agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOLp2jGEspDyA3UY9EwTNrfW6udTcc2ebEn8junpaVLrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfitVyqug%253D%253D&md5=fbf76c98b2eb9d42dbecb96a7273481b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1155%2F2011%2F403039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F403039%26sid%3Dliteratum%253Aachs%26aulast%3DHisahara%26aufirst%3DS.%26aulast%3DShimohama%26aufirst%3DS.%26atitle%3DDopamine%2520receptors%2520and%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DInt.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D2011%26spage%3D403039%26doi%3D10.1155%2F2011%2F403039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Gray, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">The pipeline and future of drug development in schizophrenia</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">904</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span><span class="refDoi"> DOI: 10.1038/sj.mp.4002062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fsj.mp.4002062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=17667958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVyjtr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=904-922&author=J.+A.+Grayauthor=B.+L.+Roth&title=The+pipeline+and+future+of+drug+development+in+schizophrenia&doi=10.1038%2Fsj.mp.4002062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The pipeline and future of drug development in schizophrenia</span></div><div class="casAuthors">Gray, J. A.; Roth, B. L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">904-922</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  While the current antipsychotic medications have profoundly impacted the treatment of schizophrenia over the past 50 years, the newer atypical antipsychotics have not fulfilled initial expectations, and enormous challenges remain in long-term treatment of this debilitating disease.  In particular, improved treatment of the neg. symptoms and cognitive dysfunction in schizophrenia which greatly impact overall morbidity is needed.  In this review we will briefly discuss the current pipeline of drugs for schizophrenia, outlining many of the strategies and targets currently under investigation for the development of new schizophrenia drugs.  Many of these compds. have great potential as augmenting agents in the treatment of neg. symptoms and cognition.  In addn., we will highlight the importance of developing new paradigms for drug discovery in schizophrenia and call for an increased role of academic scientists in discovering and validating novel drug targets.  Indeed, recent breakthroughs in genetic studies of schizophrenia are allowing for the development of hypothesis-driven approaches for discovering possible disease-modifying drugs for schizophrenia.  Thus, this is an exciting and pivotal time for the development of truly novel approaches to drug development and treatment of complex disorders like schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTZ3qO-W1xFLVg90H21EOLACvtfcHk0livaq_Ooo0fhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVyjtr3L&md5=f0b2e1ece99057228282fa1ad71855b1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4002062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4002062%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520pipeline%2520and%2520future%2520of%2520drug%2520development%2520in%2520schizophrenia%26jtitle%3DMol.%2520Psychiatry%26date%3D2007%26volume%3D12%26spage%3D904%26epage%3D922%26doi%3D10.1038%2Fsj.mp.4002062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Beaulieu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinoza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span> </span><span class="NLM_article-title">Dopamine receptors - IUPHAR Review 13</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1111/bph.12906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1111%2Fbph.12906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=25671228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1-23&author=J.+M.+Beaulieuauthor=S.+Espinozaauthor=R.+R.+Gainetdinov&title=Dopamine+receptors+-+IUPHAR+Review+13&doi=10.1111%2Fbph.12906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptors - IUPHAR Review 13</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Espinoza, Stefano; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-23</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The variety of physiol. functions controlled by dopamine in the brain and periphery is mediated by the D1, D2, D3, D4 and D5 dopamine GPCRs.  Drugs acting on dopamine receptors are significant tools for the management of several neuropsychiatric disorders including schizophrenia, bipolar disorder, depression and Parkinson's disease.  Recent investigations of dopamine receptor signalling have shown that dopamine receptors, apart from their canonical action on cAMP-mediated signalling, can regulate a myriad of cellular responses to fine-tune the expression of dopamine-assocd. behaviors and functions.  Such signalling mechanisms may involve alternate G protein coupling or non-G protein mechanisms involving ion channels, receptor tyrosine kinases or proteins such as β-arrestins that are classically involved in GPCR desensitization.  Another level of complexity is the growing appreciation of the physiol. roles played by dopamine receptor heteromers.  Applications of new in vivo techniques have significantly furthered the understanding of the physiol. functions played by dopamine receptors.  Here we provide an update of the current knowledge regarding the complex biol., signalling, physiol. and pharmacol. of dopamine receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1fpdKAWrR5rVg90H21EOLACvtfcHk0livaq_Ooo0fhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ&md5=7f15533abc8fb6aa76a4ec41072b6219</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fbph.12906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12906%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DEspinoza%26aufirst%3DS.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DDopamine%2520receptors%2520-%2520IUPHAR%2520Review%252013%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D1%26epage%3D23%26doi%3D10.1111%2Fbph.12906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Beaulieu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span> </span><span class="NLM_article-title">The physiology, signaling, and pharmacology of dopamine receptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">182</span><span class="NLM_x">–</span> <span class="NLM_lpage">217</span><span class="refDoi"> DOI: 10.1124/pr.110.002642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1124%2Fpr.110.002642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=21303898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjslGis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=182-217&author=J.+M.+Beaulieuauthor=R.+R.+Gainetdinov&title=The+physiology%2C+signaling%2C+and+pharmacology+of+dopamine+receptors&doi=10.1124%2Fpr.110.002642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The physiology, signaling, and pharmacology of dopamine receptors</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-217</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiol. functions of the catecholaminergic neurotransmitter dopamine, ranging from voluntary movement and reward to hormonal regulation and hypertension.  Pharmacol. agents targeting dopaminergic neurotransmission have been clin. used in the management of several neurol. and psychiatric disorders, including Parkinson's disease, schizophrenia, bipolar disorder, Huntington's disease, attention deficit hyperactivity disorder (ADHD1), and Tourette's syndrome.  Numerous advances have occurred in understanding the general structural, biochem., and functional properties of dopamine receptors that have led to the development of multiple pharmacol. active compds. that directly target dopamine receptors, such as antiparkinson drugs and antipsychotics.  Recent progress in understanding the complex biol. of dopamine receptor-related signal transduction mechanisms has revealed that, in addn. to their primary action on cAMP-mediated signaling, dopamine receptors can act through diverse signaling mechanisms that involve alternative G protein coupling or through G protein-independent mechanisms via interactions with ion channels or proteins that are characteristically implicated in receptor desensitization, such as β-arrestins.  One of the future directions in managing dopamine-related pathol. conditions may involve a transition from the approaches that directly affect receptor function to a precise targeting of postreceptor intracellular signaling modalities either directly or through ligand-biased signaling pharmacol.  In this comprehensive review, we discuss dopamine receptor classification, their basic structural and genetic organization, their distribution and functions in the brain and the periphery, and their regulation and signal transduction mechanisms.  In addn., we discuss the abnormalities of dopamine receptor expression, function, and signaling that are documented in human disorders and the current pharmacol. and emerging trends in the development of novel therapeutic agents that act at dopamine receptors and/or on related signaling events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplp84qmbSbA7Vg90H21EOLACvtfcHk0lguy8Z6DATupg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjslGis70%253D&md5=53e6841062c98abe60c732692109e498</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.002642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.002642%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DThe%2520physiology%252C%2520signaling%252C%2520and%2520pharmacology%2520of%2520dopamine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D182%26epage%3D217%26doi%3D10.1124%2Fpr.110.002642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Noble, E. P.</span><span> </span><span class="NLM_article-title">D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes</span> <span class="citation_source-journal">Am. J. Med. Genet., Part B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">116B</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1002/ajmg.b.10005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1002%2Fajmg.b.10005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A280%3ADC%252BD38jjt12msg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116B&publication_year=2003&pages=103-125&author=E.+P.+Noble&title=D2+dopamine+receptor+gene+in+psychiatric+and+neurologic+disorders+and+its+phenotypes&doi=10.1002%2Fajmg.b.10005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes</span></div><div class="casAuthors">Noble Ernest P</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">116B</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-25</span>
        ISSN:<span class="NLM_cas:issn">1552-4841</span>.
    </div><div class="casAbstract">The D2 dopamine receptor (DRD2) has been one of the most extensively investigated gene in neuropsychiatric disorders.  After the first association of the TaqI A DRD2 minor (A1) allele with severe alcoholism in 1990, a large number of international studies have followed.  A meta-analysis of these studies of Caucasians showed a significantly higher DRD2 A1 allelic frequency and prevalence in alcoholics when compared to controls.  Variants of the DRD2 gene have also been associated with other addictive disorders including cocaine, nicotine and opioid dependence and obesity.  It is hypothesized that the DRD2 is a reinforcement or reward gene.  The DRD2 gene has also been implicated in schizophrenia, posttraumatic stress disorder, movement disorders and migraine.  Phenotypic differences have been associated with DRD2 variants.  These include reduced D2 dopamine receptor numbers and diminished glucose metabolism in brains of subjects who carry the DRD2 A1 allele.  In addition, pleiotropic effects of DRD2 variants have been observed in neurophysiologic, neuropsychologic, stress response, personality and treatment outcome characteristics.  The involvement of the DRD2 gene in certain neuropsychiatric disorders opens up the potential of a targeted pharmacogenomic approach to the treatment of these disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLYoZ5HMJynTMsgLhIoICsfW6udTcc2eaq1rwmnSV3aLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38jjt12msg%253D%253D&md5=c9e10ec0cb64728971d2fcd5ecc33702</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fajmg.b.10005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajmg.b.10005%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DE.%2BP.%26atitle%3DD2%2520dopamine%2520receptor%2520gene%2520in%2520psychiatric%2520and%2520neurologic%2520disorders%2520and%2520its%2520phenotypes%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%252C%2520Part%2520B%26date%3D2003%26volume%3D116B%26spage%3D103%26epage%3D125%26doi%3D10.1002%2Fajmg.b.10005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Fan, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, E. J.</span><span> </span><span class="NLM_article-title">D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD</span> <span class="citation_source-journal">Neurobiol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span><span class="refDoi"> DOI: 10.1016/j.nbd.2009.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.nbd.2009.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=19840852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVGms7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=228-236&author=X.+L.+Fanauthor=M.+Xuauthor=E.+J.+Hess&title=D2+dopamine+receptor+subtype-mediated+hyperactivity+and+amphetamine+responses+in+a+model+of+ADHD&doi=10.1016%2Fj.nbd.2009.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD</span></div><div class="casAuthors">Fan, Xue-Liang; Xu, Ming; Hess, Ellen J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">228-236</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Low doses of psychostimulants produce beneficial behavioral effects in ADHD patients but the mechanisms underlying the response are not understood.  Here we use the hyperactive mouse mutant coloboma to identify D2-like dopamine receptor subtypes that mediate the hyperactivity and response to amphetamine; we have previously demonstrated that D1-like dopamine receptors are not involved.  Targeted deletion of the D2, but not the D3 or the D4, dopamine receptor in coloboma mice eliminated the hyperactivity; depleting D2 dopamine receptors also restored the excess dopamine overflow that may drive the hyperactivity to normal concns.  Similar to its effects on ADHD patients, amphetamine reduced the hyperactivity of coloboma mice.  The D2 dopamine receptor-selective antagonist L-741,626, but not D3 or D4 dopamine receptor-selective antagonists, blocked the amphetamine-induced redn. in locomotor activity.  Thus, the D2 dopamine receptor subtype mediates both the hyperactivity and response to amphetamine, suggesting a specific target for novel therapeutics in ADHD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEUwUaV6iqprVg90H21EOLACvtfcHk0lguy8Z6DATupg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVGms7vI&md5=beac1924be92f794c4ead36e58d5ef19</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2009.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2009.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DX.%2BL.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DE.%2BJ.%26atitle%3DD2%2520dopamine%2520receptor%2520subtype-mediated%2520hyperactivity%2520and%2520amphetamine%2520responses%2520in%2520a%2520model%2520of%2520ADHD%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2010%26volume%3D37%26spage%3D228%26epage%3D236%26doi%3D10.1016%2Fj.nbd.2009.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheffler, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroeze, W. K.</span><span> </span><span class="NLM_article-title">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span><span class="refDoi"> DOI: 10.1038/nrd1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+shotguns+versus+magic+bullets%3A+selectively+non-selective+drugs+for+mood+disorders+and+schizophrenia&doi=10.1038%2Fnrd1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0ligKtbt3GySFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520shotguns%2520versus%2520magic%2520bullets%253A%2520selectively%2520non-selective%2520drugs%2520for%2520mood%2520disorders%2520and%2520schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D353%26epage%3D359%26doi%3D10.1038%2Fnrd1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Davis, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, M.</span><span> </span><span class="NLM_article-title">Dopamine in schizophrenia: a review and reconceptualization</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">148</span><span class="NLM_x">, </span> <span class="NLM_fpage">1474</span><span class="NLM_x">–</span> <span class="NLM_lpage">1486</span><span class="refDoi"> DOI: 10.1176/ajp.148.11.1474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1176%2Fajp.148.11.1474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1681750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A280%3ADyaK38%252Fis1GksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=1991&pages=1474-1486&author=K.+L.+Davisauthor=R.+S.+Kahnauthor=M.+Davidson&title=Dopamine+in+schizophrenia%3A+a+review+and+reconceptualization&doi=10.1176%2Fajp.148.11.1474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine in schizophrenia: a review and reconceptualization</span></div><div class="casAuthors">Davis K L; Kahn R S; Ko G; Davidson M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1474-86</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The initial hypothesis that schizophrenia is a manifestation of hyperdopaminergia has recently been faulted.  However, several new findings suggest that abnormal, although not necessarily excessive, dopamine activity is an important factor in schizophrenia.  The authors discuss these findings and their implications.  METHOD:  All published studies regarding dopamine and schizophrenia and all studies on the role of dopamine in cognition were reviewed.  Attention has focused on post-mortem studies, positron emission tomography, neuroleptic drug actions, plasma levels of the dopamine metabolite homovanillic acid (HVA), and cerebral blood flow.  RESULTS:  Evidence, particularly from intracellular recording studies in animals and plasma HVA measurements, suggests that neuroleptics act by reducing dopamine activity in mesolimbic dopamine neurons.  Post-mortem studies have shown high dopamine and HVA concentrations in various subcortical brain regions and greater than normal dopamine receptor densities in the brains of schizophrenic patients.  On the other hand, the negative/deficit symptom complex of schizophrenia may be associated with low dopamine activity in the prefrontal cortex.  Recent animal and human studies suggest that prefrontal dopamine neurons inhibit subcortical dopamine activity.  The authors hypothesize that schizophrenia is characterized by abnormally low prefrontal dopamine activity (causing deficit symptoms) leading to excessive dopamine activity in mesolimbic dopamine neurons (causing positive symptoms).  CONCLUSIONS:  The possible co-occurrence of high and low dopamine activity in schizophrenia has implications for the conceptualization of dopamine's role in schizophrenia.  It would explain the concurrent presence of negative and positive symptoms.  This hypothesis is testable and has important implications for treatment of schizophrenia and schizophrenia spectrum disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjdRe5bVrnXhJ5E29YNGvQfW6udTcc2eak4XD16U3SZ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252Fis1GksQ%253D%253D&md5=15af042ac86f1634ea1c0b7c0fb76582</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1176%2Fajp.148.11.1474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fajp.148.11.1474%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DK.%2BL.%26aulast%3DKahn%26aufirst%3DR.%2BS.%26aulast%3DDavidson%26aufirst%3DM.%26atitle%3DDopamine%2520in%2520schizophrenia%253A%2520a%2520review%2520and%2520reconceptualization%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1991%26volume%3D148%26spage%3D1474%26epage%3D1486%26doi%3D10.1176%2Fajp.148.11.1474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Leucht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. M.</span><span> </span><span class="NLM_article-title">Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span><span class="refDoi"> DOI: 10.1016/S0140-6736(08)61764-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2FS0140-6736%2808%2961764-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=19058842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Wqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2009&pages=31-41&author=S.+Leuchtauthor=C.+Corvesauthor=D.+Arbterauthor=R.+R.+Engelauthor=C.+B.+Liauthor=J.+M.+Davis&title=Second-generation+versus+first-generation+antipsychotic+drugs+for+schizophrenia%3A+a+meta-analysis&doi=10.1016%2FS0140-6736%2808%2961764-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis</span></div><div class="casAuthors">Leucht, Stefan; Corves, Caroline; Arbter, Dieter; Engel, Rolf R.; Li, Chunbo; Davis, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">9657</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Because of the debate about whether second-generation antipsychotic drugs are better than first-generation antipsychotic drugs, we did a meta-anal. of randomized controlled trials to compare the effects of these two types of drugs in patients with schizophrenia.  We compared nine second-generation antipsychotic drugs with first-generation drugs for overall efficacy (main outcome), pos., neg. and depressive symptoms, relapse, quality of life, extrapyramidal side-effects, wt. gain, and sedation.  We included 150 double-blind, mostly short-term, studies, with 21,533 participants.  We excluded open studies because they systematically favored second-generation drugs.  Four of these drugs were better than first-generation antipsychotic drugs for overall efficacy, with small to medium effect sizes (amisulpride -0.31 [95% CI -0.44 to -0.19, p<0.0001], clozapine -0.52 [-0.75 to -0.29, p<0.0001], olanzapine -0.28 [-0.38 to -0.18, p<0.0001], and risperidone -0.13 [-0.22 to -0.05, p=0.002]).  The other second-generation drugs were not more efficacious than the first-generation drugs, even for neg. symptoms.  Therefore efficacy on neg. symptoms cannot be a core component of atypicality.  Second-generation antipsychotic drugs induced fewer extrapyramidal side-effects than did haloperidol (even at low doses).  Only a few have been shown to induce fewer extrapyramidal side-effects than low-potency first-generation antipsychotic drugs.  With the exception of aripiprazole and ziprasidone, second-generation antipsychotic drugs induced more wt. gain, in various degrees, than did haloperidol but not than low-potency first-generation drugs.  The second-generation drugs also differed in their sedating properties.  We did not note any consistent effects of moderator variables, such as industry sponsorship, comparator dose, or prophylactic antiparkinsonian medication.  Second-generation antipsychotic drugs differ in many properties and are not a homogeneous class.  This meta-anal. provides data for individualized treatment based on efficacy, side-effects, and cost.  Funding: National Institute of Mental Health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojXIyLwG0IPLVg90H21EOLACvtfcHk0ligKtbt3GySFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Wqsw%253D%253D&md5=b36479dbb36763237e2183f3c773e979</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2961764-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252961764-X%26sid%3Dliteratum%253Aachs%26aulast%3DLeucht%26aufirst%3DS.%26aulast%3DCorves%26aufirst%3DC.%26aulast%3DArbter%26aufirst%3DD.%26aulast%3DEngel%26aufirst%3DR.%2BR.%26aulast%3DLi%26aufirst%3DC.%2BB.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26atitle%3DSecond-generation%2520versus%2520first-generation%2520antipsychotic%2520drugs%2520for%2520schizophrenia%253A%2520a%2520meta-analysis%26jtitle%3DLancet%26date%3D2009%26volume%3D373%26spage%3D31%26epage%3D41%26doi%3D10.1016%2FS0140-6736%2808%2961764-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Caroff, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurford, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lybrand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, E. C.</span><span> </span><span class="NLM_article-title">Movement disorders induced by antipsychotic drugs: implications of the CATIE Schizophrenia trial</span> <span class="citation_source-journal">Neurologic Clinics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1016/j.ncl.2010.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.ncl.2010.10.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=127-148&author=S.+N.+Caroffauthor=I.+Hurfordauthor=J.+Lybrandauthor=E.+C.+Campbell&title=Movement+disorders+induced+by+antipsychotic+drugs%3A+implications+of+the+CATIE+Schizophrenia+trial&doi=10.1016%2Fj.ncl.2010.10.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ncl.2010.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ncl.2010.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DS.%2BN.%26aulast%3DHurford%26aufirst%3DI.%26aulast%3DLybrand%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DE.%2BC.%26atitle%3DMovement%2520disorders%2520induced%2520by%2520antipsychotic%2520drugs%253A%2520implications%2520of%2520the%2520CATIE%2520Schizophrenia%2520trial%26jtitle%3DNeurologic%2520Clinics%26date%3D2011%26volume%3D29%26spage%3D127%26epage%3D148%26doi%3D10.1016%2Fj.ncl.2010.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Koster, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correll, C. U.</span><span> </span><span class="NLM_article-title">Emerging drugs for schizophrenia: an update</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">531</span><span class="refDoi"> DOI: 10.1517/14728214.2014.958148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1517%2F14728214.2014.958148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A280%3ADC%252BC2M7ivFartg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=511-531&author=L.+S.+Kosterauthor=M.+Carbonauthor=C.+U.+Correll&title=Emerging+drugs+for+schizophrenia%3A+an+update&doi=10.1517%2F14728214.2014.958148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging drugs for schizophrenia: an update</span></div><div class="casAuthors">Koster Luisa-Sophie; Carbon Maren; Correll Christoph U</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on emerging drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">511-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Schizophrenia is one of the most serious mental disorders.  Its treatment remains challenging, as existing antipsychotic antidopaminergic medications improve only/predominantly positive symptoms, agitation and aggression but have limited/insignificant efficacy for negative and cognitive symptoms, which strongly affect functional outcome.  Therefore, new therapeutic agents are urgently needed that treat aspects of the spectrum of schizophrenia symptomatology and improve functional outcome.  AREAS COVERED:  The authors review the mechanisms of action and key clinical results of drug development targets currently in Phase II and III clinical testing for schizophrenia.  They further discuss potential barriers to the successful development of these targets and summarize the drug development status of emerging treatments for various aspects of schizophrenia.  EXPERT OPINION:  Although modifications and variations of antidopaminergic mechanisms are expected to be successful, the added benefits will likely remain small, at least regarding enhanced efficacy for negative symptoms, cognition and functional outcomes.  Greater innovation will likely come from further and deeper exploration of extra-dopaminergic mechanisms.  Investment is needed to develop clinically meaningful animal paradigms probing the different symptom domains, to discover more efficient in vivo screening methods for novel drug targets, to optimize clinical trial design and trial conduct, and to parse the heterogeneous groups of schizophrenias into biologically more homogeneous subgroups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZ25fXC8ZT23y-c-E1v-fmfW6udTcc2eamItNH1kKCTLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7ivFartg%253D%253D&md5=778d7a1dd616d6513af6330f20116fe7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F14728214.2014.958148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.2014.958148%26sid%3Dliteratum%253Aachs%26aulast%3DKoster%26aufirst%3DL.%2BS.%26aulast%3DCarbon%26aufirst%3DM.%26aulast%3DCorrell%26aufirst%3DC.%2BU.%26atitle%3DEmerging%2520drugs%2520for%2520schizophrenia%253A%2520an%2520update%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2014%26volume%3D19%26spage%3D511%26epage%3D531%26doi%3D10.1517%2F14728214.2014.958148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Leo, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Regno, P. D.</span><span> </span><span class="NLM_article-title">Atypical antipsychotic use in the treatment of psychosis in primary care</span> <span class="citation_source-journal">Prim. Care Companion J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.4088/PCC.v02n0601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.4088%2FPCC.v02n0601" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=194-204&author=R.+J.+Leoauthor=P.+D.+Del+Regno&title=Atypical+antipsychotic+use+in+the+treatment+of+psychosis+in+primary+care&doi=10.4088%2FPCC.v02n0601"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4088%2FPCC.v02n0601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FPCC.v02n0601%26sid%3Dliteratum%253Aachs%26aulast%3DLeo%26aufirst%3DR.%2BJ.%26aulast%3DDel%2BRegno%26aufirst%3DP.%2BD.%26atitle%3DAtypical%2520antipsychotic%2520use%2520in%2520the%2520treatment%2520of%2520psychosis%2520in%2520primary%2520care%26jtitle%3DPrim.%2520Care%2520Companion%2520J.%2520Clin.%2520Psychiatry%26date%3D2000%26volume%3D2%26spage%3D194%26epage%3D204%26doi%3D10.4088%2FPCC.v02n0601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Swainston Harrison, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, C. M.</span><span> </span><span class="NLM_article-title">Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1715</span><span class="NLM_x">–</span> <span class="NLM_lpage">1736</span><span class="refDoi"> DOI: 10.2165/00003495-200464150-00010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.2165%2F00003495-200464150-00010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=1715-1736&author=T.+Swainston+Harrisonauthor=C.+M.+Perry&title=Aripiprazole%3A+a+review+of+its+use+in+schizophrenia+and+schizoaffective+disorder&doi=10.2165%2F00003495-200464150-00010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2165%2F00003495-200464150-00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200464150-00010%26sid%3Dliteratum%253Aachs%26aulast%3DSwainston%2BHarrison%26aufirst%3DT.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DAripiprazole%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520schizophrenia%2520and%2520schizoaffective%2520disorder%26jtitle%3DDrugs%26date%3D2004%26volume%3D64%26spage%3D1715%26epage%3D1736%26doi%3D10.2165%2F00003495-200464150-00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Shapiro, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renock, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrington, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiodo, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R.</span><span> </span><span class="NLM_article-title">Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1400</span><span class="NLM_x">–</span> <span class="NLM_lpage">1411</span><span class="refDoi"> DOI: 10.1038/sj.npp.1300203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fsj.npp.1300203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=12784105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD3sXls1Slsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=1400-1411&author=D.+A.+Shapiroauthor=S.+Renockauthor=E.+Arringtonauthor=L.+A.+Chiodoauthor=L.+X.+Liuauthor=D.+R.+Sibleyauthor=B.+L.+Rothauthor=R.+Mailman&title=Aripiprazole%2C+a+novel+atypical+antipsychotic+drug+with+a+unique+and+robust+pharmacology&doi=10.1038%2Fsj.npp.1300203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology</span></div><div class="casAuthors">Shapiro, David A.; Renock, Sean; Arrington, Elaine; Chiodo, Louis A.; Liu, Li-Xin; Sibley, David R.; Roth, Bryan L.; Mailman, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1400-1411</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Atypical antipsychotic drugs have revolutionized the treatment of schizophrenia and related disorders.  The current clin. approved atypical antipsychotic drugs are characterized by having relatively low affinities for D2-dopamine receptors and relatively high affinities for 5-HT2A serotonin receptors (5-HT, 5-hydroxytryptamine (serotonin)).  Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug that is reported to be a high-affinity D2-dopamine receptor partial agonist.  We now provide a comprehensive pharmacol. profile of aripiprazole at a large no. of cloned G protein-coupled receptors, transporters, and ion channels.  These data reveal a no. of interesting and potentially important mol. targets for which aripiprazole has affinity.  Aripiprazole has highest affinity for h5-HT2B-, hD2L-, and hD3-dopamine receptors, but also has significant affinity (5-30 nM) for several other 5-HT receptors (5-HT1A, 5-HT2A, 5-HT7), as well as α1A-adrenergic and hH1-histamine receptors.  Aripiprazole has less affinity (30-200 nM) for other G protein-coupled receptors, including the 5-HT1D, 5-HT2C, α1B-, α2A-, α2B-, α2C-, β1-, and β2-adrenergic, and H3-histamine receptors.  Functionally, aripiprazole is an inverse agonist at 5-HT2B receptors and displays partial agonist actions at 5-HT2A, 5-HT2C, D3, and D4 receptors.  Interestingly, we also discovered that the functional actions of aripiprazole at cloned human D2-dopamine receptors are cell-type selective, and that a range of actions (eg agonism, partial agonism, antagonism) at cloned D2-dopamine receptors are possible depending upon the cell type and function examd.  This mixt. of functional actions at D2-dopamine receptors is consistent with the hypothesis proposed by Lawler et al (1999) that aripiprazole has functionally selective' actions.  Taken together, our results support the hypothesis that the unique actions of aripiprazole in humans are likely a combination of functionally selective' activation of D2 (and possibly D3)-dopamine receptors, coupled with important interactions with selected other biogenic amine receptors-particularly 5-HT receptor subtypes (5-HT1A, 5-HT2A).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc1m1pKWaDH7Vg90H21EOLACvtfcHk0lgJCVJeclQzDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXls1Slsro%253D&md5=a90dfc24826c78d9a630ae4831d99cb0</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300203%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DD.%2BA.%26aulast%3DRenock%26aufirst%3DS.%26aulast%3DArrington%26aufirst%3DE.%26aulast%3DChiodo%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DL.%2BX.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DMailman%26aufirst%3DR.%26atitle%3DAripiprazole%252C%2520a%2520novel%2520atypical%2520antipsychotic%2520drug%2520with%2520a%2520unique%2520and%2520robust%2520pharmacology%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D1400%26epage%3D1411%26doi%3D10.1038%2Fsj.npp.1300203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Gopalakrishna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aggarwal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauriello, J.</span><span> </span><span class="NLM_article-title">Long-acting injectable aripiprazole: how might it fit in our tool box?</span> <span class="citation_source-journal">Clin. Schizophr. Relat. Psychoses.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span><span class="refDoi"> DOI: 10.3371/CSRP.GOAG.043013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.3371%2FCSRP.GOAG.043013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A280%3ADC%252BC3sngsl2rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=87-92&author=G.+Gopalakrishnaauthor=A.+Aggarwalauthor=J.+Lauriello&title=Long-acting+injectable+aripiprazole%3A+how+might+it+fit+in+our+tool+box%3F&doi=10.3371%2FCSRP.GOAG.043013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting injectable aripiprazole: how might it fit in our tool box?</span></div><div class="casAuthors">Gopalakrishna Ganesh; Aggarwal Arpit; Lauriello John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical schizophrenia & related psychoses</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-92</span>
        ISSN:<span class="NLM_cas:issn">1935-1232</span>.
    </div><div class="casAbstract">Schizophrenia is a severe mental illness with a lifetime prevalence of approximately one percent worldwide.  Maintenance antipsychotic treatment has been effective in preventing relapses in long-term follow-up studies.  Logically it can be proposed that long-acting injectable antipsychotics (LAI) might reduce both unintentional and intentional nonadherence.  Long-acting injectable aripiprazole was approved for the treatment of schizophrenia by the U.S.  FDA on 28th February 2013 and will be marketed under the name Abilify Maintena.  Aripiprazole LAI (ALAI) is a lyophilized powder that needs to be reconstituted with sterile water to form an injectable suspension without affecting the original molecule.  The monthly injection interval is very attractive since patients prefer fewer injections.  From a tolerability perspective, ALAI appears to be both weight neutral and lacking metabolic side effects.  This can confer an advantage over the other currently available second-generation antipsychotic LAIs.  Simple constitution with sterile water and no requirement to refrigerate make storage and administration easier.  Like all medications, there are always potential disadvantages to ALAI.  There is a period of oral coverage, while not as long as for long-acting risperidone microspheres (RLAI), that is required.  Care must be taken to review concomitant medications for the presence of metabolic inducers and inhibitors.  One would also expect some patients to be sensitive to extrapyramidal symptoms, especially akathisia which is well documented in the oral preparation.  All things considered, we welcome our new tool, ALAI, to our work-place and predict both clinical practice and post marketing analysis and studies will discover its true value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBNb1QTCGf79j_Vg2vObihfW6udTcc2eaLVQYw8rKQDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sngsl2rtw%253D%253D&md5=7ad4d9d3b817140090d511eed49e0bcf</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3371%2FCSRP.GOAG.043013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3371%252FCSRP.GOAG.043013%26sid%3Dliteratum%253Aachs%26aulast%3DGopalakrishna%26aufirst%3DG.%26aulast%3DAggarwal%26aufirst%3DA.%26aulast%3DLauriello%26aufirst%3DJ.%26atitle%3DLong-acting%2520injectable%2520aripiprazole%253A%2520how%2520might%2520it%2520fit%2520in%2520our%2520tool%2520box%253F%26jtitle%3DClin.%2520Schizophr.%2520Relat.%2520Psychoses.%26date%3D2013%26volume%3D7%26spage%3D87%26epage%3D92%26doi%3D10.3371%2FCSRP.GOAG.043013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Allen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span> </span><span class="NLM_article-title">Discovery of beta-arrestin-biased dopamine D-2 ligands for probing signal transduction pathways essential for antipsychotic efficacy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">18488</span><span class="NLM_x">–</span> <span class="NLM_lpage">18493</span><span class="refDoi"> DOI: 10.1073/pnas.1104807108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1073%2Fpnas.1104807108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18488-18493&author=J.+A.+Allenauthor=J.+M.+Yostauthor=V.+Setolaauthor=X.+Chenauthor=M.+F.+Sassanoauthor=M.+Chenauthor=S.+Petersonauthor=P.+N.+Yadavauthor=X.+P.+Huangauthor=B.+Fengauthor=N.+H.+Jensenauthor=X.+Cheauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=M.+G.+Caronauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=J.+Jin&title=Discovery+of+beta-arrestin-biased+dopamine+D-2+ligands+for+probing+signal+transduction+pathways+essential+for+antipsychotic+efficacy&doi=10.1073%2Fpnas.1104807108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1104807108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1104807108%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DYost%26aufirst%3DJ.%2BM.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DChe%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520beta-arrestin-biased%2520dopamine%2520D-2%2520ligands%2520for%2520probing%2520signal%2520transduction%2520pathways%2520essential%2520for%2520antipsychotic%2520efficacy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D18488%26epage%3D18493%26doi%3D10.1073%2Fpnas.1104807108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Urban, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Zastrow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spedding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Functional selectivity and classical concepts of quantitative pharmacology</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">320</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.1124/jpet.106.104463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1124%2Fjpet.106.104463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=16803859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=1-13&author=J.+D.+Urbanauthor=W.+P.+Clarkeauthor=M.+von+Zastrowauthor=D.+E.+Nicholsauthor=B.+Kobilkaauthor=H.+Weinsteinauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=A.+Christopoulosauthor=P.+M.+Sextonauthor=K.+J.+Millerauthor=M.+Speddingauthor=R.+B.+Mailman&title=Functional+selectivity+and+classical+concepts+of+quantitative+pharmacology&doi=10.1124%2Fjpet.106.104463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity and classical concepts of quantitative pharmacology</span></div><div class="casAuthors">Urban, Jonathan D.; Clarke, William P.; von Zastrow, Mark; Nichols, David E.; Kobilka, Brian; Weinstein, Harel; Javitch, Jonathan A.; Roth, Bryan L.; Christopoulos, Arthur; Sexton, Patrick M.; Miller, Keith J.; Spedding, Michael; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The concept of intrinsic efficacy has been enshrined in pharmacol. for half of a century, yet recent data have revealed that many ligands can differentially activate signaling pathways mediated via a single G protein-coupled receptor in a manner that challenges the traditional definition of intrinsic efficacy.  Some terms for this phenomenon include functional selectivity, agonist-directed trafficking, and biased agonism.  At the extreme, functionally selective ligands may be both agonists and antagonists at different functions mediated by the same receptor.  Data illustrating this phenomenon are presented from serotonin, opioid, dopamine, vasopressin, and adrenergic receptor systems.  A variety of mechanisms may influence this apparently ubiquitous phenomenon.  It may be initiated by differences in ligand-induced intermediate conformational states, as shown for the β2-adrenergic receptor.  Subsequent mechanisms that may play a role include diversity of G proteins, scaffolding and signaling partners, and receptor oligomers.  Clearly, expanded research is needed to elucidate the proximal (e.g., how functionally selective ligands cause conformational changes that initiate differential signaling), intermediate (mechanisms that translate conformation changes into differential signaling), and distal mechanisms (differential effects on target tissue or organism).  Besides the heuristically interesting nature of functional selectivity, there is a clear impact on drug discovery, because this mechanism raises the possibility of selecting or designing novel ligands that differentially activate only a subset of functions of a single receptor, thereby optimizing therapeutic action.  It also may be timely to revise classic concepts in quant. pharmacol. and relevant pharmacol. conventions to incorporate these new concepts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5GzdtvWZRkbVg90H21EOLACvtfcHk0li-37ZxypPGHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFersw%253D%253D&md5=54465473b5996d0755baeee89eeb0ba9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.104463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.104463%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DJ.%2BD.%26aulast%3DClarke%26aufirst%3DW.%2BP.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DKobilka%26aufirst%3DB.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DSpedding%26aufirst%3DM.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DFunctional%2520selectivity%2520and%2520classical%2520concepts%2520of%2520quantitative%2520pharmacology%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26spage%3D1%26epage%3D13%26doi%3D10.1124%2Fjpet.106.104463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">GPCR functional selectivity has therapeutic impact</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">390</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span><span class="refDoi"> DOI: 10.1016/j.tips.2007.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.tips.2007.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=17629962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlWltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=390-396&author=R.+B.+Mailman&title=GPCR+functional+selectivity+has+therapeutic+impact&doi=10.1016%2Fj.tips.2007.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR functional selectivity has therapeutic impact</span></div><div class="casAuthors">Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">390-396</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Many in vitro data show that some ligands can cause the differential activation of signaling pathways mediated by a single receptor (termedfunctional selectivity').  It remains unclear, however, whether functionally selective properties are meaningful in vivo.  Data obtained with exptl. compds. that are functionally selective at the dopamine D2L receptor in vitro suggest that these properties might predict atypical behavioral actions.  Moreover, the antipsychotic drug aripiprazole is commonly thought to be a D2 partial agonist, but data clearly show that aripiprazole is functionally selective in vitro.  It is proposed that the effects of aripiprazole in animal models and humans can be reconciled only with its functionally selective D2 properties, not its partial D2 agonism.  Together, these data provide support for the hypothesis that compds. with functionally selective properties in vitro are likely to have novel actions in vivo, opening doors to new avenues of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGT3wJMrwLmrVg90H21EOLACvtfcHk0li-37ZxypPGHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlWltLg%253D&md5=e4647d1af70505c4711dd2d57d0b4cfd</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DGPCR%2520functional%2520selectivity%2520has%2520therapeutic%2520impact%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D390%26epage%3D396%26doi%3D10.1016%2Fj.tips.2007.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Beaulieu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">The Akt-GSK-3 signaling cascade in the actions of doparnine</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">166</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span><span class="refDoi"> DOI: 10.1016/j.tips.2007.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.tips.2007.02.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=166-172&author=J.+M.+Beaulieuauthor=R.+R.+Gainetdinovauthor=M.+G.+Caron&title=The+Akt-GSK-3+signaling+cascade+in+the+actions+of+doparnine&doi=10.1016%2Fj.tips.2007.02.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DThe%2520Akt-GSK-3%2520signaling%2520cascade%2520in%2520the%2520actions%2520of%2520doparnine%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D166%26epage%3D172%26doi%3D10.1016%2Fj.tips.2007.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Kenakin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span> </span><span class="NLM_article-title">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span><span class="refDoi"> DOI: 10.1038/nrd3954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fnrd3954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=23411724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=205-216&author=T.+Kenakinauthor=A.+Christopoulos&title=Signalling+bias+in+new+drug+discovery%3A+detection%2C+quantification+and+therapeutic+impact&doi=10.1038%2Fnrd3954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span></div><div class="casAuthors">Kenakin, Terry; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-216</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Agonists of seven-transmembrane receptors, also known as G protein-coupled receptors (GPCRs), do not uniformly activate all cellular signalling pathways linked to a given seven-transmembrane receptor (a phenomenon termed ligand or agonist bias); this discovery has changed how high-throughput screens are designed and how lead compds. are optimized for therapeutic activity.  The ability to exptl. detect ligand bias has necessitated the development of methods for quantifying agonist bias in a way that can be used to guide structure-activity studies and the selection of drug candidates.  Here, we provide a viewpoint on which methods are appropriate for quantifying bias, based on knowledge of how cellular and intracellular signalling proteins control the conformation of seven-transmembrane receptors.  We also discuss possible predictions of how biased mols. may perform in vivo, and what potential therapeutic advantages they may provide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkDNsO17tty7Vg90H21EOLACvtfcHk0lgwXHXJWCE44w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D&md5=712258b9158f753689e35fa31f1b67f0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd3954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3954%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DSignalling%2520bias%2520in%2520new%2520drug%2520discovery%253A%2520detection%252C%2520quantification%2520and%2520therapeutic%2520impact%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D205%26epage%3D216%26doi%3D10.1038%2Fnrd3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span> </span><span class="NLM_article-title">Structure-functional selectivity relationship studies of beta-arrestin-biased dopamine D-2 receptor agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7141</span><span class="NLM_x">–</span> <span class="NLM_lpage">7153</span><span class="refDoi"> DOI: 10.1021/jm300603y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300603y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7141-7153&author=X.+Chenauthor=M.+F.+Sassanoauthor=L.+Y.+Zhengauthor=V.+Setolaauthor=M.+Chenauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=J.+Jin&title=Structure-functional+selectivity+relationship+studies+of+beta-arrestin-biased+dopamine+D-2+receptor+agonists&doi=10.1021%2Fjm300603y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm300603y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300603y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DZheng%26aufirst%3DL.%2BY.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DStructure-functional%2520selectivity%2520relationship%2520studies%2520of%2520beta-arrestin-biased%2520dopamine%2520D-2%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7141%26epage%3D7153%26doi%3D10.1021%2Fjm300603y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Park, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmerberg, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span> </span><span class="NLM_article-title">Effects of beta-arrestin-biased dopamine D2 receptor ligands on Schizophrenia-like behavior in hypoglutamatergic mice</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">704</span><span class="NLM_x">–</span> <span class="NLM_lpage">715</span><span class="refDoi"> DOI: 10.1038/npp.2015.196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fnpp.2015.196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=26129680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=704-715&author=S.+M.+Parkauthor=M.+Chenauthor=C.+M.+Schmerbergauthor=R.+S.+Dulmanauthor=R.+M.+Rodriguizauthor=M.+G.+Caronauthor=J.+Jinauthor=W.+C.+Wetsel&title=Effects+of+beta-arrestin-biased+dopamine+D2+receptor+ligands+on+Schizophrenia-like+behavior+in+hypoglutamatergic+mice&doi=10.1038%2Fnpp.2015.196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice</span></div><div class="casAuthors">Park, Su M.; Chen, Meng; Schmerberg, Claire M.; Dulman, Russell S.; Rodriguiz, Ramona M.; Caron, Marc G.; Jin, Jian; Wetsel, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">704-715</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Current antipsychotic drugs (APDs) show efficacy with pos. symptoms, but are limited in treating neg. or cognitive features of schizophrenia.  Whereas all currently FDA-approved medications target primarily the dopamine D2 receptor (D2R) to inhibit Gi/o-mediated adenylyl cyclase, a recent study has shown that many APDs affect not only Gi/o- but they can also influence β-arrestin- (βArr)-mediated signaling.  The ability of ligands to differentially affect signaling through these pathways is termed functional selectivity.  We have developed ligands that are devoid of D2R-mediated Gi/o protein signaling, but are simultaneously partial agonists for D2R/βArr interactions.  The purpose of this study was to test the effectiveness of UNC9975 or UNC9994 on schizophrenia-like behaviors in phencyclidine-treated or NR1-knockdown hypoglutamatergic mice.  We have found the UNC compds. reduce hyperlocomotion in the open field, restore PPI, improve novel object recognition memory, partially normalize social behavior, decrease conditioned avoidance responding, and elicit a much lower level of catalepsy than haloperidol.  These preclin. results suggest that exploitation of functional selectivity may provide unique opportunities to develop drugs with fewer side effects, greater therapeutic selectivity, and enhanced efficacy for treating schizophrenia and related conditions than medications that are currently available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQuhB8VxuXDbVg90H21EOLACvtfcHk0lgwXHXJWCE44w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jO&md5=82de207db3a78d50ff86a48cda2d2e28</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.196%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BM.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DDulman%26aufirst%3DR.%2BS.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26atitle%3DEffects%2520of%2520beta-arrestin-biased%2520dopamine%2520D2%2520receptor%2520ligands%2520on%2520Schizophrenia-like%2520behavior%2520in%2520hypoglutamatergic%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2016%26volume%3D41%26spage%3D704%26epage%3D715%26doi%3D10.1038%2Fnpp.2015.196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Shonberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herenbrink, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, J. R.</span><span> </span><span class="NLM_article-title">A Structure-activity analysis of biased agonism at the dopamine D2 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">9199</span><span class="NLM_x">–</span> <span class="NLM_lpage">9221</span><span class="refDoi"> DOI: 10.1021/jm401318w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401318w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CktrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9199-9221&author=J.+Shonbergauthor=C.+K.+Herenbrinkauthor=L.+Lopezauthor=A.+Christopoulosauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=J.+R.+Lane&title=A+Structure-activity+analysis+of+biased+agonism+at+the+dopamine+D2+receptor&doi=10.1021%2Fjm401318w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Activity Analysis of Biased Agonism at the Dopamine D2 Receptor</span></div><div class="casAuthors">Shonberg, Jeremy; Herenbrink, Carmen Klein; Lopez, Laura; Christopoulos, Arthur; Scammells, Peter J.; Capuano, Ben; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9199-9221</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biased agonism offers an opportunity for the medicinal chemist to discover pathway-selective ligands for GPCRs.  A no. of studies have suggested that biased agonism at the dopamine D2 receptor (D2R) may be advantageous for the treatment of neuropsychiatric disorders, including schizophrenia.  As such, it is of great importance to gain insight into the SAR of biased agonism at this receptor.  The authors have generated SAR based on a novel D2R partial agonist, tert-Bu (trans-4-(2-(3,4-dihydroisoquinolin-2-(1H)-yl)-ethyl)-cyclohexyl)-carbamate.  This ligand shares structural similarity to cariprazine, a drug awaiting FDA approval for the treatment of schizophrenia, yet displays a distinct bias toward two different signaling end points.  The authors synthesized a no. of derivs. of tert-Bu (trans-4-(2-(3,4-dihydroisoquinolin-2-(1H)-yl)-ethyl)-cyclohexyl)-carbamate with subtle structural modifications, including incorporation of cariprazine fragments.  By combining pharmacol. profiling with anal. methodol. to identify and to quantify bias, the authors have demonstrated that efficacy and biased agonism can be finely tuned by minor structural modifications to the head group contg. the tertiary amine, a tail group that extends away from this moiety, and the orientation and length of a spacer region between these two moieties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocktbsOBHWB7Vg90H21EOLACvtfcHk0linq_vgdjFsXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CktrbJ&md5=124b940132336819740ec30d2962a3a3</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm401318w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401318w%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DHerenbrink%26aufirst%3DC.%2BK.%26aulast%3DLopez%26aufirst%3DL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DA%2520Structure-activity%2520analysis%2520of%2520biased%2520agonism%2520at%2520the%2520dopamine%2520D2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9199%26epage%3D9221%26doi%3D10.1021%2Fjm401318w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Hiller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinemann, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Functionally selective dopamine D-2/D-3 receptor agonists comprising an enyne moiety</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5130</span><span class="NLM_x">–</span> <span class="NLM_lpage">5141</span><span class="refDoi"> DOI: 10.1021/jm400520c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400520c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5130-5141&author=C.+Hillerauthor=R.+C.+Klingauthor=F.+W.+Heinemannauthor=K.+Meyerauthor=H.+Hubnerauthor=P.+Gmeiner&title=Functionally+selective+dopamine+D-2%2FD-3+receptor+agonists+comprising+an+enyne+moiety&doi=10.1021%2Fjm400520c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm400520c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400520c%26sid%3Dliteratum%253Aachs%26aulast%3DHiller%26aufirst%3DC.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DHeinemann%26aufirst%3DF.%2BW.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFunctionally%2520selective%2520dopamine%2520D-2%252FD-3%2520receptor%2520agonists%2520comprising%2520an%2520enyne%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5130%26epage%3D5141%26doi%3D10.1021%2Fjm400520c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Szabo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein Herenbrink, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D-2 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4924</span><span class="NLM_x">–</span> <span class="NLM_lpage">4939</span><span class="refDoi"> DOI: 10.1021/jm500457x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500457x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4924-4939&author=M.+Szaboauthor=C.+Klein+Herenbrinkauthor=A.+Christopoulosauthor=J.+R.+Laneauthor=B.+Capuano&title=Structure-activity+relationships+of+privileged+structures+lead+to+the+discovery+of+novel+biased+ligands+at+the+dopamine+D-2+receptor&doi=10.1021%2Fjm500457x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm500457x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500457x%26sid%3Dliteratum%253Aachs%26aulast%3DSzabo%26aufirst%3DM.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DStructure-activity%2520relationships%2520of%2520privileged%2520structures%2520lead%2520to%2520the%2520discovery%2520of%2520novel%2520biased%2520ligands%2520at%2520the%2520dopamine%2520D-2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4924%26epage%3D4939%26doi%3D10.1021%2Fjm500457x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Moeller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skultety, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leuner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Functionally selective dopamine D-2, D-3 receptor partial agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4861</span><span class="NLM_x">–</span> <span class="NLM_lpage">4875</span><span class="refDoi"> DOI: 10.1021/jm5004039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5004039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4861-4875&author=D.+Moellerauthor=R.+C.+Klingauthor=M.+Skultetyauthor=K.+Leunerauthor=H.+Hubnerauthor=P.+Gmeiner&title=Functionally+selective+dopamine+D-2%2C+D-3+receptor+partial+agonists&doi=10.1021%2Fjm5004039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm5004039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5004039%26sid%3Dliteratum%253Aachs%26aulast%3DMoeller%26aufirst%3DD.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DSkultety%26aufirst%3DM.%26aulast%3DLeuner%26aufirst%3DK.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFunctionally%2520selective%2520dopamine%2520D-2%252C%2520D-3%2520receptor%2520partial%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4861%26epage%3D4875%26doi%3D10.1021%2Fjm5004039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Free, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritz, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conroy, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meade, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulcey, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Titus, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant-Genevier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnaeva, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuming, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southall, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marugan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span> </span><span class="NLM_article-title">Discovery and characterization of a G protein-biased agonist that inhibits beta-arrestin recruitment to the D2 dopamine receptor</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.1124/mol.113.090563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1124%2Fmol.113.090563" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=96-105&author=R.+B.+Freeauthor=L.+S.+Chunauthor=A.+E.+Moritzauthor=B.+N.+Millerauthor=T.+B.+Doyleauthor=J.+L.+Conroyauthor=A.+Padronauthor=J.+A.+Meadeauthor=J.+B.+Xiaoauthor=X.+Huauthor=A.+E.+Dulceyauthor=Y.+Hanauthor=L.+H.+Duanauthor=S.+Titusauthor=M.+Bryant-Genevierauthor=E.+Barnaevaauthor=M.+Ferrerauthor=J.+A.+Javitchauthor=T.+Beumingauthor=L.+Shiauthor=N.+T.+Southallauthor=J.+J.+Maruganauthor=D.+R.+Sibley&title=Discovery+and+characterization+of+a+G+protein-biased+agonist+that+inhibits+beta-arrestin+recruitment+to+the+D2+dopamine+receptor&doi=10.1124%2Fmol.113.090563"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.090563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.090563%26sid%3Dliteratum%253Aachs%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DChun%26aufirst%3DL.%2BS.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DMiller%26aufirst%3DB.%2BN.%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26aulast%3DConroy%26aufirst%3DJ.%2BL.%26aulast%3DPadron%26aufirst%3DA.%26aulast%3DMeade%26aufirst%3DJ.%2BA.%26aulast%3DXiao%26aufirst%3DJ.%2BB.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDulcey%26aufirst%3DA.%2BE.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DDuan%26aufirst%3DL.%2BH.%26aulast%3DTitus%26aufirst%3DS.%26aulast%3DBryant-Genevier%26aufirst%3DM.%26aulast%3DBarnaeva%26aufirst%3DE.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DSouthall%26aufirst%3DN.%2BT.%26aulast%3DMarugan%26aufirst%3DJ.%2BJ.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520a%2520G%2520protein-biased%2520agonist%2520that%2520inhibits%2520beta-arrestin%2520recruitment%2520to%2520the%2520D2%2520dopamine%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2014%26volume%3D86%26spage%3D96%26epage%3D105%26doi%3D10.1124%2Fmol.113.090563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Houslay, M. D.</span><span> </span><span class="NLM_article-title">Arrestin times for developing antipsychotics and beta-blockers</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">pe22</span><span class="refDoi"> DOI: 10.1126/scisignal.266pe22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1126%2Fscisignal.266pe22" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=pe22&author=M.+D.+Houslay&title=Arrestin+times+for+developing+antipsychotics+and+beta-blockers&doi=10.1126%2Fscisignal.266pe22"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.266pe22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.266pe22%26sid%3Dliteratum%253Aachs%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26atitle%3DArrestin%2520times%2520for%2520developing%2520antipsychotics%2520and%2520beta-blockers%26jtitle%3DSci.%2520Signaling%26date%3D2009%26volume%3D2%26spage%3Dpe22%26doi%3D10.1126%2Fscisignal.266pe22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Mottola, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilts, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connery, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, Q. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyslop, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piercey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wightman, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawler, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">301</span><span class="NLM_x">, </span> <span class="NLM_fpage">1166</span><span class="NLM_x">–</span> <span class="NLM_lpage">1178</span><span class="refDoi"> DOI: 10.1124/jpet.301.3.1166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1124%2Fjpet.301.3.1166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=12023552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlGjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2002&pages=1166-1178&author=D.+M.+Mottolaauthor=J.+D.+Kiltsauthor=M.+M.+Lewisauthor=H.+S.+Conneryauthor=Q.+D.+Walkerauthor=S.+R.+Jonesauthor=R.+G.+Boothauthor=D.+K.+Hyslopauthor=M.+Pierceyauthor=R.+M.+Wightmanauthor=C.+P.+Lawlerauthor=D.+E.+Nicholsauthor=R.+B.+Mailman&title=Functional+selectivity+of+dopamine+receptor+agonists.+I.+Selective+activation+of+postsynaptic+dopamine+D2+receptors+linked+to+adenylate+cyclase&doi=10.1124%2Fjpet.301.3.1166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase</span></div><div class="casAuthors">Mottola, David M.; Kilts, Jason D.; Lewis, Mechelle M.; Connory, Hilary S.; Walker, Q. David; Jones, Sara R.; Booth, Raymond G.; Hyslop, Deborah K.; Piercey, Monford; Wightman, R. Mark; Lawler, Cindy P.; Nichols, David E.; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1166-1179</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dihydrexidine (DHX), the first high-affinity D1 dopamine receptor full agonist, is only 10-fold selective for D1 vs. D2 receptors, having D2 affinity similar to the prototypical agonist quinpirole.  The D2 functional properties of DHX and its more D2 selective analog N-n-propyl-dihydrexidine (PrDHX) were explored in rat brain and pituitary.  DHX and PrDHX had binding characteristics to D2 receptors in rat striatum typical of D2 agonists, binding to both high- and low-affinity sites and being sensitive to guanine-nucleotides.  Consistent with these binding data, both DHX and PrDHX inhibited forskolin-stimulated cAMP synthesis in striatum with a potency and intrinsic activity equiv. to that of quinpirole.  Unexpectedly, however, DHX and PrDHX had little functional effect at D2 receptors expressed on dopaminergic neurons that mediate inhibition of cell firing, dopamine release, or dopamine synthesis.  Quant. receptor competition autoradiog. demonstrated that DHX bound to D2 receptors in striatum (predominantly postsynaptic receptor sites) with equal affinity as D2 sites in the substantia nigra (autoreceptor sites).  The data from these expts., coupled with what is known about the location of specific dopamine receptor isoforms, lead to the hypothesis that DHX, after binding to D2L and D2S receptors, causes agonist-typical functional changes only at some of these receptors.  This phenomenon (herein termed "functional selectivity") suggests that drugs may be targeted not only at specific receptor isoforms but also at sep. functions mediated by a single isoform, yielding novel approaches to drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpif5JbU-Rs9bVg90H21EOLACvtfcHk0liE1fywpimOLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlGjtrY%253D&md5=b1d65ec3f66b3652deb9f9a4c76b70a3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fjpet.301.3.1166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.301.3.1166%26sid%3Dliteratum%253Aachs%26aulast%3DMottola%26aufirst%3DD.%2BM.%26aulast%3DKilts%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DM.%2BM.%26aulast%3DConnery%26aufirst%3DH.%2BS.%26aulast%3DWalker%26aufirst%3DQ.%2BD.%26aulast%3DJones%26aufirst%3DS.%2BR.%26aulast%3DBooth%26aufirst%3DR.%2BG.%26aulast%3DHyslop%26aufirst%3DD.%2BK.%26aulast%3DPiercey%26aufirst%3DM.%26aulast%3DWightman%26aufirst%3DR.%2BM.%26aulast%3DLawler%26aufirst%3DC.%2BP.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DFunctional%2520selectivity%2520of%2520dopamine%2520receptor%2520agonists.%2520I.%2520Selective%2520activation%2520of%2520postsynaptic%2520dopamine%2520D2%2520receptors%2520linked%2520to%2520adenylate%2520cyclase%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D301%26spage%3D1166%26epage%3D1178%26doi%3D10.1124%2Fjpet.301.3.1166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Kilts, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connery, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrington, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawler, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxford, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">301</span><span class="NLM_x">, </span> <span class="NLM_fpage">1179</span><span class="NLM_x">–</span> <span class="NLM_lpage">1189</span><span class="refDoi"> DOI: 10.1124/jpet.301.3.1179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1124%2Fjpet.301.3.1179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=12023553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlGjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2002&pages=1179-1189&author=J.+D.+Kiltsauthor=H.+S.+Conneryauthor=E.+G.+Arringtonauthor=M.+M.+Lewisauthor=C.+P.+Lawlerauthor=G.+S.+Oxfordauthor=K.+L.+O%E2%80%99Malleyauthor=R.+D.+Toddauthor=B.+L.+Blakeauthor=D.+E.+Nicholsauthor=R.+B.+Mailman&title=Functional+selectivity+of+dopamine+receptor+agonists.+II.+Actions+of+dihydrexidine+in+D2L+receptor-transfected+MN9D+cells+and+pituitary+lactotrophs&doi=10.1124%2Fjpet.301.3.1179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs</span></div><div class="casAuthors">Kilts, Jason D.; Connery, Hilary S.; Arrington, Elaine G.; Lewis, Mechelle M.; Lawler, Cindy P.; Oxford, Gerry S.; O'Malley, Karen L.; Todd, Richard D.; Blake, Bonita L.; Nichols, David E.; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1179-1189</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">D2-like dopamine receptors mediate functional changes via activation of inhibitory G proteins, including those that affect adenylate cyclase activity, and potassium and calcium channels.  Although it is assumed that the binding of a drug to a single isoform of a D2-like receptor will cause similar changes in all receptor-mediated functions, it has been demonstrated in brain that the dopamine agonists dihydrexidine (DHX) and N-n-propyl-DHX are "functionally selective".  The current study explores the underlying mechanism using transfected MN9D cells and D2-producing anterior pituitary lactotrophs.  Both dopamine and DHX inhibited adenylate cyclase activity in a concn.-dependent manner in both systems, effects blocked by D2, but not D1, antagonists.  In the MN9D cells, quinpirole and R-(-)-N-propylnorapomorphine (NPA) also inhibited the K+-stimulated release of [3H]dopamine in a concn.-responsive, antagonist-reversible manner.  Conversely, neither DHX, nor its analogs, inhibited K+-stimulated [3H]dopamine release, although they antagonized the effects of quinpirole.  S-(+)-NPA actually had the reverse functional selectivity profile from DHX (i.e., it was a full agonist at D2L receptors coupled to inhibition of dopamine release, but a weak partial agonist at D2L receptor-mediated inhibition of adenylate cyclase).  In lactotrophs, DHX had little intrinsic activity at D2 receptors coupled to G protein-coupled inwardly rectifying potassium channels, and actually antagonized the effects of dopamine at these D2 receptors.  Together, these findings provide compelling evidence for agonist-induced functional selectivity with the D2L receptor.  Although the underlying mol. mechanism is controversial (e.g., "conformational induction" vs. "drug-active state selection"), such data are irreconcilable with the widely held view that drugs have "intrinsic efficacy".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxKyo-BPUi-LVg90H21EOLACvtfcHk0lhtJfgBBxOdQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlGjtrc%253D&md5=6686ca6fae277969b216781088d74a87</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fjpet.301.3.1179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.301.3.1179%26sid%3Dliteratum%253Aachs%26aulast%3DKilts%26aufirst%3DJ.%2BD.%26aulast%3DConnery%26aufirst%3DH.%2BS.%26aulast%3DArrington%26aufirst%3DE.%2BG.%26aulast%3DLewis%26aufirst%3DM.%2BM.%26aulast%3DLawler%26aufirst%3DC.%2BP.%26aulast%3DOxford%26aufirst%3DG.%2BS.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DK.%2BL.%26aulast%3DTodd%26aufirst%3DR.%2BD.%26aulast%3DBlake%26aufirst%3DB.%2BL.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DFunctional%2520selectivity%2520of%2520dopamine%2520receptor%2520agonists.%2520II.%2520Actions%2520of%2520dihydrexidine%2520in%2520D2L%2520receptor-transfected%2520MN9D%2520cells%2520and%2520pituitary%2520lactotrophs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D301%26spage%3D1179%26epage%3D1189%26doi%3D10.1124%2Fjpet.301.3.1179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Masri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salahpour, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Didriksen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghisi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">13656</span><span class="NLM_x">–</span> <span class="NLM_lpage">13661</span><span class="refDoi"> DOI: 10.1073/pnas.0803522105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1073%2Fpnas.0803522105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=13656-13661&author=B.+Masriauthor=A.+Salahpourauthor=M.+Didriksenauthor=V.+Ghisiauthor=J.+M.+Beaulieuauthor=R.+R.+Gainetdinovauthor=M.+G.+Caron&title=Antagonism+of+dopamine+D2+receptor%2Fbeta-arrestin+2+interaction+is+a+common+property+of+clinically+effective+antipsychotics&doi=10.1073%2Fpnas.0803522105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0803522105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0803522105%26sid%3Dliteratum%253Aachs%26aulast%3DMasri%26aufirst%3DB.%26aulast%3DSalahpour%26aufirst%3DA.%26aulast%3DDidriksen%26aufirst%3DM.%26aulast%3DGhisi%26aufirst%3DV.%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DAntagonism%2520of%2520dopamine%2520D2%2520receptor%252Fbeta-arrestin%25202%2520interaction%2520is%2520a%2520common%2520property%2520of%2520clinically%2520effective%2520antipsychotics%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D13656%26epage%3D13661%26doi%3D10.1073%2Fpnas.0803522105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Beaulieu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotnikova, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marion, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1016/j.cell.2005.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.cell.2005.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=16051150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFGjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2005&pages=261-273&author=J.+M.+Beaulieuauthor=T.+D.+Sotnikovaauthor=S.+Marionauthor=R.+J.+Lefkowitzauthor=R.+R.+Gainetdinovauthor=M.+G.+Caron&title=An+Akt%2Fbeta-arrestin+2%2FPP2A+signaling+complex+mediates+dopaminergic+neurotransmission+and+behavior&doi=10.1016%2Fj.cell.2005.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Sotnikova, Tatyana D.; Marion, Sebastien; Lefkowitz, Robert J.; Gainetdinov, Raul R.; Caron, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">261-273</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Dopamine plays an important role in the etiol. of schizophrenia, and D2 class dopamine receptors are the best-established target of antipsychotic drugs.  Here we show that D2 class-receptor-mediated Akt regulation involves the formation of signaling complexes contg. β-arrestin 2, PP2A, and Akt.  β-Arrestin 2 deficiency in mice results in redn. of dopamine-dependent behaviors, loss of Akt regulation by dopamine in the striatum, and disruption of the dopamine-dependent interaction of Akt with its neg. regulator, protein phosphatase 2A.  Importantly, canonical cAMP-mediated dopamine-receptor signaling is not inhibited in the absence of β-arrestin 2.  These results demonstrate that, apart from its classical function in receptor desensitization, β-arrestin 2 also acts as a signaling intermediate through a kinase/phosphatase scaffold.  Furthermore, this function of β-arrestin 2 is important for the expression of dopamine-assocd. behaviors, thus implicating β-arrestin 2 as a pos. mediator of dopaminergic synaptic transmission and a potential pharmacol. target for dopamine-related psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC2L_HMvsJuLVg90H21EOLACvtfcHk0lhtJfgBBxOdQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFGjsLw%253D&md5=841fbd1ab433f4795631118d9de65e4b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DSotnikova%26aufirst%3DT.%2BD.%26aulast%3DMarion%26aufirst%3DS.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DAn%2520Akt%252Fbeta-arrestin%25202%252FPP2A%2520signaling%2520complex%2520mediates%2520dopaminergic%2520neurotransmission%2520and%2520behavior%26jtitle%3DCell%26date%3D2005%26volume%3D122%26spage%3D261%26epage%3D273%26doi%3D10.1016%2Fj.cell.2005.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Luttrell, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maudsley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Rocca, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttrell, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span> </span><span class="NLM_article-title">Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">661</span><span class="refDoi"> DOI: 10.1126/science.283.5402.655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1126%2Fscience.283.5402.655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=9924018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADyaK1MXot1Kmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1999&pages=655-661&author=L.+M.+Luttrellauthor=S.+S.+Fergusonauthor=Y.+Daakaauthor=W.+E.+Millerauthor=S.+Maudsleyauthor=G.+J.+Della+Roccaauthor=F.+Linauthor=H.+Kawakatsuauthor=K.+Owadaauthor=D.+K.+Luttrellauthor=M.+G.+Caronauthor=R.+J.+Lefkowitz&title=Beta-arrestin-dependent+formation+of+beta2+adrenergic+receptor-Src+protein+kinase+complexes&doi=10.1126%2Fscience.283.5402.655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">β-Arrestin-dependent formation of β2 adrenergic receptor-Src protein kinase complexes</span></div><div class="casAuthors">Luttrell, L. M.; Ferguson, S. S. G.; Daaka, Y.; Miller, W. E.; Maudsley, S.; Rocca, G. J. Della; Lin, F.-T.; Kawakatsu, H.; Owada, K.; Luttrell, D. K.; Caron, M. G.; Lefkowitz, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">5402</span>),
    <span class="NLM_cas:pages">655-661</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The Ras-dependent activation of mitogen-activated protein (MAP) kinase pathways by many receptors coupled to heterotrimeric guanine nucleotide binding proteins (G proteins) requires the activation of Src family tyrosine kinases.  Stimulation of β2 adrenergic receptors resulted in the assembly of a protein complex contg. activated c-Src and the receptor.  Src recruitment was mediated by β-arrestin, which functions as an adapter protein, binding both c-Src and the agonist-occupied receptor.  β-Arrestin 1 mutants, impaired either in c-Src binding or in the ability to target receptors to clathrin-coated pits, acted as dominant neg. inhibitors of β2 adrenergic receptor-mediated activation of the MAP kinases Erk1 and Erk2.  These data suggest that β-arrestin binding, which terminates receptor-G protein coupling, also initiates a second wave of signal transduction in which the "desensitized" receptor functions as a crit. structural component of a mitogenic signaling complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_2hPyTs99rbVg90H21EOLACvtfcHk0lhtJfgBBxOdQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXot1Kmug%253D%253D&md5=3fc55fc9a12ae32562bf0693a0050803</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1126%2Fscience.283.5402.655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.283.5402.655%26sid%3Dliteratum%253Aachs%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26aulast%3DFerguson%26aufirst%3DS.%2BS.%26aulast%3DDaaka%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DW.%2BE.%26aulast%3DMaudsley%26aufirst%3DS.%26aulast%3DDella%2BRocca%26aufirst%3DG.%2BJ.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DKawakatsu%26aufirst%3DH.%26aulast%3DOwada%26aufirst%3DK.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DBeta-arrestin-dependent%2520formation%2520of%2520beta2%2520adrenergic%2520receptor-Src%2520protein%2520kinase%2520complexes%26jtitle%3DScience%26date%3D1999%26volume%3D283%26spage%3D655%26epage%3D661%26doi%3D10.1126%2Fscience.283.5402.655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S. K.</span><span> </span><span class="NLM_article-title">Transduction of receptor signals by beta-arrestins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">512</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.1126/science.1109237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1126%2Fscience.1109237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=15845844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlOjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=512-517&author=R.+J.+Lefkowitzauthor=S.+K.+Shenoy&title=Transduction+of+receptor+signals+by+beta-arrestins&doi=10.1126%2Fscience.1109237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Transduction of Receptor Signals by β-Arrestins</span></div><div class="casAuthors">Lefkowitz, Robert J.; Shenoy, Sudha K.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5721</span>),
    <span class="NLM_cas:pages">512-517</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The transmission of extracellular signals to the interior of the cell is a function of plasma membrane receptors, of which the seven transmembrane receptor family is by far the largest and most versatile.  Classically, these receptors stimulate heterotrimeric G proteins, which control rates of generation of diffusible second messengers and entry of ions at the plasma membrane.  Recent evidence, however, indicates another previously unappreciated strategy used by the receptors to regulate intracellular signaling pathways.  They direct the recruitment, activation, and scaffolding of cytoplasmic signaling complexes via two multifunctional adaptor and transducer mols., β-arrestins 1 and 2.  This mechanism regulates aspects of cell motility, chemotaxis, apoptosis, and likely other cellular functions through a rapidly expanding list of signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk2fXdqgYhC7Vg90H21EOLACvtfcHk0ljWAeOqtUSsIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlOjtLs%253D&md5=ed070237312d050e5d5ec437b3adc76c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1126%2Fscience.1109237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1109237%26sid%3Dliteratum%253Aachs%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26atitle%3DTransduction%2520of%2520receptor%2520signals%2520by%2520beta-arrestins%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D512%26epage%3D517%26doi%3D10.1126%2Fscience.1109237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Oshiro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tottori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uwahodo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishi, T.</span><span> </span><span class="NLM_article-title">Novel antipsychotic agents with dopamine autoreceptor agonist properties: Synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span><span class="refDoi"> DOI: 10.1021/jm940608g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm940608g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADyaK1cXosFaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=658-667&author=Y.+Oshiroauthor=S.+Satoauthor=N.+Kurahashiauthor=T.+Tanakaauthor=T.+Kikuchiauthor=K.+Tottoriauthor=Y.+Uwahodoauthor=T.+Nishi&title=Novel+antipsychotic+agents+with+dopamine+autoreceptor+agonist+properties%3A+Synthesis+and+pharmacology+of+7-%5B4-%284-phenyl-1-piperazinyl%29butoxy%5D-3%2C4-dihydro-2%281H%29-quinolinone+derivatives&doi=10.1021%2Fjm940608g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Antipsychotic Agents with Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone Derivatives</span></div><div class="casAuthors">Oshiro, Yasuo; Sato, Seiji; Kurahashi, Nobuyuki; Tanaka, Tatsuyoshi; Kikuchi, Tetsuro; Tottori, Katsura; Uwahodo, Yasufumi; Nishi, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">658-667</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop a novel antipsychotic agent which is an agonist of dopamine (DA) autoreceptors and an antagonist of postsynaptic DA receptors, a series of 7-[4-[4-(substituted phenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinones was synthesized and their dual activities were examd.  The postsynaptic DA receptor antagonistic activities of the compds. were evaluated by their ability to inhibit stereotypy induced by apomorphine in mice, and the autoreceptor agonist activities were detd. by their effects on the γ-butyrolactone (GBL)-induced increase in L-dihydroxyphenylalanine (DOPA) synthesis in the mouse brain.  Many compds. inhibited the stereotypic behavior, and several compds. reversed the GBL-induced increase in the DOPA synthesis.  Among them, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone (aripiprazole, OPC-14597) (I) had these 2 activities.  This compd. reversed the GBL-induced DOPA synthesis (ED50 values of 5.1 μmol/kg po) and inhibited the APO induced stereotypy (ED50 values of 0.6 mmol/kg po).  I induced catalepsy at 10-fold higher dose than that required for the antagonism of APO-induced stereotypy (ED50 value of 7.8 μmol/kg oral).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnD8-A-QQlZLVg90H21EOLACvtfcHk0ljWAeOqtUSsIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXosFaqtw%253D%253D&md5=02ff3a24cc876f68419f60acc4bae45e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm940608g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm940608g%26sid%3Dliteratum%253Aachs%26aulast%3DOshiro%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DKurahashi%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DT.%26aulast%3DTottori%26aufirst%3DK.%26aulast%3DUwahodo%26aufirst%3DY.%26aulast%3DNishi%26aufirst%3DT.%26atitle%3DNovel%2520antipsychotic%2520agents%2520with%2520dopamine%2520autoreceptor%2520agonist%2520properties%253A%2520Synthesis%2520and%2520pharmacology%2520of%25207-%255B4-%25284-phenyl-1-piperazinyl%2529butoxy%255D-3%252C4-dihydro-2%25281H%2529-quinolinone%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D658%26epage%3D667%26doi%3D10.1021%2Fjm940608g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Zhu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. M.</span><span> </span><span class="NLM_article-title">A general and straightforward method for the synthesis of 2-trifluoromethylbenzothiazoles</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2434</span><span class="NLM_x">–</span> <span class="NLM_lpage">2436</span><span class="refDoi"> DOI: 10.1021/ol1006899</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol1006899" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFaqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=2434-2436&author=J.+T.+Zhuauthor=Z.+X.+Chenauthor=H.+B.+Xieauthor=S.+Liauthor=Y.+M.+Wu&title=A+general+and+straightforward+method+for+the+synthesis+of+2-trifluoromethylbenzothiazoles&doi=10.1021%2Fol1006899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A General and Straightforward Method for the Synthesis of 2-Trifluoromethylbenzothiazoles</span></div><div class="casAuthors">Zhu, Jiangtao; Chen, Zixian; Xie, Haibo; Li, Shan; Wu, Yongming</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2434-2436</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient one-pot method for the synthesis of 2-trifluoromethylbenzothiazoles, e.g., I (R = H, H, Me, MeO, Me2N, F, Cl, Br, I, EtO2C, CN, Ac, NO2), by the treatment of trifluoromethylimidoyl chlorides with sodium hydrosulfide hydrate using PdCl2 as the sole catalyst in DMSO is described.  The reaction proceeds via thiolation/C-H bond functionalization/C-S bond formation in moderate to high yields with good functional group tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiK9nv5jmt2bVg90H21EOLACvtfcHk0ljWAeOqtUSsIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFaqtrg%253D&md5=0ef7933709345ae01fda8eb090502158</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fol1006899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol1006899%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%2BX.%26aulast%3DXie%26aufirst%3DH.%2BB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%2BM.%26atitle%3DA%2520general%2520and%2520straightforward%2520method%2520for%2520the%2520synthesis%2520of%25202-trifluoromethylbenzothiazoles%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D2434%26epage%3D2436%26doi%3D10.1021%2Fol1006899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Weissman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zewge, D.</span><span> </span><span class="NLM_article-title">Recent advances in ether dealkylation</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">7833</span><span class="NLM_x">–</span> <span class="NLM_lpage">7863</span><span class="refDoi"> DOI: 10.1016/j.tet.2005.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.tet.2005.05.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=7833-7863&author=S.+A.+Weissmanauthor=D.+Zewge&title=Recent+advances+in+ether+dealkylation&doi=10.1016%2Fj.tet.2005.05.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in ether dealkylation</span></div><div class="casAuthors">Weissman, Steven A.; Zewge, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">7833-7863</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review on the developments from 1995 through the end of 2004 with focus on reagents of practical value and some level of generality.  The following topics are discussed: deprotection of aryl and alkyl ethers (including propargylic), allyl and related ethers (including isoprenyl), benzylic ethers (including trityl), and cyclic ethers.  Aspects of regio- and chemoselectivities are also mentioned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYugNUDxpjLVg90H21EOLACvtfcHk0lh8aiUf_9RqQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFCltro%253D&md5=41a698090e3cc03e616d3c972d52e788</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2005.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2005.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DWeissman%26aufirst%3DS.%2BA.%26aulast%3DZewge%26aufirst%3DD.%26atitle%3DRecent%2520advances%2520in%2520ether%2520dealkylation%26jtitle%3DTetrahedron%26date%3D2005%26volume%3D61%26spage%3D7833%26epage%3D7863%26doi%3D10.1016%2Fj.tet.2005.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Shi, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrigley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelieveld, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fichtner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, M. F. G.</span><span> </span><span class="NLM_article-title">Antitumor benzothiazoles 0.3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">3375</span><span class="NLM_x">–</span> <span class="NLM_lpage">3384</span><span class="refDoi"> DOI: 10.1021/jm9600959</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9600959" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3375-3384&author=D.+F.+Shiauthor=T.+D.+Bradshawauthor=S.+Wrigleyauthor=C.+J.+McCallauthor=P.+Lelieveldauthor=I.+Fichtnerauthor=M.+F.+G.+Stevens&title=Antitumor+benzothiazoles+0.3.+Synthesis+of+2-%284-aminophenyl%29benzothiazoles+and+evaluation+of+their+activities+against+breast+cancer+cell+lines+in+vitro+and+in+vivo&doi=10.1021%2Fjm9600959"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm9600959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9600959%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DD.%2BF.%26aulast%3DBradshaw%26aufirst%3DT.%2BD.%26aulast%3DWrigley%26aufirst%3DS.%26aulast%3DMcCall%26aufirst%3DC.%2BJ.%26aulast%3DLelieveld%26aufirst%3DP.%26aulast%3DFichtner%26aufirst%3DI.%26aulast%3DStevens%26aufirst%3DM.%2BF.%2BG.%26atitle%3DAntitumor%2520benzothiazoles%25200.3.%2520Synthesis%2520of%25202-%25284-aminophenyl%2529benzothiazoles%2520and%2520evaluation%2520of%2520their%2520activities%2520against%2520breast%2520cancer%2520cell%2520lines%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D3375%26epage%3D3384%26doi%3D10.1021%2Fjm9600959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Jordan, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, A. B.</span><span> </span><span class="NLM_article-title">Efficient conversion of substituted aryl thioureas to 2-aminobenzothiazoles using benzyltrimethylammonium tribromide</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">8693</span><span class="NLM_x">–</span> <span class="NLM_lpage">8696</span><span class="refDoi"> DOI: 10.1021/jo0349431</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0349431" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVCrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=8693-8696&author=A.+D.+Jordanauthor=C.+Luoauthor=A.+B.+Reitz&title=Efficient+conversion+of+substituted+aryl+thioureas+to+2-aminobenzothiazoles+using+benzyltrimethylammonium+tribromide&doi=10.1021%2Fjo0349431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Conversion of Substituted Aryl Thioureas to 2-Aminobenzothiazoles Using Benzyltrimethylammonium Tribromide</span></div><div class="casAuthors">Jordan, Alfonzo D.; Luo, Chi; Reitz, Allen B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8693-8696</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The reaction of mol. bromine (Br2) with arylthioureas is known to produce 2-aminobenzothiazoles (Hugerschoff reaction).  The authors show here that benzyltrimethylammonium tribromide, a stable, cryst. org. ammonium tribromide (OATB), can be readily utilized as an alternative electrophilic bromine source.  It is easier to control the stoichiometry of addn. with an OATB, which minimizes arom. bromination caused by excess reagent.  The authors have developed a direct procedure from isothiocyanates and amines using tetrabutylammonium thiocyanate (Bu4NSCN) and PhCH2NMe3Br3 to afford functionalized 2-aminobenzothiazoles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog7je3cRW9g7Vg90H21EOLACvtfcHk0lh8aiUf_9RqQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVCrs70%253D&md5=b556244031d365d36fce4fba9d8f7e93</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjo0349431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0349431%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DA.%2BD.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DReitz%26aufirst%3DA.%2BB.%26atitle%3DEfficient%2520conversion%2520of%2520substituted%2520aryl%2520thioureas%2520to%25202-aminobenzothiazoles%2520using%2520benzyltrimethylammonium%2520tribromide%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D8693%26epage%3D8696%26doi%3D10.1021%2Fjo0349431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Kimple, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soundararajan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutsell, S. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roos, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, B. R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willard, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siderovski, D. P.</span><span> </span><span class="NLM_article-title">Structural determinants of G-protein alpha subunit selectivity by regulator of G-protein signaling 2 (RGS2)</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">19402</span><span class="NLM_x">–</span> <span class="NLM_lpage">19411</span><span class="refDoi"> DOI: 10.1074/jbc.M109.024711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1074%2Fjbc.M109.024711" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=19402-19411&author=A.+J.+Kimpleauthor=M.+Soundararajanauthor=S.+Q.+Hutsellauthor=A.+K.+Roosauthor=D.+J.+Urbanauthor=V.+Setolaauthor=B.+R.+S.+Templeauthor=B.+L.+Rothauthor=S.+Knappauthor=F.+S.+Willardauthor=D.+P.+Siderovski&title=Structural+determinants+of+G-protein+alpha+subunit+selectivity+by+regulator+of+G-protein+signaling+2+%28RGS2%29&doi=10.1074%2Fjbc.M109.024711"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.024711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.024711%26sid%3Dliteratum%253Aachs%26aulast%3DKimple%26aufirst%3DA.%2BJ.%26aulast%3DSoundararajan%26aufirst%3DM.%26aulast%3DHutsell%26aufirst%3DS.%2BQ.%26aulast%3DRoos%26aufirst%3DA.%2BK.%26aulast%3DUrban%26aufirst%3DD.%2BJ.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DTemple%26aufirst%3DB.%2BR.%2BS.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DWillard%26aufirst%3DF.%2BS.%26aulast%3DSiderovski%26aufirst%3DD.%2BP.%26atitle%3DStructural%2520determinants%2520of%2520G-protein%2520alpha%2520subunit%2520selectivity%2520by%2520regulator%2520of%2520G-protein%2520signaling%25202%2520%2528RGS2%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D19402%26epage%3D19411%26doi%3D10.1074%2Fjbc.M109.024711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Kroeze, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCorvy, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giguere, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciaky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">362</span><span class="NLM_x">–</span> <span class="NLM_lpage">369</span><span class="refDoi"> DOI: 10.1038/nsmb.3014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fnsmb.3014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=25895059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslOgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=362-369&author=W.+K.+Kroezeauthor=M.+F.+Sassanoauthor=X.+P.+Huangauthor=K.+Lansuauthor=J.+D.+McCorvyauthor=P.+M.+Giguereauthor=N.+Sciakyauthor=B.+L.+Roth&title=PRESTO-Tango+as+an+open-source+resource+for+interrogation+of+the+druggable+human+GPCRome&doi=10.1038%2Fnsmb.3014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome</span></div><div class="casAuthors">Kroeze, Wesley K.; Sassano, Maria F.; Huang, Xi-Ping; Lansu, Katherine; McCorvy, John D.; Giguere, Patrick M.; Sciaky, Noah; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">362-369</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are essential mediators of cellular signaling and are important targets of drug action.  Of the approx. 350 nonolfactory human GPCRs, more than 100 are still considered to be 'orphans' because their endogenous ligands remain unknown.  Here, we describe a unique open-source resource that allows interrogation of the druggable human GPCRome via a G protein-independent β-arrestin-recruitment assay.  We validate this unique platform at more than 120 nonorphan human GPCR targets, demonstrate its utility for discovering new ligands for orphan human GPCRs and describe a method (parallel receptorome expression and screening via transcriptional output, with transcriptional activation following arrestin translocation (PRESTO-Tango)) for the simultaneous and parallel interrogation of the entire human nonolfactory GPCRome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVbl7caV9gUrVg90H21EOLACvtfcHk0lhrD_MZOIuFwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslOgtLg%253D&md5=2a78b74a5f1425fa9e8b79b730c16be6</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3014%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DLansu%26aufirst%3DK.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DSciaky%26aufirst%3DN.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DPRESTO-Tango%2520as%2520an%2520open-source%2520resource%2520for%2520interrogation%2520of%2520the%2520druggable%2520human%2520GPCRome%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D362%26epage%3D369%26doi%3D10.1038%2Fnsmb.3014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Tsuruta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grewe, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eskay, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kebabian, J. W.</span><span> </span><span class="NLM_article-title">Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">292</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span><span class="refDoi"> DOI: 10.1038/292463a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2F292463a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=7254340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADyaL38Xks1Wjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=1981&pages=463-465&author=K.+Tsurutaauthor=E.+A.+Freyauthor=C.+W.+Greweauthor=T.+E.+Coteauthor=R.+L.+Eskayauthor=J.+W.+Kebabian&title=Evidence+that+LY-141865+specifically+stimulates+the+D-2+dopamine+receptor&doi=10.1038%2F292463a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor</span></div><div class="casAuthors">Tsuruta, K.; Frey, E. A.; Grewe, C. W.; Cote, T. E.; Eskay, R. L.; Kebabian, J. W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">5822</span>),
    <span class="NLM_cas:pages">463-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The ergoline analog, LY-141865  [80373-22-4] stimulated the D-2 dopamine  [51-61-6] receptor of rat dispersed neurointermediate lobe cells, as detd. by inhibition of α-MSH release and adenylate cyclase activity, but had no effect on the D-1 receptor of carp retina.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmcHikcsQi4rVg90H21EOLACvtfcHk0lhrD_MZOIuFwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xks1Wjsw%253D%253D&md5=5dfa99a5e7bbb0a7ba047ea068711b1c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2F292463a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F292463a0%26sid%3Dliteratum%253Aachs%26aulast%3DTsuruta%26aufirst%3DK.%26aulast%3DFrey%26aufirst%3DE.%2BA.%26aulast%3DGrewe%26aufirst%3DC.%2BW.%26aulast%3DCote%26aufirst%3DT.%2BE.%26aulast%3DEskay%26aufirst%3DR.%2BL.%26aulast%3DKebabian%26aufirst%3DJ.%2BW.%26atitle%3DEvidence%2520that%2520LY-141865%2520specifically%2520stimulates%2520the%2520D-2%2520dopamine%2520receptor%26jtitle%3DNature%26date%3D1981%26volume%3D292%26spage%3D463%26epage%3D465%26doi%3D10.1038%2F292463a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Yale, H. L.</span><span> </span><span class="NLM_article-title">The trifluoromethyl group in medicinal chemistry</span> <span class="citation_source-journal">J. Med. Pharm. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1959</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">133</span><span class="refDoi"> DOI: 10.1021/jm50003a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm50003a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADyaG1MXovVygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1959&pages=121-133&author=H.+L.+Yale&title=The+trifluoromethyl+group+in+medicinal+chemistry&doi=10.1021%2Fjm50003a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The trifluoromethyl group in medicinal chemistry</span></div><div class="casAuthors">Yale, Harry L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal & Pharmaceutical Chemistry</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">121-33</span>CODEN:
                <span class="NLM_cas:coden">JMPCAS</span>;
        ISSN:<span class="NLM_cas:issn">0095-9065</span>.
    </div><div class="casAbstract">A review with 37 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd8jbHZpWAJLVg90H21EOLACvtfcHk0lhrD_MZOIuFwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG1MXovVygtw%253D%253D&md5=d4825182e66a1eddc13cf1575432b2a5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm50003a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm50003a001%26sid%3Dliteratum%253Aachs%26aulast%3DYale%26aufirst%3DH.%2BL.%26atitle%3DThe%2520trifluoromethyl%2520group%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Pharm.%2520Chem.%26date%3D1959%26volume%3D1%26spage%3D121%26epage%3D133%26doi%3D10.1021%2Fjm50003a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Feenstra, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Moes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofma, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuipers, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulp, M. T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Heyden, J. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, C. G.</span><span> </span><span class="NLM_article-title">New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D-2-receptor and serotonin 5-HT1A-receptor affinities</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2345</span><span class="NLM_x">–</span> <span class="NLM_lpage">2349</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00425-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2FS0960-894X%2801%2900425-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=2345-2349&author=R.+W.+Feenstraauthor=J.+de+Moesauthor=J.+J.+Hofmaauthor=H.+Klingauthor=W.+Kuipersauthor=S.+K.+Longauthor=M.+T.+M.+Tulpauthor=J.+A.+M.+van+der+Heydenauthor=C.+G.+Kruse&title=New+1-aryl-4-%28biarylmethylene%29piperazines+as+potential+atypical+antipsychotics+sharing+dopamine+D-2-receptor+and+serotonin+5-HT1A-receptor+affinities&doi=10.1016%2FS0960-894X%2801%2900425-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900425-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900425-5%26sid%3Dliteratum%253Aachs%26aulast%3DFeenstra%26aufirst%3DR.%2BW.%26aulast%3Dde%2BMoes%26aufirst%3DJ.%26aulast%3DHofma%26aufirst%3DJ.%2BJ.%26aulast%3DKling%26aufirst%3DH.%26aulast%3DKuipers%26aufirst%3DW.%26aulast%3DLong%26aufirst%3DS.%2BK.%26aulast%3DTulp%26aufirst%3DM.%2BT.%2BM.%26aulast%3Dvan%2Bder%2BHeyden%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DNew%25201-aryl-4-%2528biarylmethylene%2529piperazines%2520as%2520potential%2520atypical%2520antipsychotics%2520sharing%2520dopamine%2520D-2-receptor%2520and%2520serotonin%25205-HT1A-receptor%2520affinities%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D2345%26epage%3D2349%26doi%3D10.1016%2FS0960-894X%2801%2900425-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Wagaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennels, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed coupling of optically active amines with aryl bromides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">8451</span><span class="NLM_x">–</span> <span class="NLM_lpage">8458</span><span class="refDoi"> DOI: 10.1021/ja971583o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja971583o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADyaK2sXls1GjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=1997&pages=8451-8458&author=S.+Wagawauthor=R.+A.+Rennelsauthor=S.+L.+Buchwald&title=Palladium-catalyzed+coupling+of+optically+active+amines+with+aryl+bromides&doi=10.1021%2Fja971583o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Coupling of Optically Active Amines with Aryl Bromides</span></div><div class="casAuthors">Wagaw, Seble; Rennels, Roger A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">8451-8458</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The coupling of enantiomerically enriched amines with aryl bromides produces the corresponding N-aryl derivs.  The choice of ligand in the palladium-catalyzed coupling is crit. to the formation of the anilines without loss of enantiomeric purity.  While LnPd [L = P(o-tolyl)3] successfully catalyzes the intramol. aryl amination of α-substituted optically pure amines, intermol. coupling reactions with this catalyst system gives racemized products.  In contrast, intermol. N-arylations employing LnPd [L = (±)-BINAP] gives products in good yields with no erosion of enantiopurity.  A mechanism for the obsd. racemization is proposed.  The utility of the intramol. process is demonstrated by the synthesis of 3, an intermediate in the formal synthesis of 4, a potent ACE inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi5uNO7GaBTrVg90H21EOLACvtfcHk0liYTuH3BWU8kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXls1GjtLc%253D&md5=a8dcc541351ffed7a879b289569cb03d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fja971583o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja971583o%26sid%3Dliteratum%253Aachs%26aulast%3DWagaw%26aufirst%3DS.%26aulast%3DRennels%26aufirst%3DR.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DPalladium-catalyzed%2520coupling%2520of%2520optically%2520active%2520amines%2520with%2520aryl%2520bromides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1997%26volume%3D119%26spage%3D8451%26epage%3D8458%26doi%3D10.1021%2Fja971583o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Kenakin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span> </span><span class="NLM_article-title">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span><span class="refDoi"> DOI: 10.1038/nrd3954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fnrd3954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=23411724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=205-216&author=T.+Kenakinauthor=A.+Christopoulos&title=Signalling+bias+in+new+drug+discovery%3A+detection%2C+quantification+and+therapeutic+impact&doi=10.1038%2Fnrd3954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span></div><div class="casAuthors">Kenakin, Terry; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-216</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Agonists of seven-transmembrane receptors, also known as G protein-coupled receptors (GPCRs), do not uniformly activate all cellular signalling pathways linked to a given seven-transmembrane receptor (a phenomenon termed ligand or agonist bias); this discovery has changed how high-throughput screens are designed and how lead compds. are optimized for therapeutic activity.  The ability to exptl. detect ligand bias has necessitated the development of methods for quantifying agonist bias in a way that can be used to guide structure-activity studies and the selection of drug candidates.  Here, we provide a viewpoint on which methods are appropriate for quantifying bias, based on knowledge of how cellular and intracellular signalling proteins control the conformation of seven-transmembrane receptors.  We also discuss possible predictions of how biased mols. may perform in vivo, and what potential therapeutic advantages they may provide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkDNsO17tty7Vg90H21EOLACvtfcHk0liYTuH3BWU8kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D&md5=712258b9158f753689e35fa31f1b67f0</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnrd3954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3954%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DSignalling%2520bias%2520in%2520new%2520drug%2520discovery%253A%2520detection%252C%2520quantification%2520and%2520therapeutic%2520impact%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D205%26epage%3D216%26doi%3D10.1038%2Fnrd3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Klein Herenbrink, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sykes, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donthamsetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canals, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coudrat, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shonberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, J. R.</span><span> </span><span class="NLM_article-title">The role of kinetic context in apparent biased agonism at GPCRs</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">10842</span><span class="refDoi"> DOI: 10.1038/ncomms10842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fncomms10842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=26905976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=10842&author=C.+Klein+Herenbrinkauthor=D.+A.+Sykesauthor=P.+Donthamsettiauthor=M.+Canalsauthor=T.+Coudratauthor=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=P.+M.+Sextonauthor=S.+J.+Charltonauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=J.+R.+Lane&title=The+role+of+kinetic+context+in+apparent+biased+agonism+at+GPCRs&doi=10.1038%2Fncomms10842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The role of kinetic context in apparent biased agonism at GPCRs</span></div><div class="casAuthors">Klein Herenbrink, Carmen; Sykes, David A.; Donthamsetti, Prashant; Canals, Meritxell; Coudrat, Thomas; Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben; Sexton, Patrick M.; Charlton, Steven J.; Javitch, Jonathan A.; Christopoulos, Arthur; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10842</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects.  This mechanism is usually inferred from pharmacol. data with the assumption that the confounding influences of observational (i.e., assay dependent) and system (i.e., cell background dependent) bias are excluded by exptl. design and anal.  Here we reveal that 'kinetic context', as detd. by ligand-binding kinetics and the temporal pattern of receptor-signalling processes, can have a profound influence on the apparent bias of a series of agonists for the dopamine D2 receptor and can even lead to reversals in the direction of bias.  We propose that kinetic context must be acknowledged in the design and interpretation of studies of biased agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoboe6-_23rF7Vg90H21EOLACvtfcHk0liYTuH3BWU8kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D&md5=3afdebd5ad1c8a8b1db93478e9b2c7d4</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fncomms10842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10842%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DCoudrat%26aufirst%3DT.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520role%2520of%2520kinetic%2520context%2520in%2520apparent%2520biased%2520agonism%2520at%2520GPCRs%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D10842%26doi%3D10.1038%2Fncomms10842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Klewe, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarpo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urizar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dipace, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gether, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egebjerg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, K. V.</span><span> </span><span class="NLM_article-title">Recruitment of beta-arrestin2 to the dopamine D2 receptor: Insights into anti-psychotic and anti-parkinsonian drug receptor signaling</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1215</span><span class="NLM_x">–</span> <span class="NLM_lpage">1222</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2008.03.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.neuropharm.2008.03.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2008&pages=1215-1222&author=I.+V.+Kleweauthor=S.+M.+Nielsenauthor=L.+Tarpoauthor=E.+Urizarauthor=C.+Dipaceauthor=J.+A.+Javitchauthor=U.+Getherauthor=J.+Egebjergauthor=K.+V.+Christensen&title=Recruitment+of+beta-arrestin2+to+the+dopamine+D2+receptor%3A+Insights+into+anti-psychotic+and+anti-parkinsonian+drug+receptor+signaling&doi=10.1016%2Fj.neuropharm.2008.03.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2008.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2008.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DKlewe%26aufirst%3DI.%2BV.%26aulast%3DNielsen%26aufirst%3DS.%2BM.%26aulast%3DTarpo%26aufirst%3DL.%26aulast%3DUrizar%26aufirst%3DE.%26aulast%3DDipace%26aufirst%3DC.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DGether%26aufirst%3DU.%26aulast%3DEgebjerg%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DK.%2BV.%26atitle%3DRecruitment%2520of%2520beta-arrestin2%2520to%2520the%2520dopamine%2520D2%2520receptor%253A%2520Insights%2520into%2520anti-psychotic%2520and%2520anti-parkinsonian%2520drug%2520receptor%2520signaling%26jtitle%3DNeuropharmacology%26date%3D2008%26volume%3D54%26spage%3D1215%26epage%3D1222%26doi%3D10.1016%2Fj.neuropharm.2008.03.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Burris, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molski, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tottori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yocca, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinoff, P. B.</span><span> </span><span class="NLM_article-title">Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">389</span><span class="refDoi"> DOI: 10.1124/jpet.102.033175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1124%2Fjpet.102.033175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=12065741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1SnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2002&pages=381-389&author=K.+D.+Burrisauthor=T.+F.+Molskiauthor=C.+Xuauthor=E.+Ryanauthor=K.+Tottoriauthor=T.+Kikuchiauthor=F.+D.+Yoccaauthor=P.+B.+Molinoff&title=Aripiprazole%2C+a+novel+antipsychotic%2C+is+a+high-affinity+partial+agonist+at+human+dopamine+D2+receptors&doi=10.1124%2Fjpet.102.033175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors</span></div><div class="casAuthors">Burris, Kevin D.; Molski, Thaddeus F.; Xu, Cen; Ryan, Elaine; Tottori, Katsura; Kikuchi, Tetsuro; Yocca, Frank D.; Molinoff, Perry B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">381-389</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Aripiprazole is the first next-generation atypical antipsychotic with a mechanism of action that differs from currently marketed typical and atypical antipsychotics.  Aripiprazole displays properties of an agonist and antagonist in animal models of dopaminergic hypoactivity and hyperactivity, resp.  This study examd. the interactions of aripiprazole with a single population of human D2 receptors to clarify further its pharmacol. properties.  In membranes prepd. from Chinese hamster ovary cells that express recombinant D2L receptors, aripiprazole bound with high affinity to both the G protein-coupled and uncoupled states of receptors.  Aripiprazole potently activated D2 receptor-mediated inhibition of cAMP accumulation.  Partial receptor inactivation using the alkylating agent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) significantly reduced the max. effect of aripiprazole on inhibition of cAMP accumulation.  This effect was seen with concns. of EEDQ that did not alter the maximal inhibitory effect of dopamine.  Consistent with the expected effects of a partial agonist, increasing concns. of aripiprazole blocked the action of dopamine with maximal blockade equal to the agonist effect of aripiprazole alone.  The efficacy of aripiprazole relative to that of dopamine varied from 25% in cells that lacked spare receptors for dopamine to 90% in cells with receptor reserve.  These results, together with previous studies demonstrating partial agonist activity at serotonin 5-hydroxytryptamine (5-HT)1A receptors and antagonist activity at 5-HT2A receptors, support the identification of aripiprazole as a dopamine-serotonin system stabilizer.  The receptor activity profile may underlie the unique activity of aripiprazole in animals and its antipsychotic activity in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu--oNCiWjJ7Vg90H21EOLACvtfcHk0lhDubDgUf9qSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1SnsLY%253D&md5=907bbba92bdfb6c4d2ee703f289c32f6</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.033175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.033175%26sid%3Dliteratum%253Aachs%26aulast%3DBurris%26aufirst%3DK.%2BD.%26aulast%3DMolski%26aufirst%3DT.%2BF.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRyan%26aufirst%3DE.%26aulast%3DTottori%26aufirst%3DK.%26aulast%3DKikuchi%26aufirst%3DT.%26aulast%3DYocca%26aufirst%3DF.%2BD.%26aulast%3DMolinoff%26aufirst%3DP.%2BB.%26atitle%3DAripiprazole%252C%2520a%2520novel%2520antipsychotic%252C%2520is%2520a%2520high-affinity%2520partial%2520agonist%2520at%2520human%2520dopamine%2520D2%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D302%26spage%3D381%26epage%3D389%26doi%3D10.1124%2Fjpet.102.033175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Winpenny, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cawkill, D.</span><span> </span><span class="NLM_article-title">Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased opioid receptor agonists</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">1393</span><span class="NLM_x">–</span> <span class="NLM_lpage">1403</span><span class="refDoi"> DOI: 10.1111/bph.13441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1111%2Fbph.13441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlOnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=1393-1403&author=D.+Winpennyauthor=M.+Clarkauthor=D.+Cawkill&title=Biased+ligand+quantification+in+drug+discovery%3A+from+theory+to+high+throughput+screening+to+identify+new+biased+opioid+receptor+agonists&doi=10.1111%2Fbph.13441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonists</span></div><div class="casAuthors">Winpenny, David; Clark, Mellissa; Cawkill, Darren</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1393-1403</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Biased GPCR ligands are able to engage with their target receptor in a manner that preferentially activates distinct downstream signalling and offers potential for next generation therapeutics.  However, accurate quantification of ligand bias in vitro is complex, and current best practice is not amenable for testing large nos. of compd.  We have therefore sought to apply ligand bias theory to an industrial scale screening campaign for the identification of new biased μ receptor agonists.  Exptl. Approach : μ receptor assays with appropriate dynamic range were developed for both Gαi-dependent signalling and β-arrestin2 recruitment. Δlog(Emax/EC50) anal. was validated as an alternative for the operational model of agonism in calcg. pathway bias towards Gαi-dependent signalling.  The anal. was applied to a high throughput screen to characterize the prevalence and nature of pathway bias among a diverse set of compds. with μ receptor agonist activity.  Key Results : A high throughput screening campaign yielded 440 hits with greater than 10-fold bias relative to DAMGO.  To validate these results, we quantified pathway bias of a subset of hits using the operational model of agonism.  The high degree of correlation across these biased hits confirmed that Δlog(Emax/EC50) was a suitable method for identifying genuine biased ligands within a large collection of diverse compds.  Conclusions and Implications : This work demonstrates that using Δlog(Emax/EC50), drug discovery can apply the concept of biased ligand quantification on a large scale and accelerate the deliberate discovery of novel therapeutics acting via this complex pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr27eSo6ucccrVg90H21EOLACvtfcHk0lhDubDgUf9qSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlOnsr0%253D&md5=3ca14bdd9f38add90937f8bf6c6cab37</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fbph.13441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13441%26sid%3Dliteratum%253Aachs%26aulast%3DWinpenny%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DM.%26aulast%3DCawkill%26aufirst%3DD.%26atitle%3DBiased%2520ligand%2520quantification%2520in%2520drug%2520discovery%253A%2520from%2520theory%2520to%2520high%2520throughput%2520screening%2520to%2520identify%2520new%2520biased%2520opioid%2520receptor%2520agonists%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D1393%26epage%3D1403%26doi%3D10.1111%2Fbph.13441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Gottlieb, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotlyar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nudelman, A.</span><span> </span><span class="NLM_article-title">NMR chemical shifts of common laboratory solvents as trace impurities</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">7512</span><span class="NLM_x">–</span> <span class="NLM_lpage">7515</span><span class="refDoi"> DOI: 10.1021/jo971176v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo971176v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVClsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1997&pages=7512-7515&author=H.+E.+Gottliebauthor=V.+Kotlyarauthor=A.+Nudelman&title=NMR+chemical+shifts+of+common+laboratory+solvents+as+trace+impurities&doi=10.1021%2Fjo971176v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">NMR chemical shifts of common laboratory solvents as trace impurities</span></div><div class="casAuthors">Gottlieb, Hugo E.; Kotlyar, Vadim; Nudelman, Abraham</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7512-7515</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The 1H (300 MHz) and 13C (75 MHz) NMR chem. shifts for >30 common impurities, such as lab. solvents, stabilizers, greases and water, are reported in 7 deuterated NMR solvents.  The temp. dependence of the chem. shift of the proton residual peak (HDO) in D2O is established for the entire liq. range of this sample.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocnoOemocS9LVg90H21EOLACvtfcHk0lhDubDgUf9qSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVClsbo%253D&md5=c297adda99f8c10e9f9b0ab9fe5f55be</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjo971176v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo971176v%26sid%3Dliteratum%253Aachs%26aulast%3DGottlieb%26aufirst%3DH.%2BE.%26aulast%3DKotlyar%26aufirst%3DV.%26aulast%3DNudelman%26aufirst%3DA.%26atitle%3DNMR%2520chemical%2520shifts%2520of%2520common%2520laboratory%2520solvents%2520as%2520trace%2520impurities%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1997%26volume%3D62%26spage%3D7512%26epage%3D7515%26doi%3D10.1021%2Fjo971176v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Barnea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strapps, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrada, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berman, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kloss, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. J.</span><span> </span><span class="NLM_article-title">The genetic design of signaling cascades to record receptor activation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">64</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span><span class="refDoi"> DOI: 10.1073/pnas.0710487105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1073%2Fpnas.0710487105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=18165312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvV2ktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=64-69&author=G.+Barneaauthor=W.+Strappsauthor=G.+Herradaauthor=Y.+Bermanauthor=J.+Ongauthor=B.+Klossauthor=R.+Axelauthor=K.+J.+Lee&title=The+genetic+design+of+signaling+cascades+to+record+receptor+activation&doi=10.1073%2Fpnas.0710487105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The genetic design of signaling cascades to record receptor activation</span></div><div class="casAuthors">Barnea, Gilad; Strapps, Walter; Herrada, Gilles; Berman, Yemiliya; Ong, Jane; Kloss, Brian; Axel, Richard; Lee, Kevin J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-69</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The authors have developed an exptl. strategy to monitor protein interactions in a cell with a high degree of selectivity and sensitivity.  A transcription factor is tethered to a membrane-bound receptor with a linker that contains a cleavage site for a specific protease.  Activation of the receptor recruits a signaling protein fused to the protease that then cleaves and releases the transcription factor to activate reporter genes in the nucleus.  This strategy converts a transient interaction into a stable and amplifiable reporter gene signal to record the activation of a receptor without interference from endogenous signaling pathways.  The authors have developed this assay for three classes of receptors: G protein-coupled receptors, receptor tyrosine kinases, and steroid hormone receptors.  Finally, the authors use the assay to identify a ligand for the orphan receptor GPR1, suggesting a role for this receptor in the regulation of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ugB7pgEqlrVg90H21EOLACvtfcHk0lin-sDcnY_rtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvV2ktA%253D%253D&md5=3b49dfdb2949d947e145084ac87bb343</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0710487105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0710487105%26sid%3Dliteratum%253Aachs%26aulast%3DBarnea%26aufirst%3DG.%26aulast%3DStrapps%26aufirst%3DW.%26aulast%3DHerrada%26aufirst%3DG.%26aulast%3DBerman%26aufirst%3DY.%26aulast%3DOng%26aufirst%3DJ.%26aulast%3DKloss%26aufirst%3DB.%26aulast%3DAxel%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26atitle%3DThe%2520genetic%2520design%2520of%2520signaling%2520cascades%2520to%2520record%2520receptor%2520activation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D64%26epage%3D69%26doi%3D10.1073%2Fpnas.0710487105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 31 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ana Mallo-Abreu, Irene Reyes-Resina, Jhonny Azuaje, Rafael Franco, Aitor García-Rey, Maria Majellaro, Darío Miranda-Pastoriza, Xerardo García-Mera, Willem Jespers, Hugo Gutiérrez-de-Terán, Gemma Navarro, <span class="NLM_string-name hlFld-ContribAuthor">Eddy Sotelo</span>. </span><span class="cited-content_cbyCitation_article-title">Potent and Subtype-Selective Dopamine D2 Receptor Biased Partial Agonists Discovered via an Ugi-Based Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 8710-8726. <a href="https://doi.org/10.1021/acs.jmedchem.1c00704" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00704</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00704&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00704%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252Band%252BSubtype-Selective%252BDopamine%252BD2%252BReceptor%252BBiased%252BPartial%252BAgonists%252BDiscovered%252Bvia%252Ban%252BUgi-Based%252BApproach%26aulast%3DMallo-Abreu%26aufirst%3DAna%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19042021%26date%3D10062021%26volume%3D64%26issue%3D12%26spage%3D8710%26epage%3D8726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Amy Hauck Newman, Francisco O. Battiti, <span class="NLM_string-name hlFld-ContribAuthor">Alessandro Bonifazi</span>. </span><span class="cited-content_cbyCitation_article-title">2016 Philip S. Portoghese Medicinal Chemistry Lectureship: Designing Bivalent or Bitopic Molecules for G-Protein Coupled Receptors. The Whole Is Greater Than the Sum of Its Parts. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (5)
                                     , 1779-1797. <a href="https://doi.org/10.1021/acs.jmedchem.9b01105" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01105</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01105%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2016%252BPhilip%252BS.%252BPortoghese%252BMedicinal%252BChemistry%252BLectureship%25253A%252BDesigning%252BBivalent%252Bor%252BBitopic%252BMolecules%252Bfor%252BG-Protein%252BCoupled%252BReceptors.%252BThe%252BWhole%252BIs%252BGreater%252BThan%252Bthe%252BSum%252Bof%252BIts%252BParts%26aulast%3DNewman%26aufirst%3DAmy%2BHauck%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D09072019%26date%3D24092019%26date%3D09092019%26volume%3D63%26issue%3D5%26spage%3D1779%26epage%3D1797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael
L. Martini, Caroline Ray, Xufen Yu, Jing Liu, Vladimir M. Pogorelov, William C. Wetsel, Xi-Ping Huang, John D. McCorvy, Marc G. Caron, <span class="NLM_string-name hlFld-ContribAuthor">Jian Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2019,</strong> <em>10 </em>
                                    (9)
                                     , 4160-4182. <a href="https://doi.org/10.1021/acschemneuro.9b00410" title="DOI URL">https://doi.org/10.1021/acschemneuro.9b00410</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.9b00410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.9b00410%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DDesigning%252BFunctionally%252BSelective%252BNoncatechol%252BDopamine%252BD1%252BReceptor%252BAgonists%252Bwith%252BPotent%252BIn%252BVivo%252BAntiparkinsonian%252BActivity%26aulast%3DMartini%26aufirst%3DMichael%2BL.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D20072019%26date%3D06082019%26date%3D20082019%26date%3D06082019%26volume%3D10%26issue%3D9%26spage%3D4160%26epage%3D4182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yudao Shen, John D. McCorvy, Michael L. Martini, Ramona M. Rodriguiz, Vladimir M. Pogorelov, Karen M. Ward, William C. Wetsel, Jing Liu, Bryan L. Roth, <span class="NLM_string-name hlFld-ContribAuthor">Jian Jin</span>. </span><span class="cited-content_cbyCitation_article-title">D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (9)
                                     , 4755-4771. <a href="https://doi.org/10.1021/acs.jmedchem.9b00508" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00508%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DD2%252BDopamine%252BReceptor%252BG%252BProtein-Biased%252BPartial%252BAgonists%252BBased%252Bon%252BCariprazine%26aulast%3DShen%26aufirst%3DYudao%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22032019%26date%3D18042019%26date%3D09042019%26volume%3D62%26issue%3D9%26spage%3D4755%26epage%3D4771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Michael
L. Martini, Jing Liu, Caroline Ray, Xufen Yu, Xi-Ping Huang, Aarti Urs, Nikhil Urs, John D. McCorvy, Marc G. Caron, Bryan L. Roth, <span class="NLM_string-name hlFld-ContribAuthor">Jian Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Defining Structure–Functional Selectivity Relationships (SFSR) for a Class of Non-Catechol Dopamine D1 Receptor Agonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (7)
                                     , 3753-3772. <a href="https://doi.org/10.1021/acs.jmedchem.9b00351" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00351</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00351%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDefining%252BStructure%2525E2%252580%252593Functional%252BSelectivity%252BRelationships%252B%252528SFSR%252529%252Bfor%252Ba%252BClass%252Bof%252BNon-Catechol%252BDopamine%252BD1%252BReceptor%252BAgonists%26aulast%3DMartini%26aufirst%3DMichael%2BL.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D25022019%26date%3D27032019%26date%3D15032019%26volume%3D62%26issue%3D7%26spage%3D3753%26epage%3D3772" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alessandro Bonifazi, Hideaki Yano, Adrian M. Guerrero, Vivek Kumar, Alexander F. Hoffman, Carl R. Lupica, Lei Shi, <span class="NLM_string-name hlFld-ContribAuthor">Amy Hauck Newman</span>. </span><span class="cited-content_cbyCitation_article-title">Novel and Potent Dopamine D2 Receptor Go-Protein Biased Agonists. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2019,</strong> <em>2 </em>
                                    (1)
                                     , 52-65. <a href="https://doi.org/10.1021/acsptsci.8b00060" title="DOI URL">https://doi.org/10.1021/acsptsci.8b00060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.8b00060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.8b00060%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DNovel%252Band%252BPotent%252BDopamine%252BD2%252BReceptor%252BGo-Protein%252BBiased%252BAgonists%26aulast%3DBonifazi%26aufirst%3DAlessandro%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21122018%26date%3D28012019%26date%3D14012019%26volume%3D2%26issue%3D1%26spage%3D52%26epage%3D65" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Liang Tan, Wenzhong Yan, John D. McCorvy, <span class="NLM_string-name hlFld-ContribAuthor">Jianjun Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure–Functional Selectivity Relationships (SFSRs) and Therapeutic Potential. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (22)
                                     , 9841-9878. <a href="https://doi.org/10.1021/acs.jmedchem.8b00435" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00435</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00435%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBiased%252BLigands%252Bof%252BG%252BProtein-Coupled%252BReceptors%252B%252528GPCRs%252529%25253A%252BStructure%2525E2%252580%252593Functional%252BSelectivity%252BRelationships%252B%252528SFSRs%252529%252Band%252BTherapeutic%252BPotential%26aulast%3DTan%26aufirst%3DLiang%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19032018%26date%3D10072018%26date%3D25062018%26volume%3D61%26issue%3D22%26spage%3D9841%26epage%3D9878" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Männel</span>, <span class="hlFld-ContribAuthor ">Mariama  Jaiteh</span>, <span class="hlFld-ContribAuthor ">Alexey  Zeifman</span>, <span class="hlFld-ContribAuthor ">Alena  Randakova</span>, <span class="hlFld-ContribAuthor ">Dorothee  Möller</span>, <span class="hlFld-ContribAuthor ">Harald  Hübner</span>, <span class="hlFld-ContribAuthor ">Peter  Gmeiner</span>, and <span class="hlFld-ContribAuthor ">Jens  Carlsson</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Guided Screening for Functionally Selective D2 Dopamine Receptor Ligands from a Virtual Chemical Library. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2017,</strong> <em>12 </em>
                                    (10)
                                     , 2652-2661. <a href="https://doi.org/10.1021/acschembio.7b00493" title="DOI URL">https://doi.org/10.1021/acschembio.7b00493</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.7b00493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.7b00493%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DStructure-Guided%252BScreening%252Bfor%252BFunctionally%252BSelective%252BD2%252BDopamine%252BReceptor%252BLigands%252Bfrom%252Ba%252BVirtual%252BChemical%252BLibrary%26aulast%3DM%25C3%25A4nnel%26aufirst%3DBarbara%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D15062017%26date%3D28082017%26date%3D19092017%26date%3D20102017%26date%3D28082017%26volume%3D12%26issue%3D10%26spage%3D2652%26epage%3D2661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Männel</span>, <span class="hlFld-ContribAuthor ">Daniela  Dengler</span>, <span class="hlFld-ContribAuthor ">Jeremy  Shonberg</span>, <span class="hlFld-ContribAuthor ">Harald  Hübner</span>, <span class="hlFld-ContribAuthor ">Dorothee  Möller</span>, and <span class="hlFld-ContribAuthor ">Peter  Gmeiner</span>  . </span><span class="cited-content_cbyCitation_article-title">Hydroxy-Substituted Heteroarylpiperazines: Novel Scaffolds for β-Arrestin-Biased D2R Agonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (11)
                                     , 4693-4713. <a href="https://doi.org/10.1021/acs.jmedchem.7b00363" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00363</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00363%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHydroxy-Substituted%252BHeteroarylpiperazines%25253A%252BNovel%252BScaffolds%252Bfor%252B%2525CE%2525B2-Arrestin-Biased%252BD2R%252BAgonists%26aulast%3DM%25C3%25A4nnel%26aufirst%3DBarbara%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07032017%26date%3D18052017%26date%3D08062017%26date%3D10052017%26volume%3D60%26issue%3D11%26spage%3D4693%26epage%3D4713" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dorothee  Möller</span>, <span class="hlFld-ContribAuthor ">Ashutosh  Banerjee</span>, <span class="hlFld-ContribAuthor ">Taygun C.  Uzuneser</span>, <span class="hlFld-ContribAuthor ">Marika  Skultety</span>, <span class="hlFld-ContribAuthor ">Tobias  Huth</span>, <span class="hlFld-ContribAuthor ">Bianca  Plouffe</span>, <span class="hlFld-ContribAuthor ">Harald  Hübner</span>, <span class="hlFld-ContribAuthor ">Christian  Alzheimer</span>, <span class="hlFld-ContribAuthor ">Kristina  Friedland</span>, <span class="hlFld-ContribAuthor ">Christian P.  Müller</span>, <span class="hlFld-ContribAuthor ">Michel  Bouvier</span>, and <span class="hlFld-ContribAuthor ">Peter  Gmeiner</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of G Protein-Biased Dopaminergics with a Pyrazolo[1,5-a]pyridine Substructure. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 2908-2929. <a href="https://doi.org/10.1021/acs.jmedchem.6b01857" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01857</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01857%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BG%252BProtein-Biased%252BDopaminergics%252Bwith%252Ba%252BPyrazolo%25255B1%25252C5-a%25255Dpyridine%252BSubstructure%26aulast%3DM%25C3%25B6ller%26aufirst%3DDorothee%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D21122016%26date%3D22032017%26date%3D13042017%26date%3D01032017%26volume%3D60%26issue%3D7%26spage%3D2908%26epage%3D2929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marshall W.  Tyler</span>, <span class="hlFld-ContribAuthor ">Josefa  Zaldivar-Diez</span>, and <span class="hlFld-ContribAuthor ">Stephen J.  Haggarty</span>  . </span><span class="cited-content_cbyCitation_article-title">Classics in Chemical Neuroscience: Haloperidol. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2017,</strong> <em>8 </em>
                                    (3)
                                     , 444-453. <a href="https://doi.org/10.1021/acschemneuro.7b00018" title="DOI URL">https://doi.org/10.1021/acschemneuro.7b00018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.7b00018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.7b00018%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DClassics%252Bin%252BChemical%252BNeuroscience%25253A%252BHaloperidol%26aulast%3DTyler%26aufirst%3DMarshall%2BW.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D19012017%26date%3D07022017%26date%3D15022017%26date%3D15032017%26date%3D07022017%26volume%3D8%26issue%3D3%26spage%3D444%26epage%3D453" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ee  Von Moo</span>, <span class="hlFld-ContribAuthor ">Kasper  Harpsøe</span>, <span class="hlFld-ContribAuthor ">Alexander S.  Hauser</span>, <span class="hlFld-ContribAuthor ">Ikuo  Masuho</span>, <span class="hlFld-ContribAuthor ">Hans  Bräuner-Osborne</span>, <span class="hlFld-ContribAuthor ">David E.  Gloriam</span>, <span class="hlFld-ContribAuthor ">Kirill A.  Martemyanov</span>. </span><span class="cited-content_cbyCitation_article-title">Ligand-directed bias of G protein signaling at the dopamine D2 receptor. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>176 </em><a href="https://doi.org/10.1016/j.chembiol.2021.07.004" title="DOI URL">https://doi.org/10.1016/j.chembiol.2021.07.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2021.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2021.07.004%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DLigand-directed%252Bbias%252Bof%252BG%252Bprotein%252Bsignaling%252Bat%252Bthe%252Bdopamine%252BD2%252Breceptor%26aulast%3DVon%2BMoo%26aufirst%3DEe%26date%3D2021%26volume%3D176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sam R. J.  Hoare</span>, <span class="hlFld-ContribAuthor ">Paul H.  Tewson</span>, <span class="hlFld-ContribAuthor ">Anne Marie  Quinn</span>, <span class="hlFld-ContribAuthor ">Thomas E.  Hughes</span>. </span><span class="cited-content_cbyCitation_article-title">A kinetic method for measuring agonist efficacy and ligand bias using high resolution biosensors and a kinetic data analysis framework. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2020,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-020-58421-9" title="DOI URL">https://doi.org/10.1038/s41598-020-58421-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-020-58421-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-020-58421-9%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DA%252Bkinetic%252Bmethod%252Bfor%252Bmeasuring%252Bagonist%252Befficacy%252Band%252Bligand%252Bbias%252Busing%252Bhigh%252Bresolution%252Bbiosensors%252Band%252Ba%252Bkinetic%252Bdata%252Banalysis%252Bframework%26aulast%3DHoare%26aufirst%3DSam%2BR.%2BJ.%26date%3D2020%26date%3D2020%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shetty Ravi  Dyavar</span>, <span class="hlFld-ContribAuthor ">Lisa F.  Potts</span>, <span class="hlFld-ContribAuthor ">Goichi  Beck</span>, <span class="hlFld-ContribAuthor ">Bhagya Laxmi  Dyavar Shetty</span>, <span class="hlFld-ContribAuthor ">Benton  Lawson</span>, <span class="hlFld-ContribAuthor ">Anthony T.  Podany</span>, <span class="hlFld-ContribAuthor ">Courtney V.  Fletcher</span>, <span class="hlFld-ContribAuthor ">Rama Rao  Amara</span>, <span class="hlFld-ContribAuthor ">Stella M.  Papa</span>. </span><span class="cited-content_cbyCitation_article-title">Transcriptomic approach predicts a major role for transforming growth factor beta type 1 pathway in
              L‐Dopa
              ‐induced dyskinesia in parkinsonian rats. </span><span class="cited-content_cbyCitation_journal-name">Genes, Brain and Behavior</span><span> <strong>2020,</strong> <em>19 </em>
                                    (8)
                                     <a href="https://doi.org/10.1111/gbb.12690" title="DOI URL">https://doi.org/10.1111/gbb.12690</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/gbb.12690&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fgbb.12690%26sid%3Dliteratum%253Aachs%26jtitle%3DGenes%252C%2520Brain%2520and%2520Behavior%26atitle%3DTranscriptomic%252Bapproach%252Bpredicts%252Ba%252Bmajor%252Brole%252Bfor%252Btransforming%252Bgrowth%252Bfactor%252Bbeta%252Btype%252B1%252Bpathway%252Bin%252BL%2525E2%252580%252590Dopa%252B%2525E2%252580%252590induced%252Bdyskinesia%252Bin%252Bparkinsonian%252Brats%26aulast%3DDyavar%26aufirst%3DShetty%2BRavi%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Paweł  Sobczuk</span>, <span class="hlFld-ContribAuthor ">Michał  Łomiak</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Cudnoch-Jędrzejewska</span>. </span><span class="cited-content_cbyCitation_article-title">Dopamine D1 Receptor in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (11)
                                     , 3232. <a href="https://doi.org/10.3390/cancers12113232" title="DOI URL">https://doi.org/10.3390/cancers12113232</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12113232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12113232%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DDopamine%252BD1%252BReceptor%252Bin%252BCancer%26aulast%3DSobczuk%26aufirst%3DPawe%25C5%2582%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D11%26spage%3D3232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Prashant  Donthamsetti</span>, <span class="hlFld-ContribAuthor ">Eduardo F.  Gallo</span>, <span class="hlFld-ContribAuthor ">David C.  Buck</span>, <span class="hlFld-ContribAuthor ">Edward L.  Stahl</span>, <span class="hlFld-ContribAuthor ">Ying  Zhu</span>, <span class="hlFld-ContribAuthor ">J. Robert  Lane</span>, <span class="hlFld-ContribAuthor ">Laura M.  Bohn</span>, <span class="hlFld-ContribAuthor ">Kim A.  Neve</span>, <span class="hlFld-ContribAuthor ">Christoph  Kellendonk</span>, <span class="hlFld-ContribAuthor ">Jonathan A.  Javitch</span>. </span><span class="cited-content_cbyCitation_article-title">Arrestin recruitment to dopamine D2 receptor mediates locomotion but not incentive motivation. </span><span class="cited-content_cbyCitation_journal-name">Molecular Psychiatry</span><span> <strong>2020,</strong> <em>25 </em>
                                    (9)
                                     , 2086-2100. <a href="https://doi.org/10.1038/s41380-018-0212-4" title="DOI URL">https://doi.org/10.1038/s41380-018-0212-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41380-018-0212-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41380-018-0212-4%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Psychiatry%26atitle%3DArrestin%252Brecruitment%252Bto%252Bdopamine%252BD2%252Breceptor%252Bmediates%252Blocomotion%252Bbut%252Bnot%252Bincentive%252Bmotivation%26aulast%3DDonthamsetti%26aufirst%3DPrashant%26date%3D2020%26date%3D2018%26volume%3D25%26issue%3D9%26spage%3D2086%26epage%3D2100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean Claude  Martel</span>, <span class="hlFld-ContribAuthor ">Silvia  Gatti McArthur</span>. </span><span class="cited-content_cbyCitation_article-title">Dopamine Receptor Subtypes, Physiology and Pharmacology: New Ligands and Concepts in Schizophrenia. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.01003" title="DOI URL">https://doi.org/10.3389/fphar.2020.01003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.01003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.01003%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DDopamine%252BReceptor%252BSubtypes%25252C%252BPhysiology%252Band%252BPharmacology%25253A%252BNew%252BLigands%252Band%252BConcepts%252Bin%252BSchizophrenia%26aulast%3DMartel%26aufirst%3DJean%2BClaude%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marta  Sanchez-Soto</span>, <span class="hlFld-ContribAuthor ">Ravi Kumar  Verma</span>, <span class="hlFld-ContribAuthor ">Blair K. A.  Willette</span>, <span class="hlFld-ContribAuthor ">Elizabeth C.  Gonye</span>, <span class="hlFld-ContribAuthor ">Annah M.  Moore</span>, <span class="hlFld-ContribAuthor ">Amy E.  Moritz</span>, <span class="hlFld-ContribAuthor ">Comfort A.  Boateng</span>, <span class="hlFld-ContribAuthor ">Hideaki  Yano</span>, <span class="hlFld-ContribAuthor ">R. Benjamin  Free</span>, <span class="hlFld-ContribAuthor ">Lei  Shi</span>, <span class="hlFld-ContribAuthor ">David R.  Sibley</span>. </span><span class="cited-content_cbyCitation_article-title">A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity. </span><span class="cited-content_cbyCitation_journal-name">Science Signaling</span><span> <strong>2020,</strong> <em>13 </em>
                                    (617)
                                     , eaaw5885. <a href="https://doi.org/10.1126/scisignal.aaw5885" title="DOI URL">https://doi.org/10.1126/scisignal.aaw5885</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/scisignal.aaw5885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscisignal.aaw5885%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Signaling%26atitle%3DA%252Bstructural%252Bbasis%252Bfor%252Bhow%252Bligand%252Bbinding%252Bsite%252Bchanges%252Bcan%252Ballosterically%252Bregulate%252BGPCR%252Bsignaling%252Band%252Bengender%252Bfunctional%252Bselectivity%26aulast%3DSanchez-Soto%26aufirst%3DMarta%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D617%26spage%3Deaaw5885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Su</span>, <span class="hlFld-ContribAuthor ">Zixi  Xue</span>, <span class="hlFld-ContribAuthor ">Yaoyao  Feng</span>, <span class="hlFld-ContribAuthor ">Ying  Xie</span>, <span class="hlFld-ContribAuthor ">Bo  Deng</span>, <span class="hlFld-ContribAuthor ">Ye  Yao</span>, <span class="hlFld-ContribAuthor ">Xiuyun  Tian</span>, <span class="hlFld-ContribAuthor ">Qiming  An</span>, <span class="hlFld-ContribAuthor ">Liang  Yang</span>, <span class="hlFld-ContribAuthor ">Qingyu  Yao</span>, <span class="hlFld-ContribAuthor ">Junsheng  Xue</span>, <span class="hlFld-ContribAuthor ">Guoshu  Chen</span>, <span class="hlFld-ContribAuthor ">Chunyi  Hao</span>, <span class="hlFld-ContribAuthor ">Tianyan  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">N-arylpiperazine-containing compound (C2): An enhancer of sunitinib in the treatment of pancreatic cancer, involving D1DR activation. </span><span class="cited-content_cbyCitation_journal-name">Toxicology and Applied Pharmacology</span><span> <strong>2019,</strong> <em>384 </em>, 114789. <a href="https://doi.org/10.1016/j.taap.2019.114789" title="DOI URL">https://doi.org/10.1016/j.taap.2019.114789</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.taap.2019.114789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.taap.2019.114789%26sid%3Dliteratum%253Aachs%26jtitle%3DToxicology%2520and%2520Applied%2520Pharmacology%26atitle%3DN-arylpiperazine-containing%252Bcompound%252B%252528C2%252529%25253A%252BAn%252Benhancer%252Bof%252Bsunitinib%252Bin%252Bthe%252Btreatment%252Bof%252Bpancreatic%252Bcancer%25252C%252Binvolving%252BD1DR%252Bactivation%26aulast%3DSu%26aufirst%3DHong%26date%3D2019%26volume%3D384%26spage%3D114789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marlene  Jacobson</span>, <span class="hlFld-ContribAuthor ">Wayne  Childers</span>, <span class="hlFld-ContribAuthor ">Magid  Abou‐Gharbia</span>. </span><span class="cited-content_cbyCitation_article-title">Dopamine D
              2
              Partial Agonists – Discovery, Evolution, and Therapeutic Potential. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 83-130. <a href="https://doi.org/10.1002/9783527814695.ch4" title="DOI URL">https://doi.org/10.1002/9783527814695.ch4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527814695.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527814695.ch4%26sid%3Dliteratum%253Aachs%26atitle%3DDopamine%252BD%252B2%252BPartial%252BAgonists%252B%2525E2%252580%252593%252BDiscovery%25252C%252BEvolution%25252C%252Band%252BTherapeutic%252BPotential%26aulast%3DJacobson%26aufirst%3DMarlene%26date%3D2019%26date%3D2019%26spage%3D83%26epage%3D130%26pub%3DWiley%26atitle%3DSuccessful%252BDrug%252BDiscovery%26aulast%3DFischer%26aufirst%3DJ%25C3%25A1nos%26date%3D2019%26date%3D2019%26volume%3D107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bryan L.  Roth</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs. </span><span class="cited-content_cbyCitation_journal-name">Nature Structural & Molecular Biology</span><span> <strong>2019,</strong> <em>26 </em>
                                    (7)
                                     , 535-544. <a href="https://doi.org/10.1038/s41594-019-0252-8" title="DOI URL">https://doi.org/10.1038/s41594-019-0252-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41594-019-0252-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41594-019-0252-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Structural%2520%2526%2520Molecular%2520Biology%26atitle%3DMolecular%252Bpharmacology%252Bof%252Bmetabotropic%252Breceptors%252Btargeted%252Bby%252Bneuropsychiatric%252Bdrugs%26aulast%3DRoth%26aufirst%3DBryan%2BL.%26date%3D2019%26date%3D2019%26volume%3D26%26issue%3D7%26spage%3D535%26epage%3D544" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rafaela R.  Silva</span>, <span class="hlFld-ContribAuthor ">Lucas T.  Parreiras-e-Silva</span>, <span class="hlFld-ContribAuthor ">Thais E.T.  Pompeu</span>, <span class="hlFld-ContribAuthor ">Diego A.  Duarte</span>, <span class="hlFld-ContribAuthor ">Carlos A.M.  Fraga</span>, <span class="hlFld-ContribAuthor ">Eliezer J.  Barreiro</span>, <span class="hlFld-ContribAuthor ">Ricardo  Menegatti</span>, <span class="hlFld-ContribAuthor ">Claudio M.  Costa-Neto</span>, <span class="hlFld-ContribAuthor ">François  Noël</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation of Functional Selectivity of Haloperidol, Clozapine, and LASSBio-579, an Experimental Compound With Antipsychotic-Like Actions in Rodents, at G Protein and Arrestin Signaling Downstream of the Dopamine D2 Receptor. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2019,</strong> <em>10 </em><a href="https://doi.org/10.3389/fphar.2019.00628" title="DOI URL">https://doi.org/10.3389/fphar.2019.00628</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2019.00628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2019.00628%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DEvaluation%252Bof%252BFunctional%252BSelectivity%252Bof%252BHaloperidol%25252C%252BClozapine%25252C%252Band%252BLASSBio-579%25252C%252Ban%252BExperimental%252BCompound%252BWith%252BAntipsychotic-Like%252BActions%252Bin%252BRodents%25252C%252Bat%252BG%252BProtein%252Band%252BArrestin%252BSignaling%252BDownstream%252Bof%252Bthe%252BDopamine%252BD2%252BReceptor%26aulast%3DSilva%26aufirst%3DRafaela%2BR.%26date%3D2019%26date%3D2019%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Metehan  Ilter</span>, <span class="hlFld-ContribAuthor ">Samman  Mansoor</span>, <span class="hlFld-ContribAuthor ">Ozge  Sensoy</span>. </span><span class="cited-content_cbyCitation_article-title">Utilization of Biased G Protein-Coupled Receptor Signaling towards Development of Safer and Personalized Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (11)
                                     , 2052. <a href="https://doi.org/10.3390/molecules24112052" title="DOI URL">https://doi.org/10.3390/molecules24112052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24112052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24112052%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DUtilization%252Bof%252BBiased%252BG%252BProtein-Coupled%252BReceptor%252BSignaling%252Btowards%252BDevelopment%252Bof%252BSafer%252Band%252BPersonalized%252BTherapeutics%26aulast%3DIlter%26aufirst%3DMetehan%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D11%26spage%3D2052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haixia  Ge</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhuo  Yang</span>, <span class="hlFld-ContribAuthor ">Kun  Qiang</span>, <span class="hlFld-ContribAuthor ">Chao  Chen</span>, <span class="hlFld-ContribAuthor ">Laiyu  Sun</span>, <span class="hlFld-ContribAuthor ">Ming  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical synthesis, microbial transformation and biological evaluation of tetrahydroprotoberberines as dopamine D1/D2 receptor ligands. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (10)
                                     , 2100-2111. <a href="https://doi.org/10.1016/j.bmc.2019.04.014" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.04.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.04.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.04.014%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DChemical%252Bsynthesis%25252C%252Bmicrobial%252Btransformation%252Band%252Bbiological%252Bevaluation%252Bof%252Btetrahydroprotoberberines%252Bas%252Bdopamine%252BD1%25252FD2%252Breceptor%252Bligands%26aulast%3DGe%26aufirst%3DHaixia%26date%3D2019%26volume%3D27%26issue%3D10%26spage%3D2100%26epage%3D2111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcel  Bermudez</span>, <span class="hlFld-ContribAuthor ">Trung Ngoc  Nguyen</span>, <span class="hlFld-ContribAuthor ">Christian  Omieczynski</span>, <span class="hlFld-ContribAuthor ">Gerhard  Wolber</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies for the discovery of biased GPCR ligands. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (4)
                                     , 1031-1037. <a href="https://doi.org/10.1016/j.drudis.2019.02.010" title="DOI URL">https://doi.org/10.1016/j.drudis.2019.02.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2019.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2019.02.010%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DStrategies%252Bfor%252Bthe%252Bdiscovery%252Bof%252Bbiased%252BGPCR%252Bligands%26aulast%3DBermudez%26aufirst%3DMarcel%26date%3D2019%26volume%3D24%26issue%3D4%26spage%3D1031%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antonella  Rigo</span>, <span class="hlFld-ContribAuthor ">Isacco  Ferrarini</span>, <span class="hlFld-ContribAuthor ">Giulio  Innamorati</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Vinante</span>. </span><span class="cited-content_cbyCitation_article-title">A single amino acid substitution in CXCL12 confers functional selectivity at the beta-arrestin level. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (48)
                                     , 28830-28841. <a href="https://doi.org/10.18632/oncotarget.25533" title="DOI URL">https://doi.org/10.18632/oncotarget.25533</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.25533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.25533%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DA%252Bsingle%252Bamino%252Bacid%252Bsubstitution%252Bin%252BCXCL12%252Bconfers%252Bfunctional%252Bselectivity%252Bat%252Bthe%252Bbeta-arrestin%252Blevel%26aulast%3DRigo%26aufirst%3DAntonella%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D48%26spage%3D28830%26epage%3D28841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lani S.  Chun</span>, <span class="hlFld-ContribAuthor ">Rakesh H.  Vekariya</span>, <span class="hlFld-ContribAuthor ">R. Benjamin  Free</span>, <span class="hlFld-ContribAuthor ">Yun  Li</span>, <span class="hlFld-ContribAuthor ">Da-Ting  Lin</span>, <span class="hlFld-ContribAuthor ">Ping  Su</span>, <span class="hlFld-ContribAuthor ">Fang  Liu</span>, <span class="hlFld-ContribAuthor ">Yoon  Namkung</span>, <span class="hlFld-ContribAuthor ">Stephane A.  Laporte</span>, <span class="hlFld-ContribAuthor ">Amy E.  Moritz</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Aubé</span>, <span class="hlFld-ContribAuthor ">Kevin J.  Frankowski</span>, <span class="hlFld-ContribAuthor ">David R.  Sibley</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Activity Investigation of a G Protein-Biased Agonist Reveals Molecular Determinants for Biased Signaling of the D2 Dopamine Receptor. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Synaptic Neuroscience</span><span> <strong>2018,</strong> <em>10 </em><a href="https://doi.org/10.3389/fnsyn.2018.00002" title="DOI URL">https://doi.org/10.3389/fnsyn.2018.00002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fnsyn.2018.00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffnsyn.2018.00002%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Synaptic%2520Neuroscience%26atitle%3DStructure-Activity%252BInvestigation%252Bof%252Ba%252BG%252BProtein-Biased%252BAgonist%252BReveals%252BMolecular%252BDeterminants%252Bfor%252BBiased%252BSignaling%252Bof%252Bthe%252BD2%252BDopamine%252BReceptor%26aulast%3DChun%26aufirst%3DLani%2BS.%26date%3D2018%26date%3D2018%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John D  McCorvy</span>, <span class="hlFld-ContribAuthor ">Kyle V  Butler</span>, <span class="hlFld-ContribAuthor ">Brendan  Kelly</span>, <span class="hlFld-ContribAuthor ">Katie  Rechsteiner</span>, <span class="hlFld-ContribAuthor ">Joel  Karpiak</span>, <span class="hlFld-ContribAuthor ">Robin M  Betz</span>, <span class="hlFld-ContribAuthor ">Bethany L  Kormos</span>, <span class="hlFld-ContribAuthor ">Brian K  Shoichet</span>, <span class="hlFld-ContribAuthor ">Ron O  Dror</span>, <span class="hlFld-ContribAuthor ">Jian  Jin</span>, <span class="hlFld-ContribAuthor ">Bryan L  Roth</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs. </span><span class="cited-content_cbyCitation_journal-name">Nature Chemical Biology</span><span> <strong>2018,</strong> <em>14 </em>
                                    (2)
                                     , 126-134. <a href="https://doi.org/10.1038/nchembio.2527" title="DOI URL">https://doi.org/10.1038/nchembio.2527</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nchembio.2527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnchembio.2527%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Chemical%2520Biology%26atitle%3DStructure-inspired%252Bdesign%252Bof%252B%2525CE%2525B2-arrestin-biased%252Bligands%252Bfor%252Baminergic%252BGPCRs%26aulast%3DMcCorvy%26aufirst%3DJohn%2BD%26date%3D2018%26date%3D2017%26volume%3D14%26issue%3D2%26spage%3D126%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amy E.  Moritz</span>, <span class="hlFld-ContribAuthor ">R. Benjamin  Free</span>, <span class="hlFld-ContribAuthor ">David R.  Sibley</span>. </span><span class="cited-content_cbyCitation_article-title">Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds. </span><span class="cited-content_cbyCitation_journal-name">Cellular Signalling</span><span> <strong>2018,</strong> <em>41 </em>, 75-81. <a href="https://doi.org/10.1016/j.cellsig.2017.07.003" title="DOI URL">https://doi.org/10.1016/j.cellsig.2017.07.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cellsig.2017.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cellsig.2017.07.003%26sid%3Dliteratum%253Aachs%26jtitle%3DCellular%2520Signalling%26atitle%3DAdvances%252Band%252Bchallenges%252Bin%252Bthe%252Bsearch%252Bfor%252BD2%252Band%252BD3%252Bdopamine%252Breceptor-selective%252Bcompounds%26aulast%3DMoritz%26aufirst%3DAmy%2BE.%26date%3D2018%26volume%3D41%26spage%3D75%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Barbara  Männel</span>, <span class="hlFld-ContribAuthor ">Harald  Hübner</span>, <span class="hlFld-ContribAuthor ">Dorothée  Möller</span>, <span class="hlFld-ContribAuthor ">Peter  Gmeiner</span>. </span><span class="cited-content_cbyCitation_article-title">β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (20)
                                     , 5613-5628. <a href="https://doi.org/10.1016/j.bmc.2017.08.037" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.08.037</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.08.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.08.037%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3D%2525CE%2525B2-Arrestin%252Bbiased%252Bdopamine%252BD2%252Breceptor%252Bpartial%252Bagonists%25253A%252BSynthesis%252Band%252Bpharmacological%252Bevaluation%26aulast%3DM%25C3%25A4nnel%26aufirst%3DBarbara%26date%3D2017%26volume%3D25%26issue%3D20%26spage%3D5613%26epage%3D5628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cai-Zhu  Chang</span>, <span class="hlFld-ContribAuthor ">Wan  Xu</span>, <span class="hlFld-ContribAuthor ">Meng-Tian  Zeng</span>, <span class="hlFld-ContribAuthor ">Min  Liu</span>, <span class="hlFld-ContribAuthor ">Xing  Liu</span>, <span class="hlFld-ContribAuthor ">Hui  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhi-Bing  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-catalyzed tandem reaction of 2-haloanilines with thiocarbamoyl chloride: Synthesis of 2-aminobenzothiazoles. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2017,</strong> <em>47 </em>
                                    (13)
                                     , 1262-1267. <a href="https://doi.org/10.1080/00397911.2017.1324033" title="DOI URL">https://doi.org/10.1080/00397911.2017.1324033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2017.1324033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2017.1324033%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DCopper-catalyzed%252Btandem%252Breaction%252Bof%252B2-haloanilines%252Bwith%252Bthiocarbamoyl%252Bchloride%25253A%252BSynthesis%252Bof%252B2-aminobenzothiazoles%26aulast%3DChang%26aufirst%3DCai-Zhu%26date%3D2017%26date%3D2017%26volume%3D47%26issue%3D13%26spage%3D1262%26epage%3D1267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0001.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0003.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Discovery of compound <b>1</b>, a G protein-biased D2R partial agonist. Benzothiazole substitution and linker modification of a β-arrestin-biased D2R agonist led to compound <b>1</b>, which is a D2R Gi/o partial agonist with weak efficacy for β-arrestin recruitment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0006.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compound <b>1</b> Analogues to Explore the RHS Benzothiazole Moiety<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, EtOH, reflux, 6 h, 30–80% yield; (b) NaI/K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 6 h, 50–70% yield; (c) (i) Ph<sub>3</sub>P, Et<sub>3</sub>N, CCl<sub>4</sub>, TFA, 0 °C, 10 min, (ii) 3-methoxyaniline/CCl<sub>4</sub>, reflux, 3 h, 86% yield; (d) NaSH·<i>x</i>H<sub>2</sub>O, PdCl<sub>2</sub>, DMSO, 50–110 °C, 3 h, 85% yield; (e) HI, reflux, 5 h, 83–90%; (f) RMgBr, THF, −10 °C, 90 min, ∼100% yield; (g) (i) K<sub>3</sub>Fe(CN)<sub>6</sub>, NaOH, H<sub>2</sub>O, CH<sub>3</sub>OH, 60 °C, 2 h, (ii) K<sub>2</sub>CO<sub>3</sub>, 60 °C, 1 h, 82–87% yield; (h) NHR′R′′, PhCH<sub>2</sub>N(CH<sub>3</sub>)<sub>3</sub>Br<sub>3</sub>, THF, rt, overnight, 93–96% yield.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0007.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound <b>1</b> Analogues to Explore the LHS Phenylpiperazine Moiety<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NaI/K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 6 h, 50–70% yield; (b) Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, <i>t</i>-BuONa, toluene, sealed tube, 100 °C, overnight, 52–89% yield; (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1 h, 92–96% yield; (d) Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, <i>t</i>-BuONa, toluene, sealed tube, 100 °C, 4 h, 56–67% yield; (e) Pd(PPh<sub>3</sub>)<sub>4</sub>, K<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, microwave, 93% yield.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0008.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Combination Compounds<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3,</sub> EtOH, reflux, 6 h, 30–80% yield; (b) NaI/K<sub>2</sub>CO<sub>3</sub>, CH<sub>3</sub>CN, reflux, 6 h, 50–70% yield.</p></p></figure><figure data-id="fig2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0004.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> are G protein-biased D2R partial agonists. (A) Activity of compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, <b>54</b>, and quinpirole in the D2R-mediated Gi/o coupled isoproterenol-stimulated cAMP production assay using HEK293T cells expressing D2R and GloSensor-22F. All six tested compounds were partial agonists compared to quinpirole (EC<sub>50</sub> = 1.7 nM), which was used as a positive control. (B) Activity of compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, <b>54</b>, and quinpirole in the D2R-mediated β-arrestin-2 translocation Tango assay using HTLA cells transfected with a D2 V2-TCS-tTA construct. <b>1</b> recruited β-arrestin weakly, and the other five compounds did not substantially recruit β-arrestin compared to the full agonist quinpirole (EC<sub>50</sub> = 0.8 nM). Data are representative of at least three independent experiments performed in triplicate. (C) Bias plot of compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, <b>54</b>, and quinpirole in the D2R-mediated cAMP inhibition GloSensor assay versus the D2R-mediated β-arrestin-2 translocation Tango assay. Quinpirole shows equal activity in both assays, but compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> cluster toward G protein activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/medium/jm-2016-01208w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0005.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> do not activate β-arrestin recruitment in the D2R-mediated BRET assay, while compound <b>59</b> is a partial agonist in the D2R β-arrestin-2 recruitment Tango assay and D2R Gi/o-mediated cAMP inhibition assay. (A) Activity of aripiprazole, compound <b>1</b>, compound <b>59</b>, and quinpirole in the D2R-mediated BRET-based β-arrestin-2 recruitment assay using HEK293 cells expressing GRK2. Aripiprazole and compound <b>59</b> were partial agonists that promote β-arrestin recruitment to D2R, while compound <b>1</b> was not active in the BRET assay. Quinpirole (EC<sub>50</sub> = 7.0 nM) was used as a positive control. (B) Activity of compound <b>59</b> and quinpirole in the D2R-mediated β-arrestin-2 translocation Tango assay using HTLA cells transfected with a D2 V2-TCS-tTA construct. Compound <b>59</b> displayed robust β-arrestin recruitment in the Tango assay (EC<sub>50</sub> = 46 nM, <i>E</i><sub>max</sub> = 67%) compared to the full agonist quinpirole (EC<sub>50</sub> = 2.3 nM). (C) Activity of compound <b>59</b> and quinpirole in the D2R-mediated Gi/o coupled isoproterenol-stimulated cAMP production assay using HEK293T cells expressing D2R and GloSensor-22F. Compound <b>59</b> was a partial agonist (EC<sub>50</sub> = 102 nM, <i>E</i><sub>max</sub> = 63%) compared to quinpirole (EC<sub>50</sub> = 1.2 nM), which was used as a positive control. (D) D2R β-arrestin recruitment activity by compounds <b>1</b>, <b>53</b>, and <b>59</b> as measured by DiscoverX in D2R-expressing CHO cells. Compounds <b>1</b>, <b>53</b>, and <b>59</b> showed no activity up to 10 μM. Quinpirole (EC<sub>50</sub> = 28 nM) was used as a positive control. (E) Compound <b>1</b> (IC<sub>50</sub> = 18 nM) blocked dopamine (DA, EC<sub>50</sub> = 11 nM) stimulated β-arrestin recruitment in the BRET assay. (F) Activity of compounds <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b> in the BRET assay. All compounds were not active in the BRET-based β-arrestin-2 recruitment assay, while quinpirole (EC<sub>50</sub> = 12 nM) was used as a positive control. (G) Activity of aripiprazole and compounds <b>1</b> and <b>53</b> in the D2R Gαi1–Gγ2 dissociation BRET assay. Aripiprazole (EC<sub>50</sub> = 0.99 nM), compound <b>1</b> (EC<sub>50</sub> = 3.6 nM), and <b>53</b> (EC<sub>50</sub> = 4.6 nM) all displayed partial agonist activity (78%, 57%, and 47%, respectively) relative to quinpirole. Quinpirole (EC<sub>50</sub> = 1.7 nM) was used as a positive control. Except for the DiscoverX assay (<i>n</i> = 1, performed in duplicate), data are representative of at least three independent experiments performed in triplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-23/acs.jmedchem.6b01208/20161202/images/large/jm-2016-01208w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01208&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i83">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27031" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27031" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 52 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Hisahara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimohama, S.</span><span> </span><span class="NLM_article-title">Dopamine receptors and Parkinson’s Disease</span> <span class="citation_source-journal">Int. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">403039</span><span class="refDoi"> DOI: 10.1155/2011/403039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1155%2F2011%2F403039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=25954517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A280%3ADC%252BC2MfitVyqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=403039&author=S.+Hisaharaauthor=S.+Shimohama&title=Dopamine+receptors+and+Parkinson%E2%80%99s+Disease&doi=10.1155%2F2011%2F403039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptors and Parkinson's disease</span></div><div class="casAuthors">Hisahara Shin; Shimohama Shun</div><div class="citationInfo"><span class="NLM_cas:title">International journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">403039</span>
        ISSN:<span class="NLM_cas:issn">2090-2069</span>.
    </div><div class="casAbstract">Parkinson's disease (PD) is a progressive extrapyramidal motor disorder.  Pathologically, this disease is characterized by the selective dopaminergic (DAergic) neuronal degeneration in the substantia nigra.  Correcting the DA deficiency in PD with levodopa (L-dopa) significantly attenuates the motor symptoms; however, its effectiveness often declines, and L-dopa-related adverse effects emerge after long-term treatment.  Nowadays, DA receptor agonists are useful medication even regarded as first choice to delay the starting of L-dopa therapy.  In advanced stage of PD, they are also used as adjunct therapy together with L-dopa.  DA receptor agonists act by stimulation of presynaptic and postsynaptic DA receptors.  Despite the usefulness, they could be causative drugs for valvulopathy and nonmotor complication such as DA dysregulation syndrome (DDS).  In this paper, physiological characteristics of DA receptor familyare discussed.  We also discuss the validity, benefits, and specific adverse effects of pharmaceutical DA receptor agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOLp2jGEspDyA3UY9EwTNrfW6udTcc2eZZFncfhyPzzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MfitVyqug%253D%253D&md5=fbf76c98b2eb9d42dbecb96a7273481b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1155%2F2011%2F403039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F403039%26sid%3Dliteratum%253Aachs%26aulast%3DHisahara%26aufirst%3DS.%26aulast%3DShimohama%26aufirst%3DS.%26atitle%3DDopamine%2520receptors%2520and%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DInt.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D2011%26spage%3D403039%26doi%3D10.1155%2F2011%2F403039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Gray, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">The pipeline and future of drug development in schizophrenia</span> <span class="citation_source-journal">Mol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">904</span><span class="NLM_x">–</span> <span class="NLM_lpage">922</span><span class="refDoi"> DOI: 10.1038/sj.mp.4002062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fsj.mp.4002062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=17667958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVyjtr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=904-922&author=J.+A.+Grayauthor=B.+L.+Roth&title=The+pipeline+and+future+of+drug+development+in+schizophrenia&doi=10.1038%2Fsj.mp.4002062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The pipeline and future of drug development in schizophrenia</span></div><div class="casAuthors">Gray, J. A.; Roth, B. L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Psychiatry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">904-922</span>CODEN:
                <span class="NLM_cas:coden">MOPSFQ</span>;
        ISSN:<span class="NLM_cas:issn">1359-4184</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  While the current antipsychotic medications have profoundly impacted the treatment of schizophrenia over the past 50 years, the newer atypical antipsychotics have not fulfilled initial expectations, and enormous challenges remain in long-term treatment of this debilitating disease.  In particular, improved treatment of the neg. symptoms and cognitive dysfunction in schizophrenia which greatly impact overall morbidity is needed.  In this review we will briefly discuss the current pipeline of drugs for schizophrenia, outlining many of the strategies and targets currently under investigation for the development of new schizophrenia drugs.  Many of these compds. have great potential as augmenting agents in the treatment of neg. symptoms and cognition.  In addn., we will highlight the importance of developing new paradigms for drug discovery in schizophrenia and call for an increased role of academic scientists in discovering and validating novel drug targets.  Indeed, recent breakthroughs in genetic studies of schizophrenia are allowing for the development of hypothesis-driven approaches for discovering possible disease-modifying drugs for schizophrenia.  Thus, this is an exciting and pivotal time for the development of truly novel approaches to drug development and treatment of complex disorders like schizophrenia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTZ3qO-W1xFLVg90H21EOLACvtfcHk0liySQQoe9lATg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVyjtr3L&md5=f0b2e1ece99057228282fa1ad71855b1</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.mp.4002062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.mp.4002062%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DThe%2520pipeline%2520and%2520future%2520of%2520drug%2520development%2520in%2520schizophrenia%26jtitle%3DMol.%2520Psychiatry%26date%3D2007%26volume%3D12%26spage%3D904%26epage%3D922%26doi%3D10.1038%2Fsj.mp.4002062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Beaulieu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinoza, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span> </span><span class="NLM_article-title">Dopamine receptors - IUPHAR Review 13</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">172</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1111/bph.12906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1111%2Fbph.12906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=25671228" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=172&publication_year=2015&pages=1-23&author=J.+M.+Beaulieuauthor=S.+Espinozaauthor=R.+R.+Gainetdinov&title=Dopamine+receptors+-+IUPHAR+Review+13&doi=10.1111%2Fbph.12906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine receptors - IUPHAR Review 13</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Espinoza, Stefano; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">172</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-23</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The variety of physiol. functions controlled by dopamine in the brain and periphery is mediated by the D1, D2, D3, D4 and D5 dopamine GPCRs.  Drugs acting on dopamine receptors are significant tools for the management of several neuropsychiatric disorders including schizophrenia, bipolar disorder, depression and Parkinson's disease.  Recent investigations of dopamine receptor signalling have shown that dopamine receptors, apart from their canonical action on cAMP-mediated signalling, can regulate a myriad of cellular responses to fine-tune the expression of dopamine-assocd. behaviors and functions.  Such signalling mechanisms may involve alternate G protein coupling or non-G protein mechanisms involving ion channels, receptor tyrosine kinases or proteins such as β-arrestins that are classically involved in GPCR desensitization.  Another level of complexity is the growing appreciation of the physiol. roles played by dopamine receptor heteromers.  Applications of new in vivo techniques have significantly furthered the understanding of the physiol. functions played by dopamine receptors.  Here we provide an update of the current knowledge regarding the complex biol., signalling, physiol. and pharmacol. of dopamine receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1fpdKAWrR5rVg90H21EOLACvtfcHk0liySQQoe9lATg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFWlsLjJ&md5=7f15533abc8fb6aa76a4ec41072b6219</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1111%2Fbph.12906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12906%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DEspinoza%26aufirst%3DS.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DDopamine%2520receptors%2520-%2520IUPHAR%2520Review%252013%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2015%26volume%3D172%26spage%3D1%26epage%3D23%26doi%3D10.1111%2Fbph.12906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Beaulieu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span> </span><span class="NLM_article-title">The physiology, signaling, and pharmacology of dopamine receptors</span> <span class="citation_source-journal">Pharmacol. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">63</span><span class="NLM_x">, </span> <span class="NLM_fpage">182</span><span class="NLM_x">–</span> <span class="NLM_lpage">217</span><span class="refDoi"> DOI: 10.1124/pr.110.002642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1124%2Fpr.110.002642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=21303898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjslGis70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2011&pages=182-217&author=J.+M.+Beaulieuauthor=R.+R.+Gainetdinov&title=The+physiology%2C+signaling%2C+and+pharmacology+of+dopamine+receptors&doi=10.1124%2Fpr.110.002642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The physiology, signaling, and pharmacology of dopamine receptors</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Gainetdinov, Raul R.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">182-217</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  G protein-coupled dopamine receptors (D1, D2, D3, D4, and D5) mediate all of the physiol. functions of the catecholaminergic neurotransmitter dopamine, ranging from voluntary movement and reward to hormonal regulation and hypertension.  Pharmacol. agents targeting dopaminergic neurotransmission have been clin. used in the management of several neurol. and psychiatric disorders, including Parkinson's disease, schizophrenia, bipolar disorder, Huntington's disease, attention deficit hyperactivity disorder (ADHD1), and Tourette's syndrome.  Numerous advances have occurred in understanding the general structural, biochem., and functional properties of dopamine receptors that have led to the development of multiple pharmacol. active compds. that directly target dopamine receptors, such as antiparkinson drugs and antipsychotics.  Recent progress in understanding the complex biol. of dopamine receptor-related signal transduction mechanisms has revealed that, in addn. to their primary action on cAMP-mediated signaling, dopamine receptors can act through diverse signaling mechanisms that involve alternative G protein coupling or through G protein-independent mechanisms via interactions with ion channels or proteins that are characteristically implicated in receptor desensitization, such as β-arrestins.  One of the future directions in managing dopamine-related pathol. conditions may involve a transition from the approaches that directly affect receptor function to a precise targeting of postreceptor intracellular signaling modalities either directly or through ligand-biased signaling pharmacol.  In this comprehensive review, we discuss dopamine receptor classification, their basic structural and genetic organization, their distribution and functions in the brain and the periphery, and their regulation and signal transduction mechanisms.  In addn., we discuss the abnormalities of dopamine receptor expression, function, and signaling that are documented in human disorders and the current pharmacol. and emerging trends in the development of novel therapeutic agents that act at dopamine receptors and/or on related signaling events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplp84qmbSbA7Vg90H21EOLACvtfcHk0liySQQoe9lATg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjslGis70%253D&md5=53e6841062c98abe60c732692109e498</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1124%2Fpr.110.002642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.110.002642%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26atitle%3DThe%2520physiology%252C%2520signaling%252C%2520and%2520pharmacology%2520of%2520dopamine%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2011%26volume%3D63%26spage%3D182%26epage%3D217%26doi%3D10.1124%2Fpr.110.002642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Noble, E. P.</span><span> </span><span class="NLM_article-title">D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes</span> <span class="citation_source-journal">Am. J. Med. Genet., Part B</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">116B</span><span class="NLM_x">, </span> <span class="NLM_fpage">103</span><span class="NLM_x">–</span> <span class="NLM_lpage">125</span><span class="refDoi"> DOI: 10.1002/ajmg.b.10005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1002%2Fajmg.b.10005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A280%3ADC%252BD38jjt12msg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116B&publication_year=2003&pages=103-125&author=E.+P.+Noble&title=D2+dopamine+receptor+gene+in+psychiatric+and+neurologic+disorders+and+its+phenotypes&doi=10.1002%2Fajmg.b.10005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes</span></div><div class="casAuthors">Noble Ernest P</div><div class="citationInfo"><span class="NLM_cas:title">American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">116B</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-25</span>
        ISSN:<span class="NLM_cas:issn">1552-4841</span>.
    </div><div class="casAbstract">The D2 dopamine receptor (DRD2) has been one of the most extensively investigated gene in neuropsychiatric disorders.  After the first association of the TaqI A DRD2 minor (A1) allele with severe alcoholism in 1990, a large number of international studies have followed.  A meta-analysis of these studies of Caucasians showed a significantly higher DRD2 A1 allelic frequency and prevalence in alcoholics when compared to controls.  Variants of the DRD2 gene have also been associated with other addictive disorders including cocaine, nicotine and opioid dependence and obesity.  It is hypothesized that the DRD2 is a reinforcement or reward gene.  The DRD2 gene has also been implicated in schizophrenia, posttraumatic stress disorder, movement disorders and migraine.  Phenotypic differences have been associated with DRD2 variants.  These include reduced D2 dopamine receptor numbers and diminished glucose metabolism in brains of subjects who carry the DRD2 A1 allele.  In addition, pleiotropic effects of DRD2 variants have been observed in neurophysiologic, neuropsychologic, stress response, personality and treatment outcome characteristics.  The involvement of the DRD2 gene in certain neuropsychiatric disorders opens up the potential of a targeted pharmacogenomic approach to the treatment of these disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLYoZ5HMJynTMsgLhIoICsfW6udTcc2ebNdJDKMYjK9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38jjt12msg%253D%253D&md5=c9e10ec0cb64728971d2fcd5ecc33702</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fajmg.b.10005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fajmg.b.10005%26sid%3Dliteratum%253Aachs%26aulast%3DNoble%26aufirst%3DE.%2BP.%26atitle%3DD2%2520dopamine%2520receptor%2520gene%2520in%2520psychiatric%2520and%2520neurologic%2520disorders%2520and%2520its%2520phenotypes%26jtitle%3DAm.%2520J.%2520Med.%2520Genet.%252C%2520Part%2520B%26date%3D2003%26volume%3D116B%26spage%3D103%26epage%3D125%26doi%3D10.1002%2Fajmg.b.10005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Fan, X. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hess, E. J.</span><span> </span><span class="NLM_article-title">D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD</span> <span class="citation_source-journal">Neurobiol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">228</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span><span class="refDoi"> DOI: 10.1016/j.nbd.2009.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.nbd.2009.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=19840852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVGms7vI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2010&pages=228-236&author=X.+L.+Fanauthor=M.+Xuauthor=E.+J.+Hess&title=D2+dopamine+receptor+subtype-mediated+hyperactivity+and+amphetamine+responses+in+a+model+of+ADHD&doi=10.1016%2Fj.nbd.2009.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD</span></div><div class="casAuthors">Fan, Xue-Liang; Xu, Ming; Hess, Ellen J.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">228-236</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Low doses of psychostimulants produce beneficial behavioral effects in ADHD patients but the mechanisms underlying the response are not understood.  Here we use the hyperactive mouse mutant coloboma to identify D2-like dopamine receptor subtypes that mediate the hyperactivity and response to amphetamine; we have previously demonstrated that D1-like dopamine receptors are not involved.  Targeted deletion of the D2, but not the D3 or the D4, dopamine receptor in coloboma mice eliminated the hyperactivity; depleting D2 dopamine receptors also restored the excess dopamine overflow that may drive the hyperactivity to normal concns.  Similar to its effects on ADHD patients, amphetamine reduced the hyperactivity of coloboma mice.  The D2 dopamine receptor-selective antagonist L-741,626, but not D3 or D4 dopamine receptor-selective antagonists, blocked the amphetamine-induced redn. in locomotor activity.  Thus, the D2 dopamine receptor subtype mediates both the hyperactivity and response to amphetamine, suggesting a specific target for novel therapeutics in ADHD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEUwUaV6iqprVg90H21EOLACvtfcHk0lj1FKnj_Kh9CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVGms7vI&md5=beac1924be92f794c4ead36e58d5ef19</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2009.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2009.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DX.%2BL.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DE.%2BJ.%26atitle%3DD2%2520dopamine%2520receptor%2520subtype-mediated%2520hyperactivity%2520and%2520amphetamine%2520responses%2520in%2520a%2520model%2520of%2520ADHD%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2010%26volume%3D37%26spage%3D228%26epage%3D236%26doi%3D10.1016%2Fj.nbd.2009.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheffler, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroeze, W. K.</span><span> </span><span class="NLM_article-title">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">353</span><span class="NLM_x">–</span> <span class="NLM_lpage">359</span><span class="refDoi"> DOI: 10.1038/nrd1346</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fnrd1346" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=15060530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=353-359&author=B.+L.+Rothauthor=D.+J.+Shefflerauthor=W.+K.+Kroeze&title=Magic+shotguns+versus+magic+bullets%3A+selectively+non-selective+drugs+for+mood+disorders+and+schizophrenia&doi=10.1038%2Fnrd1346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia</span></div><div class="casAuthors">Roth, Bryan L.; Sheffler, Douglas J.; Kroeze, Wesley K.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">353-359</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Most common central nervous system disorders - such as depression, bipolar disorder, and schizophrenia - seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies.  Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single mol. targets (i.e., 'magic bullets') have, not surprisingly, been largely unsuccessful.  Here the authors propose that designing selectively non-selective drugs (i.e., 'magic shotguns') that interact with several mol. targets will lead to new and more effective medications for a variety of central nervous system disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnSsuUXzmbirVg90H21EOLACvtfcHk0lj1FKnj_Kh9CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Gkt78%253D&md5=77196583acccca65457fec7a67218463</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnrd1346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1346%26sid%3Dliteratum%253Aachs%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DSheffler%26aufirst%3DD.%2BJ.%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26atitle%3DMagic%2520shotguns%2520versus%2520magic%2520bullets%253A%2520selectively%2520non-selective%2520drugs%2520for%2520mood%2520disorders%2520and%2520schizophrenia%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D353%26epage%3D359%26doi%3D10.1038%2Fnrd1346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Davis, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahn, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, M.</span><span> </span><span class="NLM_article-title">Dopamine in schizophrenia: a review and reconceptualization</span> <span class="citation_source-journal">Am. J. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">148</span><span class="NLM_x">, </span> <span class="NLM_fpage">1474</span><span class="NLM_x">–</span> <span class="NLM_lpage">1486</span><span class="refDoi"> DOI: 10.1176/ajp.148.11.1474</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1176%2Fajp.148.11.1474" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1681750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A280%3ADyaK38%252Fis1GksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=148&publication_year=1991&pages=1474-1486&author=K.+L.+Davisauthor=R.+S.+Kahnauthor=M.+Davidson&title=Dopamine+in+schizophrenia%3A+a+review+and+reconceptualization&doi=10.1176%2Fajp.148.11.1474"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Dopamine in schizophrenia: a review and reconceptualization</span></div><div class="casAuthors">Davis K L; Kahn R S; Ko G; Davidson M</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">148</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1474-86</span>
        ISSN:<span class="NLM_cas:issn">0002-953X</span>.
    </div><div class="casAbstract">OBJECTIVE:  The initial hypothesis that schizophrenia is a manifestation of hyperdopaminergia has recently been faulted.  However, several new findings suggest that abnormal, although not necessarily excessive, dopamine activity is an important factor in schizophrenia.  The authors discuss these findings and their implications.  METHOD:  All published studies regarding dopamine and schizophrenia and all studies on the role of dopamine in cognition were reviewed.  Attention has focused on post-mortem studies, positron emission tomography, neuroleptic drug actions, plasma levels of the dopamine metabolite homovanillic acid (HVA), and cerebral blood flow.  RESULTS:  Evidence, particularly from intracellular recording studies in animals and plasma HVA measurements, suggests that neuroleptics act by reducing dopamine activity in mesolimbic dopamine neurons.  Post-mortem studies have shown high dopamine and HVA concentrations in various subcortical brain regions and greater than normal dopamine receptor densities in the brains of schizophrenic patients.  On the other hand, the negative/deficit symptom complex of schizophrenia may be associated with low dopamine activity in the prefrontal cortex.  Recent animal and human studies suggest that prefrontal dopamine neurons inhibit subcortical dopamine activity.  The authors hypothesize that schizophrenia is characterized by abnormally low prefrontal dopamine activity (causing deficit symptoms) leading to excessive dopamine activity in mesolimbic dopamine neurons (causing positive symptoms).  CONCLUSIONS:  The possible co-occurrence of high and low dopamine activity in schizophrenia has implications for the conceptualization of dopamine's role in schizophrenia.  It would explain the concurrent presence of negative and positive symptoms.  This hypothesis is testable and has important implications for treatment of schizophrenia and schizophrenia spectrum disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTjdRe5bVrnXhJ5E29YNGvQfW6udTcc2eZCqXnpz6FHqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK38%252Fis1GksQ%253D%253D&md5=15af042ac86f1634ea1c0b7c0fb76582</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1176%2Fajp.148.11.1474&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fajp.148.11.1474%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DK.%2BL.%26aulast%3DKahn%26aufirst%3DR.%2BS.%26aulast%3DDavidson%26aufirst%3DM.%26atitle%3DDopamine%2520in%2520schizophrenia%253A%2520a%2520review%2520and%2520reconceptualization%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D1991%26volume%3D148%26spage%3D1474%26epage%3D1486%26doi%3D10.1176%2Fajp.148.11.1474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Leucht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, J. M.</span><span> </span><span class="NLM_article-title">Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">31</span><span class="NLM_x">–</span> <span class="NLM_lpage">41</span><span class="refDoi"> DOI: 10.1016/S0140-6736(08)61764-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2FS0140-6736%2808%2961764-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=19058842" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1Wqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2009&pages=31-41&author=S.+Leuchtauthor=C.+Corvesauthor=D.+Arbterauthor=R.+R.+Engelauthor=C.+B.+Liauthor=J.+M.+Davis&title=Second-generation+versus+first-generation+antipsychotic+drugs+for+schizophrenia%3A+a+meta-analysis&doi=10.1016%2FS0140-6736%2808%2961764-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis</span></div><div class="casAuthors">Leucht, Stefan; Corves, Caroline; Arbter, Dieter; Engel, Rolf R.; Li, Chunbo; Davis, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">9657</span>),
    <span class="NLM_cas:pages">31-41</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Because of the debate about whether second-generation antipsychotic drugs are better than first-generation antipsychotic drugs, we did a meta-anal. of randomized controlled trials to compare the effects of these two types of drugs in patients with schizophrenia.  We compared nine second-generation antipsychotic drugs with first-generation drugs for overall efficacy (main outcome), pos., neg. and depressive symptoms, relapse, quality of life, extrapyramidal side-effects, wt. gain, and sedation.  We included 150 double-blind, mostly short-term, studies, with 21,533 participants.  We excluded open studies because they systematically favored second-generation drugs.  Four of these drugs were better than first-generation antipsychotic drugs for overall efficacy, with small to medium effect sizes (amisulpride -0.31 [95% CI -0.44 to -0.19, p<0.0001], clozapine -0.52 [-0.75 to -0.29, p<0.0001], olanzapine -0.28 [-0.38 to -0.18, p<0.0001], and risperidone -0.13 [-0.22 to -0.05, p=0.002]).  The other second-generation drugs were not more efficacious than the first-generation drugs, even for neg. symptoms.  Therefore efficacy on neg. symptoms cannot be a core component of atypicality.  Second-generation antipsychotic drugs induced fewer extrapyramidal side-effects than did haloperidol (even at low doses).  Only a few have been shown to induce fewer extrapyramidal side-effects than low-potency first-generation antipsychotic drugs.  With the exception of aripiprazole and ziprasidone, second-generation antipsychotic drugs induced more wt. gain, in various degrees, than did haloperidol but not than low-potency first-generation drugs.  The second-generation drugs also differed in their sedating properties.  We did not note any consistent effects of moderator variables, such as industry sponsorship, comparator dose, or prophylactic antiparkinsonian medication.  Second-generation antipsychotic drugs differ in many properties and are not a homogeneous class.  This meta-anal. provides data for individualized treatment based on efficacy, side-effects, and cost.  Funding: National Institute of Mental Health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojXIyLwG0IPLVg90H21EOLACvtfcHk0lgro4ak0n79zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1Wqsw%253D%253D&md5=b36479dbb36763237e2183f3c773e979</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2808%2961764-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252808%252961764-X%26sid%3Dliteratum%253Aachs%26aulast%3DLeucht%26aufirst%3DS.%26aulast%3DCorves%26aufirst%3DC.%26aulast%3DArbter%26aufirst%3DD.%26aulast%3DEngel%26aufirst%3DR.%2BR.%26aulast%3DLi%26aufirst%3DC.%2BB.%26aulast%3DDavis%26aufirst%3DJ.%2BM.%26atitle%3DSecond-generation%2520versus%2520first-generation%2520antipsychotic%2520drugs%2520for%2520schizophrenia%253A%2520a%2520meta-analysis%26jtitle%3DLancet%26date%3D2009%26volume%3D373%26spage%3D31%26epage%3D41%26doi%3D10.1016%2FS0140-6736%2808%2961764-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Caroff, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hurford, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lybrand, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, E. C.</span><span> </span><span class="NLM_article-title">Movement disorders induced by antipsychotic drugs: implications of the CATIE Schizophrenia trial</span> <span class="citation_source-journal">Neurologic Clinics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1016/j.ncl.2010.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.ncl.2010.10.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=127-148&author=S.+N.+Caroffauthor=I.+Hurfordauthor=J.+Lybrandauthor=E.+C.+Campbell&title=Movement+disorders+induced+by+antipsychotic+drugs%3A+implications+of+the+CATIE+Schizophrenia+trial&doi=10.1016%2Fj.ncl.2010.10.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.ncl.2010.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ncl.2010.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DCaroff%26aufirst%3DS.%2BN.%26aulast%3DHurford%26aufirst%3DI.%26aulast%3DLybrand%26aufirst%3DJ.%26aulast%3DCampbell%26aufirst%3DE.%2BC.%26atitle%3DMovement%2520disorders%2520induced%2520by%2520antipsychotic%2520drugs%253A%2520implications%2520of%2520the%2520CATIE%2520Schizophrenia%2520trial%26jtitle%3DNeurologic%2520Clinics%26date%3D2011%26volume%3D29%26spage%3D127%26epage%3D148%26doi%3D10.1016%2Fj.ncl.2010.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Koster, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carbon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correll, C. U.</span><span> </span><span class="NLM_article-title">Emerging drugs for schizophrenia: an update</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">511</span><span class="NLM_x">–</span> <span class="NLM_lpage">531</span><span class="refDoi"> DOI: 10.1517/14728214.2014.958148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1517%2F14728214.2014.958148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A280%3ADC%252BC2M7ivFartg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=511-531&author=L.+S.+Kosterauthor=M.+Carbonauthor=C.+U.+Correll&title=Emerging+drugs+for+schizophrenia%3A+an+update&doi=10.1517%2F14728214.2014.958148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging drugs for schizophrenia: an update</span></div><div class="casAuthors">Koster Luisa-Sophie; Carbon Maren; Correll Christoph U</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on emerging drugs</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">511-31</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Schizophrenia is one of the most serious mental disorders.  Its treatment remains challenging, as existing antipsychotic antidopaminergic medications improve only/predominantly positive symptoms, agitation and aggression but have limited/insignificant efficacy for negative and cognitive symptoms, which strongly affect functional outcome.  Therefore, new therapeutic agents are urgently needed that treat aspects of the spectrum of schizophrenia symptomatology and improve functional outcome.  AREAS COVERED:  The authors review the mechanisms of action and key clinical results of drug development targets currently in Phase II and III clinical testing for schizophrenia.  They further discuss potential barriers to the successful development of these targets and summarize the drug development status of emerging treatments for various aspects of schizophrenia.  EXPERT OPINION:  Although modifications and variations of antidopaminergic mechanisms are expected to be successful, the added benefits will likely remain small, at least regarding enhanced efficacy for negative symptoms, cognition and functional outcomes.  Greater innovation will likely come from further and deeper exploration of extra-dopaminergic mechanisms.  Investment is needed to develop clinically meaningful animal paradigms probing the different symptom domains, to discover more efficient in vivo screening methods for novel drug targets, to optimize clinical trial design and trial conduct, and to parse the heterogeneous groups of schizophrenias into biologically more homogeneous subgroups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQZ25fXC8ZT23y-c-E1v-fmfW6udTcc2eYWU2do8Xw8_7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7ivFartg%253D%253D&md5=778d7a1dd616d6513af6330f20116fe7</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1517%2F14728214.2014.958148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728214.2014.958148%26sid%3Dliteratum%253Aachs%26aulast%3DKoster%26aufirst%3DL.%2BS.%26aulast%3DCarbon%26aufirst%3DM.%26aulast%3DCorrell%26aufirst%3DC.%2BU.%26atitle%3DEmerging%2520drugs%2520for%2520schizophrenia%253A%2520an%2520update%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2014%26volume%3D19%26spage%3D511%26epage%3D531%26doi%3D10.1517%2F14728214.2014.958148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Leo, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Regno, P. D.</span><span> </span><span class="NLM_article-title">Atypical antipsychotic use in the treatment of psychosis in primary care</span> <span class="citation_source-journal">Prim. Care Companion J. Clin. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">204</span><span class="refDoi"> DOI: 10.4088/PCC.v02n0601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.4088%2FPCC.v02n0601" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2000&pages=194-204&author=R.+J.+Leoauthor=P.+D.+Del+Regno&title=Atypical+antipsychotic+use+in+the+treatment+of+psychosis+in+primary+care&doi=10.4088%2FPCC.v02n0601"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.4088%2FPCC.v02n0601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FPCC.v02n0601%26sid%3Dliteratum%253Aachs%26aulast%3DLeo%26aufirst%3DR.%2BJ.%26aulast%3DDel%2BRegno%26aufirst%3DP.%2BD.%26atitle%3DAtypical%2520antipsychotic%2520use%2520in%2520the%2520treatment%2520of%2520psychosis%2520in%2520primary%2520care%26jtitle%3DPrim.%2520Care%2520Companion%2520J.%2520Clin.%2520Psychiatry%26date%3D2000%26volume%3D2%26spage%3D194%26epage%3D204%26doi%3D10.4088%2FPCC.v02n0601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Swainston Harrison, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, C. M.</span><span> </span><span class="NLM_article-title">Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">1715</span><span class="NLM_x">–</span> <span class="NLM_lpage">1736</span><span class="refDoi"> DOI: 10.2165/00003495-200464150-00010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.2165%2F00003495-200464150-00010" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=1715-1736&author=T.+Swainston+Harrisonauthor=C.+M.+Perry&title=Aripiprazole%3A+a+review+of+its+use+in+schizophrenia+and+schizoaffective+disorder&doi=10.2165%2F00003495-200464150-00010"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2165%2F00003495-200464150-00010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2165%252F00003495-200464150-00010%26sid%3Dliteratum%253Aachs%26aulast%3DSwainston%2BHarrison%26aufirst%3DT.%26aulast%3DPerry%26aufirst%3DC.%2BM.%26atitle%3DAripiprazole%253A%2520a%2520review%2520of%2520its%2520use%2520in%2520schizophrenia%2520and%2520schizoaffective%2520disorder%26jtitle%3DDrugs%26date%3D2004%26volume%3D64%26spage%3D1715%26epage%3D1736%26doi%3D10.2165%2F00003495-200464150-00010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Shapiro, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renock, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrington, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiodo, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R.</span><span> </span><span class="NLM_article-title">Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1400</span><span class="NLM_x">–</span> <span class="NLM_lpage">1411</span><span class="refDoi"> DOI: 10.1038/sj.npp.1300203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fsj.npp.1300203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=12784105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD3sXls1Slsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2003&pages=1400-1411&author=D.+A.+Shapiroauthor=S.+Renockauthor=E.+Arringtonauthor=L.+A.+Chiodoauthor=L.+X.+Liuauthor=D.+R.+Sibleyauthor=B.+L.+Rothauthor=R.+Mailman&title=Aripiprazole%2C+a+novel+atypical+antipsychotic+drug+with+a+unique+and+robust+pharmacology&doi=10.1038%2Fsj.npp.1300203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology</span></div><div class="casAuthors">Shapiro, David A.; Renock, Sean; Arrington, Elaine; Chiodo, Louis A.; Liu, Li-Xin; Sibley, David R.; Roth, Bryan L.; Mailman, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1400-1411</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Atypical antipsychotic drugs have revolutionized the treatment of schizophrenia and related disorders.  The current clin. approved atypical antipsychotic drugs are characterized by having relatively low affinities for D2-dopamine receptors and relatively high affinities for 5-HT2A serotonin receptors (5-HT, 5-hydroxytryptamine (serotonin)).  Aripiprazole (OPC-14597) is a novel atypical antipsychotic drug that is reported to be a high-affinity D2-dopamine receptor partial agonist.  We now provide a comprehensive pharmacol. profile of aripiprazole at a large no. of cloned G protein-coupled receptors, transporters, and ion channels.  These data reveal a no. of interesting and potentially important mol. targets for which aripiprazole has affinity.  Aripiprazole has highest affinity for h5-HT2B-, hD2L-, and hD3-dopamine receptors, but also has significant affinity (5-30 nM) for several other 5-HT receptors (5-HT1A, 5-HT2A, 5-HT7), as well as α1A-adrenergic and hH1-histamine receptors.  Aripiprazole has less affinity (30-200 nM) for other G protein-coupled receptors, including the 5-HT1D, 5-HT2C, α1B-, α2A-, α2B-, α2C-, β1-, and β2-adrenergic, and H3-histamine receptors.  Functionally, aripiprazole is an inverse agonist at 5-HT2B receptors and displays partial agonist actions at 5-HT2A, 5-HT2C, D3, and D4 receptors.  Interestingly, we also discovered that the functional actions of aripiprazole at cloned human D2-dopamine receptors are cell-type selective, and that a range of actions (eg agonism, partial agonism, antagonism) at cloned D2-dopamine receptors are possible depending upon the cell type and function examd.  This mixt. of functional actions at D2-dopamine receptors is consistent with the hypothesis proposed by Lawler et al (1999) that aripiprazole has functionally selective' actions.  Taken together, our results support the hypothesis that the unique actions of aripiprazole in humans are likely a combination of functionally selective' activation of D2 (and possibly D3)-dopamine receptors, coupled with important interactions with selected other biogenic amine receptors-particularly 5-HT receptor subtypes (5-HT1A, 5-HT2A).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc1m1pKWaDH7Vg90H21EOLACvtfcHk0ljLx_VOuRtKsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXls1Slsro%253D&md5=a90dfc24826c78d9a630ae4831d99cb0</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fsj.npp.1300203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.npp.1300203%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DD.%2BA.%26aulast%3DRenock%26aufirst%3DS.%26aulast%3DArrington%26aufirst%3DE.%26aulast%3DChiodo%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DL.%2BX.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DMailman%26aufirst%3DR.%26atitle%3DAripiprazole%252C%2520a%2520novel%2520atypical%2520antipsychotic%2520drug%2520with%2520a%2520unique%2520and%2520robust%2520pharmacology%26jtitle%3DNeuropsychopharmacology%26date%3D2003%26volume%3D28%26spage%3D1400%26epage%3D1411%26doi%3D10.1038%2Fsj.npp.1300203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Gopalakrishna, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aggarwal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lauriello, J.</span><span> </span><span class="NLM_article-title">Long-acting injectable aripiprazole: how might it fit in our tool box?</span> <span class="citation_source-journal">Clin. Schizophr. Relat. Psychoses.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">92</span><span class="refDoi"> DOI: 10.3371/CSRP.GOAG.043013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.3371%2FCSRP.GOAG.043013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A280%3ADC%252BC3sngsl2rtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2013&pages=87-92&author=G.+Gopalakrishnaauthor=A.+Aggarwalauthor=J.+Lauriello&title=Long-acting+injectable+aripiprazole%3A+how+might+it+fit+in+our+tool+box%3F&doi=10.3371%2FCSRP.GOAG.043013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Long-acting injectable aripiprazole: how might it fit in our tool box?</span></div><div class="casAuthors">Gopalakrishna Ganesh; Aggarwal Arpit; Lauriello John</div><div class="citationInfo"><span class="NLM_cas:title">Clinical schizophrenia & related psychoses</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">87-92</span>
        ISSN:<span class="NLM_cas:issn">1935-1232</span>.
    </div><div class="casAbstract">Schizophrenia is a severe mental illness with a lifetime prevalence of approximately one percent worldwide.  Maintenance antipsychotic treatment has been effective in preventing relapses in long-term follow-up studies.  Logically it can be proposed that long-acting injectable antipsychotics (LAI) might reduce both unintentional and intentional nonadherence.  Long-acting injectable aripiprazole was approved for the treatment of schizophrenia by the U.S.  FDA on 28th February 2013 and will be marketed under the name Abilify Maintena.  Aripiprazole LAI (ALAI) is a lyophilized powder that needs to be reconstituted with sterile water to form an injectable suspension without affecting the original molecule.  The monthly injection interval is very attractive since patients prefer fewer injections.  From a tolerability perspective, ALAI appears to be both weight neutral and lacking metabolic side effects.  This can confer an advantage over the other currently available second-generation antipsychotic LAIs.  Simple constitution with sterile water and no requirement to refrigerate make storage and administration easier.  Like all medications, there are always potential disadvantages to ALAI.  There is a period of oral coverage, while not as long as for long-acting risperidone microspheres (RLAI), that is required.  Care must be taken to review concomitant medications for the presence of metabolic inducers and inhibitors.  One would also expect some patients to be sensitive to extrapyramidal symptoms, especially akathisia which is well documented in the oral preparation.  All things considered, we welcome our new tool, ALAI, to our work-place and predict both clinical practice and post marketing analysis and studies will discover its true value.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTBNb1QTCGf79j_Vg2vObihfW6udTcc2ea4qGKRHo_7mbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sngsl2rtw%253D%253D&md5=7ad4d9d3b817140090d511eed49e0bcf</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3371%2FCSRP.GOAG.043013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3371%252FCSRP.GOAG.043013%26sid%3Dliteratum%253Aachs%26aulast%3DGopalakrishna%26aufirst%3DG.%26aulast%3DAggarwal%26aufirst%3DA.%26aulast%3DLauriello%26aufirst%3DJ.%26atitle%3DLong-acting%2520injectable%2520aripiprazole%253A%2520how%2520might%2520it%2520fit%2520in%2520our%2520tool%2520box%253F%26jtitle%3DClin.%2520Schizophr.%2520Relat.%2520Psychoses.%26date%3D2013%26volume%3D7%26spage%3D87%26epage%3D92%26doi%3D10.3371%2FCSRP.GOAG.043013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Allen, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yost, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yadav, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jensen, N. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span> </span><span class="NLM_article-title">Discovery of beta-arrestin-biased dopamine D-2 ligands for probing signal transduction pathways essential for antipsychotic efficacy</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">18488</span><span class="NLM_x">–</span> <span class="NLM_lpage">18493</span><span class="refDoi"> DOI: 10.1073/pnas.1104807108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1073%2Fpnas.1104807108" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=18488-18493&author=J.+A.+Allenauthor=J.+M.+Yostauthor=V.+Setolaauthor=X.+Chenauthor=M.+F.+Sassanoauthor=M.+Chenauthor=S.+Petersonauthor=P.+N.+Yadavauthor=X.+P.+Huangauthor=B.+Fengauthor=N.+H.+Jensenauthor=X.+Cheauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=M.+G.+Caronauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=J.+Jin&title=Discovery+of+beta-arrestin-biased+dopamine+D-2+ligands+for+probing+signal+transduction+pathways+essential+for+antipsychotic+efficacy&doi=10.1073%2Fpnas.1104807108"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1104807108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1104807108%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DJ.%2BA.%26aulast%3DYost%26aufirst%3DJ.%2BM.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DPeterson%26aufirst%3DS.%26aulast%3DYadav%26aufirst%3DP.%2BN.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DJensen%26aufirst%3DN.%2BH.%26aulast%3DChe%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520beta-arrestin-biased%2520dopamine%2520D-2%2520ligands%2520for%2520probing%2520signal%2520transduction%2520pathways%2520essential%2520for%2520antipsychotic%2520efficacy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D18488%26epage%3D18493%26doi%3D10.1073%2Fpnas.1104807108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Urban, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Zastrow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobilka, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spedding, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Functional selectivity and classical concepts of quantitative pharmacology</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">320</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span><span class="refDoi"> DOI: 10.1124/jpet.106.104463</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1124%2Fjpet.106.104463" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=16803859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsFersw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=320&publication_year=2007&pages=1-13&author=J.+D.+Urbanauthor=W.+P.+Clarkeauthor=M.+von+Zastrowauthor=D.+E.+Nicholsauthor=B.+Kobilkaauthor=H.+Weinsteinauthor=J.+A.+Javitchauthor=B.+L.+Rothauthor=A.+Christopoulosauthor=P.+M.+Sextonauthor=K.+J.+Millerauthor=M.+Speddingauthor=R.+B.+Mailman&title=Functional+selectivity+and+classical+concepts+of+quantitative+pharmacology&doi=10.1124%2Fjpet.106.104463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity and classical concepts of quantitative pharmacology</span></div><div class="casAuthors">Urban, Jonathan D.; Clarke, William P.; von Zastrow, Mark; Nichols, David E.; Kobilka, Brian; Weinstein, Harel; Javitch, Jonathan A.; Roth, Bryan L.; Christopoulos, Arthur; Sexton, Patrick M.; Miller, Keith J.; Spedding, Michael; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">320</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-13</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  The concept of intrinsic efficacy has been enshrined in pharmacol. for half of a century, yet recent data have revealed that many ligands can differentially activate signaling pathways mediated via a single G protein-coupled receptor in a manner that challenges the traditional definition of intrinsic efficacy.  Some terms for this phenomenon include functional selectivity, agonist-directed trafficking, and biased agonism.  At the extreme, functionally selective ligands may be both agonists and antagonists at different functions mediated by the same receptor.  Data illustrating this phenomenon are presented from serotonin, opioid, dopamine, vasopressin, and adrenergic receptor systems.  A variety of mechanisms may influence this apparently ubiquitous phenomenon.  It may be initiated by differences in ligand-induced intermediate conformational states, as shown for the β2-adrenergic receptor.  Subsequent mechanisms that may play a role include diversity of G proteins, scaffolding and signaling partners, and receptor oligomers.  Clearly, expanded research is needed to elucidate the proximal (e.g., how functionally selective ligands cause conformational changes that initiate differential signaling), intermediate (mechanisms that translate conformation changes into differential signaling), and distal mechanisms (differential effects on target tissue or organism).  Besides the heuristically interesting nature of functional selectivity, there is a clear impact on drug discovery, because this mechanism raises the possibility of selecting or designing novel ligands that differentially activate only a subset of functions of a single receptor, thereby optimizing therapeutic action.  It also may be timely to revise classic concepts in quant. pharmacol. and relevant pharmacol. conventions to incorporate these new concepts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5GzdtvWZRkbVg90H21EOLACvtfcHk0lgzm9gYb96-qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsFersw%253D%253D&md5=54465473b5996d0755baeee89eeb0ba9</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1124%2Fjpet.106.104463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.106.104463%26sid%3Dliteratum%253Aachs%26aulast%3DUrban%26aufirst%3DJ.%2BD.%26aulast%3DClarke%26aufirst%3DW.%2BP.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DKobilka%26aufirst%3DB.%26aulast%3DWeinstein%26aufirst%3DH.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DMiller%26aufirst%3DK.%2BJ.%26aulast%3DSpedding%26aufirst%3DM.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DFunctional%2520selectivity%2520and%2520classical%2520concepts%2520of%2520quantitative%2520pharmacology%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2007%26volume%3D320%26spage%3D1%26epage%3D13%26doi%3D10.1124%2Fjpet.106.104463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">GPCR functional selectivity has therapeutic impact</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">390</span><span class="NLM_x">–</span> <span class="NLM_lpage">396</span><span class="refDoi"> DOI: 10.1016/j.tips.2007.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.tips.2007.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=17629962" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2sXotlWltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=390-396&author=R.+B.+Mailman&title=GPCR+functional+selectivity+has+therapeutic+impact&doi=10.1016%2Fj.tips.2007.06.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">GPCR functional selectivity has therapeutic impact</span></div><div class="casAuthors">Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">390-396</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Many in vitro data show that some ligands can cause the differential activation of signaling pathways mediated by a single receptor (termedfunctional selectivity').  It remains unclear, however, whether functionally selective properties are meaningful in vivo.  Data obtained with exptl. compds. that are functionally selective at the dopamine D2L receptor in vitro suggest that these properties might predict atypical behavioral actions.  Moreover, the antipsychotic drug aripiprazole is commonly thought to be a D2 partial agonist, but data clearly show that aripiprazole is functionally selective in vitro.  It is proposed that the effects of aripiprazole in animal models and humans can be reconciled only with its functionally selective D2 properties, not its partial D2 agonism.  Together, these data provide support for the hypothesis that compds. with functionally selective properties in vitro are likely to have novel actions in vivo, opening doors to new avenues of drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGT3wJMrwLmrVg90H21EOLACvtfcHk0lgzm9gYb96-qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXotlWltLg%253D&md5=e4647d1af70505c4711dd2d57d0b4cfd</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DGPCR%2520functional%2520selectivity%2520has%2520therapeutic%2520impact%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D390%26epage%3D396%26doi%3D10.1016%2Fj.tips.2007.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Beaulieu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">The Akt-GSK-3 signaling cascade in the actions of doparnine</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">166</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span><span class="refDoi"> DOI: 10.1016/j.tips.2007.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.tips.2007.02.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=166-172&author=J.+M.+Beaulieuauthor=R.+R.+Gainetdinovauthor=M.+G.+Caron&title=The+Akt-GSK-3+signaling+cascade+in+the+actions+of+doparnine&doi=10.1016%2Fj.tips.2007.02.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DThe%2520Akt-GSK-3%2520signaling%2520cascade%2520in%2520the%2520actions%2520of%2520doparnine%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D166%26epage%3D172%26doi%3D10.1016%2Fj.tips.2007.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Kenakin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span> </span><span class="NLM_article-title">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span><span class="refDoi"> DOI: 10.1038/nrd3954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fnrd3954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=23411724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=205-216&author=T.+Kenakinauthor=A.+Christopoulos&title=Signalling+bias+in+new+drug+discovery%3A+detection%2C+quantification+and+therapeutic+impact&doi=10.1038%2Fnrd3954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span></div><div class="casAuthors">Kenakin, Terry; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-216</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Agonists of seven-transmembrane receptors, also known as G protein-coupled receptors (GPCRs), do not uniformly activate all cellular signalling pathways linked to a given seven-transmembrane receptor (a phenomenon termed ligand or agonist bias); this discovery has changed how high-throughput screens are designed and how lead compds. are optimized for therapeutic activity.  The ability to exptl. detect ligand bias has necessitated the development of methods for quantifying agonist bias in a way that can be used to guide structure-activity studies and the selection of drug candidates.  Here, we provide a viewpoint on which methods are appropriate for quantifying bias, based on knowledge of how cellular and intracellular signalling proteins control the conformation of seven-transmembrane receptors.  We also discuss possible predictions of how biased mols. may perform in vivo, and what potential therapeutic advantages they may provide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkDNsO17tty7Vg90H21EOLACvtfcHk0ljt9haLCk6QJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D&md5=712258b9158f753689e35fa31f1b67f0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd3954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3954%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DSignalling%2520bias%2520in%2520new%2520drug%2520discovery%253A%2520detection%252C%2520quantification%2520and%2520therapeutic%2520impact%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D205%26epage%3D216%26doi%3D10.1038%2Fnrd3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span> </span><span class="NLM_article-title">Structure-functional selectivity relationship studies of beta-arrestin-biased dopamine D-2 receptor agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7141</span><span class="NLM_x">–</span> <span class="NLM_lpage">7153</span><span class="refDoi"> DOI: 10.1021/jm300603y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300603y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7141-7153&author=X.+Chenauthor=M.+F.+Sassanoauthor=L.+Y.+Zhengauthor=V.+Setolaauthor=M.+Chenauthor=X.+Baiauthor=S.+V.+Fryeauthor=W.+C.+Wetselauthor=B.+L.+Rothauthor=J.+Jin&title=Structure-functional+selectivity+relationship+studies+of+beta-arrestin-biased+dopamine+D-2+receptor+agonists&doi=10.1021%2Fjm300603y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm300603y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300603y%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DZheng%26aufirst%3DL.%2BY.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DJin%26aufirst%3DJ.%26atitle%3DStructure-functional%2520selectivity%2520relationship%2520studies%2520of%2520beta-arrestin-biased%2520dopamine%2520D-2%2520receptor%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7141%26epage%3D7153%26doi%3D10.1021%2Fjm300603y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Park, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmerberg, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulman, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodriguiz, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetsel, W. C.</span><span> </span><span class="NLM_article-title">Effects of beta-arrestin-biased dopamine D2 receptor ligands on Schizophrenia-like behavior in hypoglutamatergic mice</span> <span class="citation_source-journal">Neuropsychopharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">704</span><span class="NLM_x">–</span> <span class="NLM_lpage">715</span><span class="refDoi"> DOI: 10.1038/npp.2015.196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fnpp.2015.196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=26129680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2016&pages=704-715&author=S.+M.+Parkauthor=M.+Chenauthor=C.+M.+Schmerbergauthor=R.+S.+Dulmanauthor=R.+M.+Rodriguizauthor=M.+G.+Caronauthor=J.+Jinauthor=W.+C.+Wetsel&title=Effects+of+beta-arrestin-biased+dopamine+D2+receptor+ligands+on+Schizophrenia-like+behavior+in+hypoglutamatergic+mice&doi=10.1038%2Fnpp.2015.196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice</span></div><div class="casAuthors">Park, Su M.; Chen, Meng; Schmerberg, Claire M.; Dulman, Russell S.; Rodriguiz, Ramona M.; Caron, Marc G.; Jin, Jian; Wetsel, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">704-715</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Current antipsychotic drugs (APDs) show efficacy with pos. symptoms, but are limited in treating neg. or cognitive features of schizophrenia.  Whereas all currently FDA-approved medications target primarily the dopamine D2 receptor (D2R) to inhibit Gi/o-mediated adenylyl cyclase, a recent study has shown that many APDs affect not only Gi/o- but they can also influence β-arrestin- (βArr)-mediated signaling.  The ability of ligands to differentially affect signaling through these pathways is termed functional selectivity.  We have developed ligands that are devoid of D2R-mediated Gi/o protein signaling, but are simultaneously partial agonists for D2R/βArr interactions.  The purpose of this study was to test the effectiveness of UNC9975 or UNC9994 on schizophrenia-like behaviors in phencyclidine-treated or NR1-knockdown hypoglutamatergic mice.  We have found the UNC compds. reduce hyperlocomotion in the open field, restore PPI, improve novel object recognition memory, partially normalize social behavior, decrease conditioned avoidance responding, and elicit a much lower level of catalepsy than haloperidol.  These preclin. results suggest that exploitation of functional selectivity may provide unique opportunities to develop drugs with fewer side effects, greater therapeutic selectivity, and enhanced efficacy for treating schizophrenia and related conditions than medications that are currently available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQuhB8VxuXDbVg90H21EOLACvtfcHk0ljt9haLCk6QJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Chu7jO&md5=82de207db3a78d50ff86a48cda2d2e28</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2015.196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2015.196%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DS.%2BM.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DSchmerberg%26aufirst%3DC.%2BM.%26aulast%3DDulman%26aufirst%3DR.%2BS.%26aulast%3DRodriguiz%26aufirst%3DR.%2BM.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DJin%26aufirst%3DJ.%26aulast%3DWetsel%26aufirst%3DW.%2BC.%26atitle%3DEffects%2520of%2520beta-arrestin-biased%2520dopamine%2520D2%2520receptor%2520ligands%2520on%2520Schizophrenia-like%2520behavior%2520in%2520hypoglutamatergic%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2016%26volume%3D41%26spage%3D704%26epage%3D715%26doi%3D10.1038%2Fnpp.2015.196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Shonberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herenbrink, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, J. R.</span><span> </span><span class="NLM_article-title">A Structure-activity analysis of biased agonism at the dopamine D2 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">9199</span><span class="NLM_x">–</span> <span class="NLM_lpage">9221</span><span class="refDoi"> DOI: 10.1021/jm401318w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401318w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1CktrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9199-9221&author=J.+Shonbergauthor=C.+K.+Herenbrinkauthor=L.+Lopezauthor=A.+Christopoulosauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=J.+R.+Lane&title=A+Structure-activity+analysis+of+biased+agonism+at+the+dopamine+D2+receptor&doi=10.1021%2Fjm401318w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A Structure-Activity Analysis of Biased Agonism at the Dopamine D2 Receptor</span></div><div class="casAuthors">Shonberg, Jeremy; Herenbrink, Carmen Klein; Lopez, Laura; Christopoulos, Arthur; Scammells, Peter J.; Capuano, Ben; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9199-9221</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Biased agonism offers an opportunity for the medicinal chemist to discover pathway-selective ligands for GPCRs.  A no. of studies have suggested that biased agonism at the dopamine D2 receptor (D2R) may be advantageous for the treatment of neuropsychiatric disorders, including schizophrenia.  As such, it is of great importance to gain insight into the SAR of biased agonism at this receptor.  The authors have generated SAR based on a novel D2R partial agonist, tert-Bu (trans-4-(2-(3,4-dihydroisoquinolin-2-(1H)-yl)-ethyl)-cyclohexyl)-carbamate.  This ligand shares structural similarity to cariprazine, a drug awaiting FDA approval for the treatment of schizophrenia, yet displays a distinct bias toward two different signaling end points.  The authors synthesized a no. of derivs. of tert-Bu (trans-4-(2-(3,4-dihydroisoquinolin-2-(1H)-yl)-ethyl)-cyclohexyl)-carbamate with subtle structural modifications, including incorporation of cariprazine fragments.  By combining pharmacol. profiling with anal. methodol. to identify and to quantify bias, the authors have demonstrated that efficacy and biased agonism can be finely tuned by minor structural modifications to the head group contg. the tertiary amine, a tail group that extends away from this moiety, and the orientation and length of a spacer region between these two moieties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocktbsOBHWB7Vg90H21EOLACvtfcHk0ljt9haLCk6QJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1CktrbJ&md5=124b940132336819740ec30d2962a3a3</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm401318w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401318w%26sid%3Dliteratum%253Aachs%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DHerenbrink%26aufirst%3DC.%2BK.%26aulast%3DLopez%26aufirst%3DL.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DA%2520Structure-activity%2520analysis%2520of%2520biased%2520agonism%2520at%2520the%2520dopamine%2520D2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9199%26epage%3D9221%26doi%3D10.1021%2Fjm401318w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Hiller, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heinemann, F. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Functionally selective dopamine D-2/D-3 receptor agonists comprising an enyne moiety</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5130</span><span class="NLM_x">–</span> <span class="NLM_lpage">5141</span><span class="refDoi"> DOI: 10.1021/jm400520c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400520c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5130-5141&author=C.+Hillerauthor=R.+C.+Klingauthor=F.+W.+Heinemannauthor=K.+Meyerauthor=H.+Hubnerauthor=P.+Gmeiner&title=Functionally+selective+dopamine+D-2%2FD-3+receptor+agonists+comprising+an+enyne+moiety&doi=10.1021%2Fjm400520c"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm400520c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400520c%26sid%3Dliteratum%253Aachs%26aulast%3DHiller%26aufirst%3DC.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DHeinemann%26aufirst%3DF.%2BW.%26aulast%3DMeyer%26aufirst%3DK.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFunctionally%2520selective%2520dopamine%2520D-2%252FD-3%2520receptor%2520agonists%2520comprising%2520an%2520enyne%2520moiety%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5130%26epage%3D5141%26doi%3D10.1021%2Fjm400520c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Szabo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klein Herenbrink, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span> </span><span class="NLM_article-title">Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D-2 receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4924</span><span class="NLM_x">–</span> <span class="NLM_lpage">4939</span><span class="refDoi"> DOI: 10.1021/jm500457x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500457x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4924-4939&author=M.+Szaboauthor=C.+Klein+Herenbrinkauthor=A.+Christopoulosauthor=J.+R.+Laneauthor=B.+Capuano&title=Structure-activity+relationships+of+privileged+structures+lead+to+the+discovery+of+novel+biased+ligands+at+the+dopamine+D-2+receptor&doi=10.1021%2Fjm500457x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm500457x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500457x%26sid%3Dliteratum%253Aachs%26aulast%3DSzabo%26aufirst%3DM.%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26aulast%3DCapuano%26aufirst%3DB.%26atitle%3DStructure-activity%2520relationships%2520of%2520privileged%2520structures%2520lead%2520to%2520the%2520discovery%2520of%2520novel%2520biased%2520ligands%2520at%2520the%2520dopamine%2520D-2%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4924%26epage%3D4939%26doi%3D10.1021%2Fjm500457x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Moeller, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skultety, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leuner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hubner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gmeiner, P.</span><span> </span><span class="NLM_article-title">Functionally selective dopamine D-2, D-3 receptor partial agonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4861</span><span class="NLM_x">–</span> <span class="NLM_lpage">4875</span><span class="refDoi"> DOI: 10.1021/jm5004039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5004039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4861-4875&author=D.+Moellerauthor=R.+C.+Klingauthor=M.+Skultetyauthor=K.+Leunerauthor=H.+Hubnerauthor=P.+Gmeiner&title=Functionally+selective+dopamine+D-2%2C+D-3+receptor+partial+agonists&doi=10.1021%2Fjm5004039"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm5004039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5004039%26sid%3Dliteratum%253Aachs%26aulast%3DMoeller%26aufirst%3DD.%26aulast%3DKling%26aufirst%3DR.%2BC.%26aulast%3DSkultety%26aufirst%3DM.%26aulast%3DLeuner%26aufirst%3DK.%26aulast%3DHubner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26atitle%3DFunctionally%2520selective%2520dopamine%2520D-2%252C%2520D-3%2520receptor%2520partial%2520agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4861%26epage%3D4875%26doi%3D10.1021%2Fjm5004039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Free, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chun, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moritz, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, B. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conroy, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padron, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meade, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dulcey, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Titus, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bryant-Genevier, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnaeva, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferrer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beuming, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Southall, N. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marugan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, D. R.</span><span> </span><span class="NLM_article-title">Discovery and characterization of a G protein-biased agonist that inhibits beta-arrestin recruitment to the D2 dopamine receptor</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">86</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.1124/mol.113.090563</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1124%2Fmol.113.090563" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2014&pages=96-105&author=R.+B.+Freeauthor=L.+S.+Chunauthor=A.+E.+Moritzauthor=B.+N.+Millerauthor=T.+B.+Doyleauthor=J.+L.+Conroyauthor=A.+Padronauthor=J.+A.+Meadeauthor=J.+B.+Xiaoauthor=X.+Huauthor=A.+E.+Dulceyauthor=Y.+Hanauthor=L.+H.+Duanauthor=S.+Titusauthor=M.+Bryant-Genevierauthor=E.+Barnaevaauthor=M.+Ferrerauthor=J.+A.+Javitchauthor=T.+Beumingauthor=L.+Shiauthor=N.+T.+Southallauthor=J.+J.+Maruganauthor=D.+R.+Sibley&title=Discovery+and+characterization+of+a+G+protein-biased+agonist+that+inhibits+beta-arrestin+recruitment+to+the+D2+dopamine+receptor&doi=10.1124%2Fmol.113.090563"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.090563&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.090563%26sid%3Dliteratum%253Aachs%26aulast%3DFree%26aufirst%3DR.%2BB.%26aulast%3DChun%26aufirst%3DL.%2BS.%26aulast%3DMoritz%26aufirst%3DA.%2BE.%26aulast%3DMiller%26aufirst%3DB.%2BN.%26aulast%3DDoyle%26aufirst%3DT.%2BB.%26aulast%3DConroy%26aufirst%3DJ.%2BL.%26aulast%3DPadron%26aufirst%3DA.%26aulast%3DMeade%26aufirst%3DJ.%2BA.%26aulast%3DXiao%26aufirst%3DJ.%2BB.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DDulcey%26aufirst%3DA.%2BE.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DDuan%26aufirst%3DL.%2BH.%26aulast%3DTitus%26aufirst%3DS.%26aulast%3DBryant-Genevier%26aufirst%3DM.%26aulast%3DBarnaeva%26aufirst%3DE.%26aulast%3DFerrer%26aufirst%3DM.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DBeuming%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DSouthall%26aufirst%3DN.%2BT.%26aulast%3DMarugan%26aufirst%3DJ.%2BJ.%26aulast%3DSibley%26aufirst%3DD.%2BR.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520a%2520G%2520protein-biased%2520agonist%2520that%2520inhibits%2520beta-arrestin%2520recruitment%2520to%2520the%2520D2%2520dopamine%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2014%26volume%3D86%26spage%3D96%26epage%3D105%26doi%3D10.1124%2Fmol.113.090563" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Houslay, M. D.</span><span> </span><span class="NLM_article-title">Arrestin times for developing antipsychotics and beta-blockers</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">pe22</span><span class="refDoi"> DOI: 10.1126/scisignal.266pe22</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1126%2Fscisignal.266pe22" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=pe22&author=M.+D.+Houslay&title=Arrestin+times+for+developing+antipsychotics+and+beta-blockers&doi=10.1126%2Fscisignal.266pe22"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.266pe22&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.266pe22%26sid%3Dliteratum%253Aachs%26aulast%3DHouslay%26aufirst%3DM.%2BD.%26atitle%3DArrestin%2520times%2520for%2520developing%2520antipsychotics%2520and%2520beta-blockers%26jtitle%3DSci.%2520Signaling%26date%3D2009%26volume%3D2%26spage%3Dpe22%26doi%3D10.1126%2Fscisignal.266pe22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Mottola, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilts, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connery, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, Q. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyslop, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piercey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wightman, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawler, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">301</span><span class="NLM_x">, </span> <span class="NLM_fpage">1166</span><span class="NLM_x">–</span> <span class="NLM_lpage">1178</span><span class="refDoi"> DOI: 10.1124/jpet.301.3.1166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1124%2Fjpet.301.3.1166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=12023552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlGjtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2002&pages=1166-1178&author=D.+M.+Mottolaauthor=J.+D.+Kiltsauthor=M.+M.+Lewisauthor=H.+S.+Conneryauthor=Q.+D.+Walkerauthor=S.+R.+Jonesauthor=R.+G.+Boothauthor=D.+K.+Hyslopauthor=M.+Pierceyauthor=R.+M.+Wightmanauthor=C.+P.+Lawlerauthor=D.+E.+Nicholsauthor=R.+B.+Mailman&title=Functional+selectivity+of+dopamine+receptor+agonists.+I.+Selective+activation+of+postsynaptic+dopamine+D2+receptors+linked+to+adenylate+cyclase&doi=10.1124%2Fjpet.301.3.1166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase</span></div><div class="casAuthors">Mottola, David M.; Kilts, Jason D.; Lewis, Mechelle M.; Connory, Hilary S.; Walker, Q. David; Jones, Sara R.; Booth, Raymond G.; Hyslop, Deborah K.; Piercey, Monford; Wightman, R. Mark; Lawler, Cindy P.; Nichols, David E.; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1166-1179</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Dihydrexidine (DHX), the first high-affinity D1 dopamine receptor full agonist, is only 10-fold selective for D1 vs. D2 receptors, having D2 affinity similar to the prototypical agonist quinpirole.  The D2 functional properties of DHX and its more D2 selective analog N-n-propyl-dihydrexidine (PrDHX) were explored in rat brain and pituitary.  DHX and PrDHX had binding characteristics to D2 receptors in rat striatum typical of D2 agonists, binding to both high- and low-affinity sites and being sensitive to guanine-nucleotides.  Consistent with these binding data, both DHX and PrDHX inhibited forskolin-stimulated cAMP synthesis in striatum with a potency and intrinsic activity equiv. to that of quinpirole.  Unexpectedly, however, DHX and PrDHX had little functional effect at D2 receptors expressed on dopaminergic neurons that mediate inhibition of cell firing, dopamine release, or dopamine synthesis.  Quant. receptor competition autoradiog. demonstrated that DHX bound to D2 receptors in striatum (predominantly postsynaptic receptor sites) with equal affinity as D2 sites in the substantia nigra (autoreceptor sites).  The data from these expts., coupled with what is known about the location of specific dopamine receptor isoforms, lead to the hypothesis that DHX, after binding to D2L and D2S receptors, causes agonist-typical functional changes only at some of these receptors.  This phenomenon (herein termed "functional selectivity") suggests that drugs may be targeted not only at specific receptor isoforms but also at sep. functions mediated by a single isoform, yielding novel approaches to drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpif5JbU-Rs9bVg90H21EOLACvtfcHk0liN5h-HN_p9gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlGjtrY%253D&md5=b1d65ec3f66b3652deb9f9a4c76b70a3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1124%2Fjpet.301.3.1166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.301.3.1166%26sid%3Dliteratum%253Aachs%26aulast%3DMottola%26aufirst%3DD.%2BM.%26aulast%3DKilts%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DM.%2BM.%26aulast%3DConnery%26aufirst%3DH.%2BS.%26aulast%3DWalker%26aufirst%3DQ.%2BD.%26aulast%3DJones%26aufirst%3DS.%2BR.%26aulast%3DBooth%26aufirst%3DR.%2BG.%26aulast%3DHyslop%26aufirst%3DD.%2BK.%26aulast%3DPiercey%26aufirst%3DM.%26aulast%3DWightman%26aufirst%3DR.%2BM.%26aulast%3DLawler%26aufirst%3DC.%2BP.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DFunctional%2520selectivity%2520of%2520dopamine%2520receptor%2520agonists.%2520I.%2520Selective%2520activation%2520of%2520postsynaptic%2520dopamine%2520D2%2520receptors%2520linked%2520to%2520adenylate%2520cyclase%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D301%26spage%3D1166%26epage%3D1178%26doi%3D10.1124%2Fjpet.301.3.1166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Kilts, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Connery, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arrington, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawler, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oxford, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Malley, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Todd, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nichols, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mailman, R. B.</span><span> </span><span class="NLM_article-title">Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">301</span><span class="NLM_x">, </span> <span class="NLM_fpage">1179</span><span class="NLM_x">–</span> <span class="NLM_lpage">1189</span><span class="refDoi"> DOI: 10.1124/jpet.301.3.1179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1124%2Fjpet.301.3.1179" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=12023553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD38XktlGjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=301&publication_year=2002&pages=1179-1189&author=J.+D.+Kiltsauthor=H.+S.+Conneryauthor=E.+G.+Arringtonauthor=M.+M.+Lewisauthor=C.+P.+Lawlerauthor=G.+S.+Oxfordauthor=K.+L.+O%E2%80%99Malleyauthor=R.+D.+Toddauthor=B.+L.+Blakeauthor=D.+E.+Nicholsauthor=R.+B.+Mailman&title=Functional+selectivity+of+dopamine+receptor+agonists.+II.+Actions+of+dihydrexidine+in+D2L+receptor-transfected+MN9D+cells+and+pituitary+lactotrophs&doi=10.1124%2Fjpet.301.3.1179"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs</span></div><div class="casAuthors">Kilts, Jason D.; Connery, Hilary S.; Arrington, Elaine G.; Lewis, Mechelle M.; Lawler, Cindy P.; Oxford, Gerry S.; O'Malley, Karen L.; Todd, Richard D.; Blake, Bonita L.; Nichols, David E.; Mailman, Richard B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">301</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1179-1189</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">D2-like dopamine receptors mediate functional changes via activation of inhibitory G proteins, including those that affect adenylate cyclase activity, and potassium and calcium channels.  Although it is assumed that the binding of a drug to a single isoform of a D2-like receptor will cause similar changes in all receptor-mediated functions, it has been demonstrated in brain that the dopamine agonists dihydrexidine (DHX) and N-n-propyl-DHX are "functionally selective".  The current study explores the underlying mechanism using transfected MN9D cells and D2-producing anterior pituitary lactotrophs.  Both dopamine and DHX inhibited adenylate cyclase activity in a concn.-dependent manner in both systems, effects blocked by D2, but not D1, antagonists.  In the MN9D cells, quinpirole and R-(-)-N-propylnorapomorphine (NPA) also inhibited the K+-stimulated release of [3H]dopamine in a concn.-responsive, antagonist-reversible manner.  Conversely, neither DHX, nor its analogs, inhibited K+-stimulated [3H]dopamine release, although they antagonized the effects of quinpirole.  S-(+)-NPA actually had the reverse functional selectivity profile from DHX (i.e., it was a full agonist at D2L receptors coupled to inhibition of dopamine release, but a weak partial agonist at D2L receptor-mediated inhibition of adenylate cyclase).  In lactotrophs, DHX had little intrinsic activity at D2 receptors coupled to G protein-coupled inwardly rectifying potassium channels, and actually antagonized the effects of dopamine at these D2 receptors.  Together, these findings provide compelling evidence for agonist-induced functional selectivity with the D2L receptor.  Although the underlying mol. mechanism is controversial (e.g., "conformational induction" vs. "drug-active state selection"), such data are irreconcilable with the widely held view that drugs have "intrinsic efficacy".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxKyo-BPUi-LVg90H21EOLACvtfcHk0liN5h-HN_p9gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktlGjtrc%253D&md5=6686ca6fae277969b216781088d74a87</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fjpet.301.3.1179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.301.3.1179%26sid%3Dliteratum%253Aachs%26aulast%3DKilts%26aufirst%3DJ.%2BD.%26aulast%3DConnery%26aufirst%3DH.%2BS.%26aulast%3DArrington%26aufirst%3DE.%2BG.%26aulast%3DLewis%26aufirst%3DM.%2BM.%26aulast%3DLawler%26aufirst%3DC.%2BP.%26aulast%3DOxford%26aufirst%3DG.%2BS.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DK.%2BL.%26aulast%3DTodd%26aufirst%3DR.%2BD.%26aulast%3DBlake%26aufirst%3DB.%2BL.%26aulast%3DNichols%26aufirst%3DD.%2BE.%26aulast%3DMailman%26aufirst%3DR.%2BB.%26atitle%3DFunctional%2520selectivity%2520of%2520dopamine%2520receptor%2520agonists.%2520II.%2520Actions%2520of%2520dihydrexidine%2520in%2520D2L%2520receptor-transfected%2520MN9D%2520cells%2520and%2520pituitary%2520lactotrophs%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D301%26spage%3D1179%26epage%3D1189%26doi%3D10.1124%2Fjpet.301.3.1179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Masri, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salahpour, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Didriksen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghisi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">13656</span><span class="NLM_x">–</span> <span class="NLM_lpage">13661</span><span class="refDoi"> DOI: 10.1073/pnas.0803522105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1073%2Fpnas.0803522105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=13656-13661&author=B.+Masriauthor=A.+Salahpourauthor=M.+Didriksenauthor=V.+Ghisiauthor=J.+M.+Beaulieuauthor=R.+R.+Gainetdinovauthor=M.+G.+Caron&title=Antagonism+of+dopamine+D2+receptor%2Fbeta-arrestin+2+interaction+is+a+common+property+of+clinically+effective+antipsychotics&doi=10.1073%2Fpnas.0803522105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0803522105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0803522105%26sid%3Dliteratum%253Aachs%26aulast%3DMasri%26aufirst%3DB.%26aulast%3DSalahpour%26aufirst%3DA.%26aulast%3DDidriksen%26aufirst%3DM.%26aulast%3DGhisi%26aufirst%3DV.%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DAntagonism%2520of%2520dopamine%2520D2%2520receptor%252Fbeta-arrestin%25202%2520interaction%2520is%2520a%2520common%2520property%2520of%2520clinically%2520effective%2520antipsychotics%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D13656%26epage%3D13661%26doi%3D10.1073%2Fpnas.0803522105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Beaulieu, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotnikova, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marion, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gainetdinov, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span> </span><span class="NLM_article-title">An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">261</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1016/j.cell.2005.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.cell.2005.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=16051150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFGjsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2005&pages=261-273&author=J.+M.+Beaulieuauthor=T.+D.+Sotnikovaauthor=S.+Marionauthor=R.+J.+Lefkowitzauthor=R.+R.+Gainetdinovauthor=M.+G.+Caron&title=An+Akt%2Fbeta-arrestin+2%2FPP2A+signaling+complex+mediates+dopaminergic+neurotransmission+and+behavior&doi=10.1016%2Fj.cell.2005.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior</span></div><div class="casAuthors">Beaulieu, Jean-Martin; Sotnikova, Tatyana D.; Marion, Sebastien; Lefkowitz, Robert J.; Gainetdinov, Raul R.; Caron, Marc G.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">261-273</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Dopamine plays an important role in the etiol. of schizophrenia, and D2 class dopamine receptors are the best-established target of antipsychotic drugs.  Here we show that D2 class-receptor-mediated Akt regulation involves the formation of signaling complexes contg. β-arrestin 2, PP2A, and Akt.  β-Arrestin 2 deficiency in mice results in redn. of dopamine-dependent behaviors, loss of Akt regulation by dopamine in the striatum, and disruption of the dopamine-dependent interaction of Akt with its neg. regulator, protein phosphatase 2A.  Importantly, canonical cAMP-mediated dopamine-receptor signaling is not inhibited in the absence of β-arrestin 2.  These results demonstrate that, apart from its classical function in receptor desensitization, β-arrestin 2 also acts as a signaling intermediate through a kinase/phosphatase scaffold.  Furthermore, this function of β-arrestin 2 is important for the expression of dopamine-assocd. behaviors, thus implicating β-arrestin 2 as a pos. mediator of dopaminergic synaptic transmission and a potential pharmacol. target for dopamine-related psychiatric disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrC2L_HMvsJuLVg90H21EOLACvtfcHk0ljFmXfJSSS3Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFGjsLw%253D&md5=841fbd1ab433f4795631118d9de65e4b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2005.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2005.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DBeaulieu%26aufirst%3DJ.%2BM.%26aulast%3DSotnikova%26aufirst%3DT.%2BD.%26aulast%3DMarion%26aufirst%3DS.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DGainetdinov%26aufirst%3DR.%2BR.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26atitle%3DAn%2520Akt%252Fbeta-arrestin%25202%252FPP2A%2520signaling%2520complex%2520mediates%2520dopaminergic%2520neurotransmission%2520and%2520behavior%26jtitle%3DCell%26date%3D2005%26volume%3D122%26spage%3D261%26epage%3D273%26doi%3D10.1016%2Fj.cell.2005.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Luttrell, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferguson, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maudsley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Rocca, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Owada, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttrell, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caron, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span> </span><span class="NLM_article-title">Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">655</span><span class="NLM_x">–</span> <span class="NLM_lpage">661</span><span class="refDoi"> DOI: 10.1126/science.283.5402.655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1126%2Fscience.283.5402.655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=9924018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADyaK1MXot1Kmug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1999&pages=655-661&author=L.+M.+Luttrellauthor=S.+S.+Fergusonauthor=Y.+Daakaauthor=W.+E.+Millerauthor=S.+Maudsleyauthor=G.+J.+Della+Roccaauthor=F.+Linauthor=H.+Kawakatsuauthor=K.+Owadaauthor=D.+K.+Luttrellauthor=M.+G.+Caronauthor=R.+J.+Lefkowitz&title=Beta-arrestin-dependent+formation+of+beta2+adrenergic+receptor-Src+protein+kinase+complexes&doi=10.1126%2Fscience.283.5402.655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">β-Arrestin-dependent formation of β2 adrenergic receptor-Src protein kinase complexes</span></div><div class="casAuthors">Luttrell, L. M.; Ferguson, S. S. G.; Daaka, Y.; Miller, W. E.; Maudsley, S.; Rocca, G. J. Della; Lin, F.-T.; Kawakatsu, H.; Owada, K.; Luttrell, D. K.; Caron, M. G.; Lefkowitz, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">5402</span>),
    <span class="NLM_cas:pages">655-661</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The Ras-dependent activation of mitogen-activated protein (MAP) kinase pathways by many receptors coupled to heterotrimeric guanine nucleotide binding proteins (G proteins) requires the activation of Src family tyrosine kinases.  Stimulation of β2 adrenergic receptors resulted in the assembly of a protein complex contg. activated c-Src and the receptor.  Src recruitment was mediated by β-arrestin, which functions as an adapter protein, binding both c-Src and the agonist-occupied receptor.  β-Arrestin 1 mutants, impaired either in c-Src binding or in the ability to target receptors to clathrin-coated pits, acted as dominant neg. inhibitors of β2 adrenergic receptor-mediated activation of the MAP kinases Erk1 and Erk2.  These data suggest that β-arrestin binding, which terminates receptor-G protein coupling, also initiates a second wave of signal transduction in which the "desensitized" receptor functions as a crit. structural component of a mitogenic signaling complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_2hPyTs99rbVg90H21EOLACvtfcHk0ljFmXfJSSS3Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXot1Kmug%253D%253D&md5=3fc55fc9a12ae32562bf0693a0050803</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1126%2Fscience.283.5402.655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.283.5402.655%26sid%3Dliteratum%253Aachs%26aulast%3DLuttrell%26aufirst%3DL.%2BM.%26aulast%3DFerguson%26aufirst%3DS.%2BS.%26aulast%3DDaaka%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DW.%2BE.%26aulast%3DMaudsley%26aufirst%3DS.%26aulast%3DDella%2BRocca%26aufirst%3DG.%2BJ.%26aulast%3DLin%26aufirst%3DF.%26aulast%3DKawakatsu%26aufirst%3DH.%26aulast%3DOwada%26aufirst%3DK.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DCaron%26aufirst%3DM.%2BG.%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26atitle%3DBeta-arrestin-dependent%2520formation%2520of%2520beta2%2520adrenergic%2520receptor-Src%2520protein%2520kinase%2520complexes%26jtitle%3DScience%26date%3D1999%26volume%3D283%26spage%3D655%26epage%3D661%26doi%3D10.1126%2Fscience.283.5402.655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Lefkowitz, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenoy, S. K.</span><span> </span><span class="NLM_article-title">Transduction of receptor signals by beta-arrestins</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">308</span><span class="NLM_x">, </span> <span class="NLM_fpage">512</span><span class="NLM_x">–</span> <span class="NLM_lpage">517</span><span class="refDoi"> DOI: 10.1126/science.1109237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1126%2Fscience.1109237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=15845844" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtlOjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=2005&pages=512-517&author=R.+J.+Lefkowitzauthor=S.+K.+Shenoy&title=Transduction+of+receptor+signals+by+beta-arrestins&doi=10.1126%2Fscience.1109237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Transduction of Receptor Signals by β-Arrestins</span></div><div class="casAuthors">Lefkowitz, Robert J.; Shenoy, Sudha K.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">308</span>
        (<span class="NLM_cas:issue">5721</span>),
    <span class="NLM_cas:pages">512-517</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The transmission of extracellular signals to the interior of the cell is a function of plasma membrane receptors, of which the seven transmembrane receptor family is by far the largest and most versatile.  Classically, these receptors stimulate heterotrimeric G proteins, which control rates of generation of diffusible second messengers and entry of ions at the plasma membrane.  Recent evidence, however, indicates another previously unappreciated strategy used by the receptors to regulate intracellular signaling pathways.  They direct the recruitment, activation, and scaffolding of cytoplasmic signaling complexes via two multifunctional adaptor and transducer mols., β-arrestins 1 and 2.  This mechanism regulates aspects of cell motility, chemotaxis, apoptosis, and likely other cellular functions through a rapidly expanding list of signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk2fXdqgYhC7Vg90H21EOLACvtfcHk0ljFmXfJSSS3Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtlOjtLs%253D&md5=ed070237312d050e5d5ec437b3adc76c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1126%2Fscience.1109237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1109237%26sid%3Dliteratum%253Aachs%26aulast%3DLefkowitz%26aufirst%3DR.%2BJ.%26aulast%3DShenoy%26aufirst%3DS.%2BK.%26atitle%3DTransduction%2520of%2520receptor%2520signals%2520by%2520beta-arrestins%26jtitle%3DScience%26date%3D2005%26volume%3D308%26spage%3D512%26epage%3D517%26doi%3D10.1126%2Fscience.1109237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Oshiro, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurahashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tottori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uwahodo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishi, T.</span><span> </span><span class="NLM_article-title">Novel antipsychotic agents with dopamine autoreceptor agonist properties: Synthesis and pharmacology of 7-[4-(4-phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x">, </span> <span class="NLM_fpage">658</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span><span class="refDoi"> DOI: 10.1021/jm940608g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm940608g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADyaK1cXosFaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=658-667&author=Y.+Oshiroauthor=S.+Satoauthor=N.+Kurahashiauthor=T.+Tanakaauthor=T.+Kikuchiauthor=K.+Tottoriauthor=Y.+Uwahodoauthor=T.+Nishi&title=Novel+antipsychotic+agents+with+dopamine+autoreceptor+agonist+properties%3A+Synthesis+and+pharmacology+of+7-%5B4-%284-phenyl-1-piperazinyl%29butoxy%5D-3%2C4-dihydro-2%281H%29-quinolinone+derivatives&doi=10.1021%2Fjm940608g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Antipsychotic Agents with Dopamine Autoreceptor Agonist Properties: Synthesis and Pharmacology of 7-[4-(4-Phenyl-1-piperazinyl)butoxy]-3,4-dihydro-2(1H)-quinolinone Derivatives</span></div><div class="casAuthors">Oshiro, Yasuo; Sato, Seiji; Kurahashi, Nobuyuki; Tanaka, Tatsuyoshi; Kikuchi, Tetsuro; Tottori, Katsura; Uwahodo, Yasufumi; Nishi, Takao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">658-667</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To develop a novel antipsychotic agent which is an agonist of dopamine (DA) autoreceptors and an antagonist of postsynaptic DA receptors, a series of 7-[4-[4-(substituted phenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinones was synthesized and their dual activities were examd.  The postsynaptic DA receptor antagonistic activities of the compds. were evaluated by their ability to inhibit stereotypy induced by apomorphine in mice, and the autoreceptor agonist activities were detd. by their effects on the γ-butyrolactone (GBL)-induced increase in L-dihydroxyphenylalanine (DOPA) synthesis in the mouse brain.  Many compds. inhibited the stereotypic behavior, and several compds. reversed the GBL-induced increase in the DOPA synthesis.  Among them, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone (aripiprazole, OPC-14597) (I) had these 2 activities.  This compd. reversed the GBL-induced DOPA synthesis (ED50 values of 5.1 μmol/kg po) and inhibited the APO induced stereotypy (ED50 values of 0.6 mmol/kg po).  I induced catalepsy at 10-fold higher dose than that required for the antagonism of APO-induced stereotypy (ED50 value of 7.8 μmol/kg oral).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnD8-A-QQlZLVg90H21EOLACvtfcHk0lg1n_BwlLOR2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXosFaqtw%253D%253D&md5=02ff3a24cc876f68419f60acc4bae45e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm940608g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm940608g%26sid%3Dliteratum%253Aachs%26aulast%3DOshiro%26aufirst%3DY.%26aulast%3DSato%26aufirst%3DS.%26aulast%3DKurahashi%26aufirst%3DN.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKikuchi%26aufirst%3DT.%26aulast%3DTottori%26aufirst%3DK.%26aulast%3DUwahodo%26aufirst%3DY.%26aulast%3DNishi%26aufirst%3DT.%26atitle%3DNovel%2520antipsychotic%2520agents%2520with%2520dopamine%2520autoreceptor%2520agonist%2520properties%253A%2520Synthesis%2520and%2520pharmacology%2520of%25207-%255B4-%25284-phenyl-1-piperazinyl%2529butoxy%255D-3%252C4-dihydro-2%25281H%2529-quinolinone%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D658%26epage%3D667%26doi%3D10.1021%2Fjm940608g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Zhu, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. M.</span><span> </span><span class="NLM_article-title">A general and straightforward method for the synthesis of 2-trifluoromethylbenzothiazoles</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2434</span><span class="NLM_x">–</span> <span class="NLM_lpage">2436</span><span class="refDoi"> DOI: 10.1021/ol1006899</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol1006899" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFaqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=2434-2436&author=J.+T.+Zhuauthor=Z.+X.+Chenauthor=H.+B.+Xieauthor=S.+Liauthor=Y.+M.+Wu&title=A+general+and+straightforward+method+for+the+synthesis+of+2-trifluoromethylbenzothiazoles&doi=10.1021%2Fol1006899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A General and Straightforward Method for the Synthesis of 2-Trifluoromethylbenzothiazoles</span></div><div class="casAuthors">Zhu, Jiangtao; Chen, Zixian; Xie, Haibo; Li, Shan; Wu, Yongming</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2434-2436</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">An efficient one-pot method for the synthesis of 2-trifluoromethylbenzothiazoles, e.g., I (R = H, H, Me, MeO, Me2N, F, Cl, Br, I, EtO2C, CN, Ac, NO2), by the treatment of trifluoromethylimidoyl chlorides with sodium hydrosulfide hydrate using PdCl2 as the sole catalyst in DMSO is described.  The reaction proceeds via thiolation/C-H bond functionalization/C-S bond formation in moderate to high yields with good functional group tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiK9nv5jmt2bVg90H21EOLACvtfcHk0lg1n_BwlLOR2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFaqtrg%253D&md5=0ef7933709345ae01fda8eb090502158</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fol1006899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol1006899%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%2BT.%26aulast%3DChen%26aufirst%3DZ.%2BX.%26aulast%3DXie%26aufirst%3DH.%2BB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DY.%2BM.%26atitle%3DA%2520general%2520and%2520straightforward%2520method%2520for%2520the%2520synthesis%2520of%25202-trifluoromethylbenzothiazoles%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26spage%3D2434%26epage%3D2436%26doi%3D10.1021%2Fol1006899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Weissman, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zewge, D.</span><span> </span><span class="NLM_article-title">Recent advances in ether dealkylation</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">7833</span><span class="NLM_x">–</span> <span class="NLM_lpage">7863</span><span class="refDoi"> DOI: 10.1016/j.tet.2005.05.041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.tet.2005.05.041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2005&pages=7833-7863&author=S.+A.+Weissmanauthor=D.+Zewge&title=Recent+advances+in+ether+dealkylation&doi=10.1016%2Fj.tet.2005.05.041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in ether dealkylation</span></div><div class="casAuthors">Weissman, Steven A.; Zewge, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">7833-7863</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review on the developments from 1995 through the end of 2004 with focus on reagents of practical value and some level of generality.  The following topics are discussed: deprotection of aryl and alkyl ethers (including propargylic), allyl and related ethers (including isoprenyl), benzylic ethers (including trityl), and cyclic ethers.  Aspects of regio- and chemoselectivities are also mentioned.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHYugNUDxpjLVg90H21EOLACvtfcHk0lg1n_BwlLOR2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFCltro%253D&md5=41a698090e3cc03e616d3c972d52e788</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.tet.2005.05.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tet.2005.05.041%26sid%3Dliteratum%253Aachs%26aulast%3DWeissman%26aufirst%3DS.%2BA.%26aulast%3DZewge%26aufirst%3DD.%26atitle%3DRecent%2520advances%2520in%2520ether%2520dealkylation%26jtitle%3DTetrahedron%26date%3D2005%26volume%3D61%26spage%3D7833%26epage%3D7863%26doi%3D10.1016%2Fj.tet.2005.05.041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Shi, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrigley, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelieveld, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fichtner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, M. F. G.</span><span> </span><span class="NLM_article-title">Antitumor benzothiazoles 0.3. Synthesis of 2-(4-aminophenyl)benzothiazoles and evaluation of their activities against breast cancer cell lines in vitro and in vivo</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">3375</span><span class="NLM_x">–</span> <span class="NLM_lpage">3384</span><span class="refDoi"> DOI: 10.1021/jm9600959</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9600959" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1996&pages=3375-3384&author=D.+F.+Shiauthor=T.+D.+Bradshawauthor=S.+Wrigleyauthor=C.+J.+McCallauthor=P.+Lelieveldauthor=I.+Fichtnerauthor=M.+F.+G.+Stevens&title=Antitumor+benzothiazoles+0.3.+Synthesis+of+2-%284-aminophenyl%29benzothiazoles+and+evaluation+of+their+activities+against+breast+cancer+cell+lines+in+vitro+and+in+vivo&doi=10.1021%2Fjm9600959"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm9600959&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9600959%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DD.%2BF.%26aulast%3DBradshaw%26aufirst%3DT.%2BD.%26aulast%3DWrigley%26aufirst%3DS.%26aulast%3DMcCall%26aufirst%3DC.%2BJ.%26aulast%3DLelieveld%26aufirst%3DP.%26aulast%3DFichtner%26aufirst%3DI.%26aulast%3DStevens%26aufirst%3DM.%2BF.%2BG.%26atitle%3DAntitumor%2520benzothiazoles%25200.3.%2520Synthesis%2520of%25202-%25284-aminophenyl%2529benzothiazoles%2520and%2520evaluation%2520of%2520their%2520activities%2520against%2520breast%2520cancer%2520cell%2520lines%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1996%26volume%3D39%26spage%3D3375%26epage%3D3384%26doi%3D10.1021%2Fjm9600959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Jordan, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reitz, A. B.</span><span> </span><span class="NLM_article-title">Efficient conversion of substituted aryl thioureas to 2-aminobenzothiazoles using benzyltrimethylammonium tribromide</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">8693</span><span class="NLM_x">–</span> <span class="NLM_lpage">8696</span><span class="refDoi"> DOI: 10.1021/jo0349431</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0349431" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnvVCrs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2003&pages=8693-8696&author=A.+D.+Jordanauthor=C.+Luoauthor=A.+B.+Reitz&title=Efficient+conversion+of+substituted+aryl+thioureas+to+2-aminobenzothiazoles+using+benzyltrimethylammonium+tribromide&doi=10.1021%2Fjo0349431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient Conversion of Substituted Aryl Thioureas to 2-Aminobenzothiazoles Using Benzyltrimethylammonium Tribromide</span></div><div class="casAuthors">Jordan, Alfonzo D.; Luo, Chi; Reitz, Allen B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8693-8696</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The reaction of mol. bromine (Br2) with arylthioureas is known to produce 2-aminobenzothiazoles (Hugerschoff reaction).  The authors show here that benzyltrimethylammonium tribromide, a stable, cryst. org. ammonium tribromide (OATB), can be readily utilized as an alternative electrophilic bromine source.  It is easier to control the stoichiometry of addn. with an OATB, which minimizes arom. bromination caused by excess reagent.  The authors have developed a direct procedure from isothiocyanates and amines using tetrabutylammonium thiocyanate (Bu4NSCN) and PhCH2NMe3Br3 to afford functionalized 2-aminobenzothiazoles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog7je3cRW9g7Vg90H21EOLACvtfcHk0lgsB8IKHKtxKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnvVCrs70%253D&md5=b556244031d365d36fce4fba9d8f7e93</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjo0349431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0349431%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DA.%2BD.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DReitz%26aufirst%3DA.%2BB.%26atitle%3DEfficient%2520conversion%2520of%2520substituted%2520aryl%2520thioureas%2520to%25202-aminobenzothiazoles%2520using%2520benzyltrimethylammonium%2520tribromide%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2003%26volume%3D68%26spage%3D8693%26epage%3D8696%26doi%3D10.1021%2Fjo0349431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Kimple, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soundararajan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutsell, S. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roos, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Setola, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, B. R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willard, F. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siderovski, D. P.</span><span> </span><span class="NLM_article-title">Structural determinants of G-protein alpha subunit selectivity by regulator of G-protein signaling 2 (RGS2)</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">19402</span><span class="NLM_x">–</span> <span class="NLM_lpage">19411</span><span class="refDoi"> DOI: 10.1074/jbc.M109.024711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1074%2Fjbc.M109.024711" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=19402-19411&author=A.+J.+Kimpleauthor=M.+Soundararajanauthor=S.+Q.+Hutsellauthor=A.+K.+Roosauthor=D.+J.+Urbanauthor=V.+Setolaauthor=B.+R.+S.+Templeauthor=B.+L.+Rothauthor=S.+Knappauthor=F.+S.+Willardauthor=D.+P.+Siderovski&title=Structural+determinants+of+G-protein+alpha+subunit+selectivity+by+regulator+of+G-protein+signaling+2+%28RGS2%29&doi=10.1074%2Fjbc.M109.024711"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.024711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.024711%26sid%3Dliteratum%253Aachs%26aulast%3DKimple%26aufirst%3DA.%2BJ.%26aulast%3DSoundararajan%26aufirst%3DM.%26aulast%3DHutsell%26aufirst%3DS.%2BQ.%26aulast%3DRoos%26aufirst%3DA.%2BK.%26aulast%3DUrban%26aufirst%3DD.%2BJ.%26aulast%3DSetola%26aufirst%3DV.%26aulast%3DTemple%26aufirst%3DB.%2BR.%2BS.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DWillard%26aufirst%3DF.%2BS.%26aulast%3DSiderovski%26aufirst%3DD.%2BP.%26atitle%3DStructural%2520determinants%2520of%2520G-protein%2520alpha%2520subunit%2520selectivity%2520by%2520regulator%2520of%2520G-protein%2520signaling%25202%2520%2528RGS2%2529%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D19402%26epage%3D19411%26doi%3D10.1074%2Fjbc.M109.024711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Kroeze, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sassano, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, X. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCorvy, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giguere, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sciaky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. L.</span><span> </span><span class="NLM_article-title">PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome</span> <span class="citation_source-journal">Nat. Struct. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">362</span><span class="NLM_x">–</span> <span class="NLM_lpage">369</span><span class="refDoi"> DOI: 10.1038/nsmb.3014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fnsmb.3014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=25895059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslOgtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2015&pages=362-369&author=W.+K.+Kroezeauthor=M.+F.+Sassanoauthor=X.+P.+Huangauthor=K.+Lansuauthor=J.+D.+McCorvyauthor=P.+M.+Giguereauthor=N.+Sciakyauthor=B.+L.+Roth&title=PRESTO-Tango+as+an+open-source+resource+for+interrogation+of+the+druggable+human+GPCRome&doi=10.1038%2Fnsmb.3014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome</span></div><div class="casAuthors">Kroeze, Wesley K.; Sassano, Maria F.; Huang, Xi-Ping; Lansu, Katherine; McCorvy, John D.; Giguere, Patrick M.; Sciaky, Noah; Roth, Bryan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">362-369</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G protein-coupled receptors (GPCRs) are essential mediators of cellular signaling and are important targets of drug action.  Of the approx. 350 nonolfactory human GPCRs, more than 100 are still considered to be 'orphans' because their endogenous ligands remain unknown.  Here, we describe a unique open-source resource that allows interrogation of the druggable human GPCRome via a G protein-independent β-arrestin-recruitment assay.  We validate this unique platform at more than 120 nonorphan human GPCR targets, demonstrate its utility for discovering new ligands for orphan human GPCRs and describe a method (parallel receptorome expression and screening via transcriptional output, with transcriptional activation following arrestin translocation (PRESTO-Tango)) for the simultaneous and parallel interrogation of the entire human nonolfactory GPCRome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVbl7caV9gUrVg90H21EOLACvtfcHk0lgsB8IKHKtxKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslOgtLg%253D&md5=2a78b74a5f1425fa9e8b79b730c16be6</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.3014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.3014%26sid%3Dliteratum%253Aachs%26aulast%3DKroeze%26aufirst%3DW.%2BK.%26aulast%3DSassano%26aufirst%3DM.%2BF.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DLansu%26aufirst%3DK.%26aulast%3DMcCorvy%26aufirst%3DJ.%2BD.%26aulast%3DGiguere%26aufirst%3DP.%2BM.%26aulast%3DSciaky%26aufirst%3DN.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26atitle%3DPRESTO-Tango%2520as%2520an%2520open-source%2520resource%2520for%2520interrogation%2520of%2520the%2520druggable%2520human%2520GPCRome%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2015%26volume%3D22%26spage%3D362%26epage%3D369%26doi%3D10.1038%2Fnsmb.3014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Tsuruta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frey, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grewe, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cote, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eskay, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kebabian, J. W.</span><span> </span><span class="NLM_article-title">Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">292</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">465</span><span class="refDoi"> DOI: 10.1038/292463a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2F292463a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=7254340" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADyaL38Xks1Wjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=1981&pages=463-465&author=K.+Tsurutaauthor=E.+A.+Freyauthor=C.+W.+Greweauthor=T.+E.+Coteauthor=R.+L.+Eskayauthor=J.+W.+Kebabian&title=Evidence+that+LY-141865+specifically+stimulates+the+D-2+dopamine+receptor&doi=10.1038%2F292463a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence that LY-141865 specifically stimulates the D-2 dopamine receptor</span></div><div class="casAuthors">Tsuruta, K.; Frey, E. A.; Grewe, C. W.; Cote, T. E.; Eskay, R. L.; Kebabian, J. W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">5822</span>),
    <span class="NLM_cas:pages">463-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The ergoline analog, LY-141865  [80373-22-4] stimulated the D-2 dopamine  [51-61-6] receptor of rat dispersed neurointermediate lobe cells, as detd. by inhibition of α-MSH release and adenylate cyclase activity, but had no effect on the D-1 receptor of carp retina.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmcHikcsQi4rVg90H21EOLACvtfcHk0lgsB8IKHKtxKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38Xks1Wjsw%253D%253D&md5=5dfa99a5e7bbb0a7ba047ea068711b1c</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2F292463a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F292463a0%26sid%3Dliteratum%253Aachs%26aulast%3DTsuruta%26aufirst%3DK.%26aulast%3DFrey%26aufirst%3DE.%2BA.%26aulast%3DGrewe%26aufirst%3DC.%2BW.%26aulast%3DCote%26aufirst%3DT.%2BE.%26aulast%3DEskay%26aufirst%3DR.%2BL.%26aulast%3DKebabian%26aufirst%3DJ.%2BW.%26atitle%3DEvidence%2520that%2520LY-141865%2520specifically%2520stimulates%2520the%2520D-2%2520dopamine%2520receptor%26jtitle%3DNature%26date%3D1981%26volume%3D292%26spage%3D463%26epage%3D465%26doi%3D10.1038%2F292463a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Yale, H. L.</span><span> </span><span class="NLM_article-title">The trifluoromethyl group in medicinal chemistry</span> <span class="citation_source-journal">J. Med. Pharm. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1959</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">121</span><span class="NLM_x">–</span> <span class="NLM_lpage">133</span><span class="refDoi"> DOI: 10.1021/jm50003a001</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm50003a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADyaG1MXovVygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=1959&pages=121-133&author=H.+L.+Yale&title=The+trifluoromethyl+group+in+medicinal+chemistry&doi=10.1021%2Fjm50003a001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">The trifluoromethyl group in medicinal chemistry</span></div><div class="casAuthors">Yale, Harry L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal & Pharmaceutical Chemistry</span>
        (<span class="NLM_cas:date">1959</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">121-33</span>CODEN:
                <span class="NLM_cas:coden">JMPCAS</span>;
        ISSN:<span class="NLM_cas:issn">0095-9065</span>.
    </div><div class="casAbstract">A review with 37 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd8jbHZpWAJLVg90H21EOLACvtfcHk0lgXIrPP3xoELQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG1MXovVygtw%253D%253D&md5=d4825182e66a1eddc13cf1575432b2a5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm50003a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm50003a001%26sid%3Dliteratum%253Aachs%26aulast%3DYale%26aufirst%3DH.%2BL.%26atitle%3DThe%2520trifluoromethyl%2520group%2520in%2520medicinal%2520chemistry%26jtitle%3DJ.%2520Med.%2520Pharm.%2520Chem.%26date%3D1959%26volume%3D1%26spage%3D121%26epage%3D133%26doi%3D10.1021%2Fjm50003a001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Feenstra, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Moes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofma, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kling, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuipers, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tulp, M. T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Heyden, J. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, C. G.</span><span> </span><span class="NLM_article-title">New 1-aryl-4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D-2-receptor and serotonin 5-HT1A-receptor affinities</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">2345</span><span class="NLM_x">–</span> <span class="NLM_lpage">2349</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00425-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2FS0960-894X%2801%2900425-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=2345-2349&author=R.+W.+Feenstraauthor=J.+de+Moesauthor=J.+J.+Hofmaauthor=H.+Klingauthor=W.+Kuipersauthor=S.+K.+Longauthor=M.+T.+M.+Tulpauthor=J.+A.+M.+van+der+Heydenauthor=C.+G.+Kruse&title=New+1-aryl-4-%28biarylmethylene%29piperazines+as+potential+atypical+antipsychotics+sharing+dopamine+D-2-receptor+and+serotonin+5-HT1A-receptor+affinities&doi=10.1016%2FS0960-894X%2801%2900425-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900425-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900425-5%26sid%3Dliteratum%253Aachs%26aulast%3DFeenstra%26aufirst%3DR.%2BW.%26aulast%3Dde%2BMoes%26aufirst%3DJ.%26aulast%3DHofma%26aufirst%3DJ.%2BJ.%26aulast%3DKling%26aufirst%3DH.%26aulast%3DKuipers%26aufirst%3DW.%26aulast%3DLong%26aufirst%3DS.%2BK.%26aulast%3DTulp%26aufirst%3DM.%2BT.%2BM.%26aulast%3Dvan%2Bder%2BHeyden%26aufirst%3DJ.%2BA.%2BM.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DNew%25201-aryl-4-%2528biarylmethylene%2529piperazines%2520as%2520potential%2520atypical%2520antipsychotics%2520sharing%2520dopamine%2520D-2-receptor%2520and%2520serotonin%25205-HT1A-receptor%2520affinities%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D2345%26epage%3D2349%26doi%3D10.1016%2FS0960-894X%2801%2900425-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Wagaw, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rennels, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Palladium-catalyzed coupling of optically active amines with aryl bromides</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">119</span><span class="NLM_x">, </span> <span class="NLM_fpage">8451</span><span class="NLM_x">–</span> <span class="NLM_lpage">8458</span><span class="refDoi"> DOI: 10.1021/ja971583o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja971583o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADyaK2sXls1GjtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=1997&pages=8451-8458&author=S.+Wagawauthor=R.+A.+Rennelsauthor=S.+L.+Buchwald&title=Palladium-catalyzed+coupling+of+optically+active+amines+with+aryl+bromides&doi=10.1021%2Fja971583o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Coupling of Optically Active Amines with Aryl Bromides</span></div><div class="casAuthors">Wagaw, Seble; Rennels, Roger A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">8451-8458</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The coupling of enantiomerically enriched amines with aryl bromides produces the corresponding N-aryl derivs.  The choice of ligand in the palladium-catalyzed coupling is crit. to the formation of the anilines without loss of enantiomeric purity.  While LnPd [L = P(o-tolyl)3] successfully catalyzes the intramol. aryl amination of α-substituted optically pure amines, intermol. coupling reactions with this catalyst system gives racemized products.  In contrast, intermol. N-arylations employing LnPd [L = (±)-BINAP] gives products in good yields with no erosion of enantiopurity.  A mechanism for the obsd. racemization is proposed.  The utility of the intramol. process is demonstrated by the synthesis of 3, an intermediate in the formal synthesis of 4, a potent ACE inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi5uNO7GaBTrVg90H21EOLACvtfcHk0lgXIrPP3xoELQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXls1GjtLc%253D&md5=a8dcc541351ffed7a879b289569cb03d</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fja971583o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja971583o%26sid%3Dliteratum%253Aachs%26aulast%3DWagaw%26aufirst%3DS.%26aulast%3DRennels%26aufirst%3DR.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DPalladium-catalyzed%2520coupling%2520of%2520optically%2520active%2520amines%2520with%2520aryl%2520bromides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1997%26volume%3D119%26spage%3D8451%26epage%3D8458%26doi%3D10.1021%2Fja971583o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Kenakin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span> </span><span class="NLM_article-title">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">–</span> <span class="NLM_lpage">216</span><span class="refDoi"> DOI: 10.1038/nrd3954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fnrd3954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=23411724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=205-216&author=T.+Kenakinauthor=A.+Christopoulos&title=Signalling+bias+in+new+drug+discovery%3A+detection%2C+quantification+and+therapeutic+impact&doi=10.1038%2Fnrd3954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span></div><div class="casAuthors">Kenakin, Terry; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-216</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Agonists of seven-transmembrane receptors, also known as G protein-coupled receptors (GPCRs), do not uniformly activate all cellular signalling pathways linked to a given seven-transmembrane receptor (a phenomenon termed ligand or agonist bias); this discovery has changed how high-throughput screens are designed and how lead compds. are optimized for therapeutic activity.  The ability to exptl. detect ligand bias has necessitated the development of methods for quantifying agonist bias in a way that can be used to guide structure-activity studies and the selection of drug candidates.  Here, we provide a viewpoint on which methods are appropriate for quantifying bias, based on knowledge of how cellular and intracellular signalling proteins control the conformation of seven-transmembrane receptors.  We also discuss possible predictions of how biased mols. may perform in vivo, and what potential therapeutic advantages they may provide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkDNsO17tty7Vg90H21EOLACvtfcHk0lgXIrPP3xoELQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D&md5=712258b9158f753689e35fa31f1b67f0</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnrd3954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3954%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DSignalling%2520bias%2520in%2520new%2520drug%2520discovery%253A%2520detection%252C%2520quantification%2520and%2520therapeutic%2520impact%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D205%26epage%3D216%26doi%3D10.1038%2Fnrd3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Klein Herenbrink, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sykes, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donthamsetti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Canals, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coudrat, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shonberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scammells, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capuano, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexton, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charlton, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, J. R.</span><span> </span><span class="NLM_article-title">The role of kinetic context in apparent biased agonism at GPCRs</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">10842</span><span class="refDoi"> DOI: 10.1038/ncomms10842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1038%2Fncomms10842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=26905976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=10842&author=C.+Klein+Herenbrinkauthor=D.+A.+Sykesauthor=P.+Donthamsettiauthor=M.+Canalsauthor=T.+Coudratauthor=J.+Shonbergauthor=P.+J.+Scammellsauthor=B.+Capuanoauthor=P.+M.+Sextonauthor=S.+J.+Charltonauthor=J.+A.+Javitchauthor=A.+Christopoulosauthor=J.+R.+Lane&title=The+role+of+kinetic+context+in+apparent+biased+agonism+at+GPCRs&doi=10.1038%2Fncomms10842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The role of kinetic context in apparent biased agonism at GPCRs</span></div><div class="casAuthors">Klein Herenbrink, Carmen; Sykes, David A.; Donthamsetti, Prashant; Canals, Meritxell; Coudrat, Thomas; Shonberg, Jeremy; Scammells, Peter J.; Capuano, Ben; Sexton, Patrick M.; Charlton, Steven J.; Javitch, Jonathan A.; Christopoulos, Arthur; Lane, J. Robert</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10842</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Biased agonism describes the ability of ligands to stabilize different conformations of a GPCR linked to distinct functional outcomes and offers the prospect of designing pathway-specific drugs that avoid on-target side effects.  This mechanism is usually inferred from pharmacol. data with the assumption that the confounding influences of observational (i.e., assay dependent) and system (i.e., cell background dependent) bias are excluded by exptl. design and anal.  Here we reveal that 'kinetic context', as detd. by ligand-binding kinetics and the temporal pattern of receptor-signalling processes, can have a profound influence on the apparent bias of a series of agonists for the dopamine D2 receptor and can even lead to reversals in the direction of bias.  We propose that kinetic context must be acknowledged in the design and interpretation of studies of biased agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoboe6-_23rF7Vg90H21EOLACvtfcHk0ljhK7Ln8Vmp9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xjt1emtbk%253D&md5=3afdebd5ad1c8a8b1db93478e9b2c7d4</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1038%2Fncomms10842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10842%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%2BHerenbrink%26aufirst%3DC.%26aulast%3DSykes%26aufirst%3DD.%2BA.%26aulast%3DDonthamsetti%26aufirst%3DP.%26aulast%3DCanals%26aufirst%3DM.%26aulast%3DCoudrat%26aufirst%3DT.%26aulast%3DShonberg%26aufirst%3DJ.%26aulast%3DScammells%26aufirst%3DP.%2BJ.%26aulast%3DCapuano%26aufirst%3DB.%26aulast%3DSexton%26aufirst%3DP.%2BM.%26aulast%3DCharlton%26aufirst%3DS.%2BJ.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DLane%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520role%2520of%2520kinetic%2520context%2520in%2520apparent%2520biased%2520agonism%2520at%2520GPCRs%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D10842%26doi%3D10.1038%2Fncomms10842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Klewe, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tarpo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urizar, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dipace, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Javitch, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gether, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Egebjerg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, K. V.</span><span> </span><span class="NLM_article-title">Recruitment of beta-arrestin2 to the dopamine D2 receptor: Insights into anti-psychotic and anti-parkinsonian drug receptor signaling</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1215</span><span class="NLM_x">–</span> <span class="NLM_lpage">1222</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2008.03.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1016%2Fj.neuropharm.2008.03.015" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2008&pages=1215-1222&author=I.+V.+Kleweauthor=S.+M.+Nielsenauthor=L.+Tarpoauthor=E.+Urizarauthor=C.+Dipaceauthor=J.+A.+Javitchauthor=U.+Getherauthor=J.+Egebjergauthor=K.+V.+Christensen&title=Recruitment+of+beta-arrestin2+to+the+dopamine+D2+receptor%3A+Insights+into+anti-psychotic+and+anti-parkinsonian+drug+receptor+signaling&doi=10.1016%2Fj.neuropharm.2008.03.015"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2008.03.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2008.03.015%26sid%3Dliteratum%253Aachs%26aulast%3DKlewe%26aufirst%3DI.%2BV.%26aulast%3DNielsen%26aufirst%3DS.%2BM.%26aulast%3DTarpo%26aufirst%3DL.%26aulast%3DUrizar%26aufirst%3DE.%26aulast%3DDipace%26aufirst%3DC.%26aulast%3DJavitch%26aufirst%3DJ.%2BA.%26aulast%3DGether%26aufirst%3DU.%26aulast%3DEgebjerg%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DK.%2BV.%26atitle%3DRecruitment%2520of%2520beta-arrestin2%2520to%2520the%2520dopamine%2520D2%2520receptor%253A%2520Insights%2520into%2520anti-psychotic%2520and%2520anti-parkinsonian%2520drug%2520receptor%2520signaling%26jtitle%3DNeuropharmacology%26date%3D2008%26volume%3D54%26spage%3D1215%26epage%3D1222%26doi%3D10.1016%2Fj.neuropharm.2008.03.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Burris, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molski, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tottori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yocca, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molinoff, P. B.</span><span> </span><span class="NLM_article-title">Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">302</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">389</span><span class="refDoi"> DOI: 10.1124/jpet.102.033175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1124%2Fjpet.102.033175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=12065741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD38Xlt1SnsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=302&publication_year=2002&pages=381-389&author=K.+D.+Burrisauthor=T.+F.+Molskiauthor=C.+Xuauthor=E.+Ryanauthor=K.+Tottoriauthor=T.+Kikuchiauthor=F.+D.+Yoccaauthor=P.+B.+Molinoff&title=Aripiprazole%2C+a+novel+antipsychotic%2C+is+a+high-affinity+partial+agonist+at+human+dopamine+D2+receptors&doi=10.1124%2Fjpet.102.033175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors</span></div><div class="casAuthors">Burris, Kevin D.; Molski, Thaddeus F.; Xu, Cen; Ryan, Elaine; Tottori, Katsura; Kikuchi, Tetsuro; Yocca, Frank D.; Molinoff, Perry B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">302</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">381-389</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Aripiprazole is the first next-generation atypical antipsychotic with a mechanism of action that differs from currently marketed typical and atypical antipsychotics.  Aripiprazole displays properties of an agonist and antagonist in animal models of dopaminergic hypoactivity and hyperactivity, resp.  This study examd. the interactions of aripiprazole with a single population of human D2 receptors to clarify further its pharmacol. properties.  In membranes prepd. from Chinese hamster ovary cells that express recombinant D2L receptors, aripiprazole bound with high affinity to both the G protein-coupled and uncoupled states of receptors.  Aripiprazole potently activated D2 receptor-mediated inhibition of cAMP accumulation.  Partial receptor inactivation using the alkylating agent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) significantly reduced the max. effect of aripiprazole on inhibition of cAMP accumulation.  This effect was seen with concns. of EEDQ that did not alter the maximal inhibitory effect of dopamine.  Consistent with the expected effects of a partial agonist, increasing concns. of aripiprazole blocked the action of dopamine with maximal blockade equal to the agonist effect of aripiprazole alone.  The efficacy of aripiprazole relative to that of dopamine varied from 25% in cells that lacked spare receptors for dopamine to 90% in cells with receptor reserve.  These results, together with previous studies demonstrating partial agonist activity at serotonin 5-hydroxytryptamine (5-HT)1A receptors and antagonist activity at 5-HT2A receptors, support the identification of aripiprazole as a dopamine-serotonin system stabilizer.  The receptor activity profile may underlie the unique activity of aripiprazole in animals and its antipsychotic activity in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu--oNCiWjJ7Vg90H21EOLACvtfcHk0ljhK7Ln8Vmp9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xlt1SnsLY%253D&md5=907bbba92bdfb6c4d2ee703f289c32f6</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fjpet.102.033175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.102.033175%26sid%3Dliteratum%253Aachs%26aulast%3DBurris%26aufirst%3DK.%2BD.%26aulast%3DMolski%26aufirst%3DT.%2BF.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRyan%26aufirst%3DE.%26aulast%3DTottori%26aufirst%3DK.%26aulast%3DKikuchi%26aufirst%3DT.%26aulast%3DYocca%26aufirst%3DF.%2BD.%26aulast%3DMolinoff%26aufirst%3DP.%2BB.%26atitle%3DAripiprazole%252C%2520a%2520novel%2520antipsychotic%252C%2520is%2520a%2520high-affinity%2520partial%2520agonist%2520at%2520human%2520dopamine%2520D2%2520receptors%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2002%26volume%3D302%26spage%3D381%26epage%3D389%26doi%3D10.1124%2Fjpet.102.033175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Winpenny, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cawkill, D.</span><span> </span><span class="NLM_article-title">Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased opioid receptor agonists</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">173</span><span class="NLM_x">, </span> <span class="NLM_fpage">1393</span><span class="NLM_x">–</span> <span class="NLM_lpage">1403</span><span class="refDoi"> DOI: 10.1111/bph.13441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1111%2Fbph.13441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BC28XjtlOnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2016&pages=1393-1403&author=D.+Winpennyauthor=M.+Clarkauthor=D.+Cawkill&title=Biased+ligand+quantification+in+drug+discovery%3A+from+theory+to+high+throughput+screening+to+identify+new+biased+opioid+receptor+agonists&doi=10.1111%2Fbph.13441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Biased ligand quantification in drug discovery: from theory to high throughput screening to identify new biased μ opioid receptor agonists</span></div><div class="casAuthors">Winpenny, David; Clark, Mellissa; Cawkill, Darren</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1393-1403</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : Biased GPCR ligands are able to engage with their target receptor in a manner that preferentially activates distinct downstream signalling and offers potential for next generation therapeutics.  However, accurate quantification of ligand bias in vitro is complex, and current best practice is not amenable for testing large nos. of compd.  We have therefore sought to apply ligand bias theory to an industrial scale screening campaign for the identification of new biased μ receptor agonists.  Exptl. Approach : μ receptor assays with appropriate dynamic range were developed for both Gαi-dependent signalling and β-arrestin2 recruitment. Δlog(Emax/EC50) anal. was validated as an alternative for the operational model of agonism in calcg. pathway bias towards Gαi-dependent signalling.  The anal. was applied to a high throughput screen to characterize the prevalence and nature of pathway bias among a diverse set of compds. with μ receptor agonist activity.  Key Results : A high throughput screening campaign yielded 440 hits with greater than 10-fold bias relative to DAMGO.  To validate these results, we quantified pathway bias of a subset of hits using the operational model of agonism.  The high degree of correlation across these biased hits confirmed that Δlog(Emax/EC50) was a suitable method for identifying genuine biased ligands within a large collection of diverse compds.  Conclusions and Implications : This work demonstrates that using Δlog(Emax/EC50), drug discovery can apply the concept of biased ligand quantification on a large scale and accelerate the deliberate discovery of novel therapeutics acting via this complex pharmacol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr27eSo6ucccrVg90H21EOLACvtfcHk0lg4_KGafpyzug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjtlOnsr0%253D&md5=3ca14bdd9f38add90937f8bf6c6cab37</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Fbph.13441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.13441%26sid%3Dliteratum%253Aachs%26aulast%3DWinpenny%26aufirst%3DD.%26aulast%3DClark%26aufirst%3DM.%26aulast%3DCawkill%26aufirst%3DD.%26atitle%3DBiased%2520ligand%2520quantification%2520in%2520drug%2520discovery%253A%2520from%2520theory%2520to%2520high%2520throughput%2520screening%2520to%2520identify%2520new%2520biased%2520opioid%2520receptor%2520agonists%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2016%26volume%3D173%26spage%3D1393%26epage%3D1403%26doi%3D10.1111%2Fbph.13441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Gottlieb, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kotlyar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nudelman, A.</span><span> </span><span class="NLM_article-title">NMR chemical shifts of common laboratory solvents as trace impurities</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">7512</span><span class="NLM_x">–</span> <span class="NLM_lpage">7515</span><span class="refDoi"> DOI: 10.1021/jo971176v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo971176v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADyaK2sXmvVClsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=1997&pages=7512-7515&author=H.+E.+Gottliebauthor=V.+Kotlyarauthor=A.+Nudelman&title=NMR+chemical+shifts+of+common+laboratory+solvents+as+trace+impurities&doi=10.1021%2Fjo971176v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">NMR chemical shifts of common laboratory solvents as trace impurities</span></div><div class="casAuthors">Gottlieb, Hugo E.; Kotlyar, Vadim; Nudelman, Abraham</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7512-7515</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The 1H (300 MHz) and 13C (75 MHz) NMR chem. shifts for >30 common impurities, such as lab. solvents, stabilizers, greases and water, are reported in 7 deuterated NMR solvents.  The temp. dependence of the chem. shift of the proton residual peak (HDO) in D2O is established for the entire liq. range of this sample.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocnoOemocS9LVg90H21EOLACvtfcHk0lg4_KGafpyzug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvVClsbo%253D&md5=c297adda99f8c10e9f9b0ab9fe5f55be</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjo971176v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo971176v%26sid%3Dliteratum%253Aachs%26aulast%3DGottlieb%26aufirst%3DH.%2BE.%26aulast%3DKotlyar%26aufirst%3DV.%26aulast%3DNudelman%26aufirst%3DA.%26atitle%3DNMR%2520chemical%2520shifts%2520of%2520common%2520laboratory%2520solvents%2520as%2520trace%2520impurities%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1997%26volume%3D62%26spage%3D7512%26epage%3D7515%26doi%3D10.1021%2Fjo971176v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Barnea, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strapps, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrada, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berman, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kloss, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Axel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. J.</span><span> </span><span class="NLM_article-title">The genetic design of signaling cascades to record receptor activation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">64</span><span class="NLM_x">–</span> <span class="NLM_lpage">69</span><span class="refDoi"> DOI: 10.1073/pnas.0710487105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=10.1073%2Fpnas.0710487105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=18165312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvV2ktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=64-69&author=G.+Barneaauthor=W.+Strappsauthor=G.+Herradaauthor=Y.+Bermanauthor=J.+Ongauthor=B.+Klossauthor=R.+Axelauthor=K.+J.+Lee&title=The+genetic+design+of+signaling+cascades+to+record+receptor+activation&doi=10.1073%2Fpnas.0710487105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The genetic design of signaling cascades to record receptor activation</span></div><div class="casAuthors">Barnea, Gilad; Strapps, Walter; Herrada, Gilles; Berman, Yemiliya; Ong, Jane; Kloss, Brian; Axel, Richard; Lee, Kevin J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-69</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The authors have developed an exptl. strategy to monitor protein interactions in a cell with a high degree of selectivity and sensitivity.  A transcription factor is tethered to a membrane-bound receptor with a linker that contains a cleavage site for a specific protease.  Activation of the receptor recruits a signaling protein fused to the protease that then cleaves and releases the transcription factor to activate reporter genes in the nucleus.  This strategy converts a transient interaction into a stable and amplifiable reporter gene signal to record the activation of a receptor without interference from endogenous signaling pathways.  The authors have developed this assay for three classes of receptors: G protein-coupled receptors, receptor tyrosine kinases, and steroid hormone receptors.  Finally, the authors use the assay to identify a ligand for the orphan receptor GPR1, suggesting a role for this receptor in the regulation of inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ugB7pgEqlrVg90H21EOLACvtfcHk0lg4_KGafpyzug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvV2ktA%253D%253D&md5=3b49dfdb2949d947e145084ac87bb343</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0710487105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0710487105%26sid%3Dliteratum%253Aachs%26aulast%3DBarnea%26aufirst%3DG.%26aulast%3DStrapps%26aufirst%3DW.%26aulast%3DHerrada%26aufirst%3DG.%26aulast%3DBerman%26aufirst%3DY.%26aulast%3DOng%26aufirst%3DJ.%26aulast%3DKloss%26aufirst%3DB.%26aulast%3DAxel%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DK.%2BJ.%26atitle%3DThe%2520genetic%2520design%2520of%2520signaling%2520cascades%2520to%2520record%2520receptor%2520activation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D64%26epage%3D69%26doi%3D10.1073%2Fpnas.0710487105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i78"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01208">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_83113"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01208">10.1021/acs.jmedchem.6b01208</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline"><sup>1</sup>H and <sup>13</sup>C NMR spectra of compounds <b>1</b>, <b>24</b>, <b>46</b>, <b>49</b>, <b>53</b>, and <b>54</b>. <i>K</i><sub>d</sub> and <i>B</i><sub>MAX</sub> estimates comparing D2R GloSensor and D2R Tango cell types. GloSensor cAMP inhibition with no D2R expressed. D2R G protein antagonism by compound <b>1</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01208/suppl_file/jm6b01208_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01208/suppl_file/jm6b01208_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01208/suppl_file/jm6b01208_si_001.pdf">jm6b01208_si_001.pdf (3.89 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01208/suppl_file/jm6b01208_si_002.csv">jm6b01208_si_002.csv (2.63 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01208&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01208%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-23%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01208" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679948e07e3a3c4c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
